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Semaphorin 3B (SEMA3B) is an 83 kDa secreted protein of the semaphorin family which has 
recently been shown to play an important role in angiogenesis and tumour progression and is 
thought to act as a tumour suppressor. SEMA3B is located at a site of frequent allele loss in 
the early pathogenesis of breast cancer, and the full-length form of SEMA3B is thought to be 
cleaved by furin-like pro-protein convertases (PPCs), into an inactive 51 kDa fragment. 
However, the role and expression of SEMA3B in breast cancer remain unclear. This project, 
therefore, tests the hypothesis that PPCs cleavage of SEMA3B results in inactivation of 
SEMA3B in invasive breast cancer. In order to test the hypothesis the project used a series of 
breast cell-lines consisting of normal breast epithelial cells, pre-malignant, pre-invasive, 
invasive and metastatic cell-lines, as a model of breast cancer progression. SEMA3B and 
PPCs mRNA and protein expression were investigated in these cell-lines using qPCR and 
Western blotting, respectively. Immunohistochemistry was then performed on tissue 
microarray slides in a panel representing different stages of breast disease. In addition, the 
effect of full-length recombinant SEMA3B was assessed in cell based functional assays. 
Finally, two PPC inhibitors, namely decRVKR-CMK and alpha-1 antitrypsin Portland variant 
(α1-PDX) were used to inhibit PPC activity and potentially restore the active full-length 
SEMA3B in breast cancer cells. The data in this thesis show that SEMA3B gene and protein 
expression was detected in all cell-lines tested, with the highest level of gene expression seen 
in the normal MCF-10A cells. These cells were the only ones to express the full-length 
SEMA3B with all other cells only expressing cleaved SEMA3B, which is likely to be inactive. 
Treatment with full-length recombinant SEMA3B showed that this protein inhibited breast 
cancer cell growth, migration and invasion. PPCs analysis did not show a significant 
relationship with increasing malignancy of cell-line for either mRNA or protein expression, 
although all cell-lines expressed at least some PPCs. Histological analysis showed that 
SEMA3B expression was significantly reduced with increasing malignancy of lesion and 
correlated closely with the expression of many of the PPCs. Although the CMK inhibitor did 
not prevent cleavage of SEMA3B, the α1-PDX inhibitor partially restored full-length SEMA3B. 
These data suggest that full-length SEMA3B is a tumour suppressor in breast cancer, and that 
the PPCs may be involved in cleavage of SEMA3B to allow breast cancer progression. Further 
work is required to confirm the hypothesis and to see whether α1-PDX may be a potential 
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Chapter 1: Introduction 
 
1.1 Breast anatomy 
The breast is made up of a large fatty area that is connected to the underlying ribs via 
the pectoralis major muscle and connected to the rest of the breast via connective 
tissue. The functional part of the breast is made of several mammary glands, which 
consist of lobules of glandular tissue; known as alveoli, as well as the milk ducts which 
come together forming a lobe. Each lobe consists of secretary cells specialized in milk 
production, which will be subsequently secreted through the breast ducts. Each breast 
has 15-25 lobes that are dividing into smaller lobules and acini ending with ducts which 
open individually into the nipple. These lobules and ducts are supported by stromal 
tissue, which has fat, ligaments, nerves, arteries, veins, and lymphatics embedded 
into it (figure 1.1) (Jesinger, 2014). Breast growth in females is initiated at puberty in 
response to oestrogen and progesterone secretion. Any changes in these hormonal 











Figure 1.1: Schematic representation of the basic breast anatomy structure 
2 
 
1.2 Breast diseases 
Breast disorders can be benign or malignant and it has been shown that benign 
changes in the breast may correlate with an increased risk for the development of 
breast cancer. Benign breast diseases are classified into non-proliferative changes, 
proliferative disease without atypia and proliferative disease with atypia (Guray and 
Sahin, 2006). 
1.2.1. Non-proliferative epithelial lesions 
Non-proliferative changes which are also known as fibrocystic changes and these 
include cysts, apocrine changes, adenosis which is characterised by increasing the 
number of small terminal ductules or acini that might be additionally associated with 
calcification, mild hyperplasia and fibroadenoma without complex features. The most 
frequently common change are cysts and fibrosis which are characterized by an 
increase in fibrous stroma due to dilatation of ducts and formation of cysts that vary in 
size. However, most of these lesions were not shown to have a link to subsequent 
development of breast cancer but in some rare cases they may be able to become 
malignant (Friedenreich et al., 2000, Guray and Sahin, 2006). 
1.2.2 Proliferative disease without atypia 
Proliferative breast diseases include florid hyperplasia, papilloma, radial scar and 
fibroadenoma with complex features (Schnitt, 2003). It has been found that 
proliferative change in the breast epithelial cells without atypia (atypia is abnormality 
in a cell structure), is associated with a 1.5 to 2 fold increase in risk of cancer 
development, particularly in the presence of other factors that could enhance it such 
as patient history, age and other environmental factors. As these cells did not show 
any signs of atypia but are characterized by faster growth rate than normal cells with 
a normal identical appearance to the normal cells and therefore they often described 
as usual hyperplasia of either the duct or lobule (Schnitt, 2003). 
1.2.3 Proliferative disease with atypia 
Similarly to usual hyperplasia, atypical hyperplasia shows increased growth of the 
epithelial cells and the cells look abnormal i.e. atypical. Atypical ductal hyperplasia 
and atypical lobular hyperplasia have been categorized as proliferative disease with 
atypia and show a 4-5 fold risk of becoming malignant. In spite of the wealth of studies 
suggesting an association between proliferative lesions with atypia and the risk of 
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development of breast cancer (Dupont et al., 1993), other studies, such as that by 
Fowble et al have found no significant influence of such risk factors for the later 
development of breast cancer (Fowble et al., 1998, Sasaki et al., 2018). 
1.3 Morphology and progression of breast cancer 
Normal human breast tissue consists of two layers of epithelial cells that line the 
lobules and ducts, the luminal epithelium and the myoepithelial layer. It is believed that 
the progression of breast cancer, which is a heterogeneous disease, is due to 
alterations in the luminal epithelial cells of the ducts and lobules. Cancer development 
is dependent on various factors, some of which also determine the type of breast 
cancer that the patient will present with. Breast cancer cells express a variety of 
different receptors and any alterations in their activity could cause changes in their 
progression (Allison, 2012). Oestrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor 2 receptor (HER2) are considered the most 
important receptors that correlate with breast cancer development. For instance, ER 
positive breast cancer is caused by an alteration in the expression of oestrogen 
receptors that induce a conformational change and uncontrolled binding to its ligand 
resulting in uncontrolled activation of the receptor and induced transcription of target 
genes resulting in uncontrolled proliferation. Just like ER, PR positive breast cancer 
results from uncontrolled activation of PR receptor and usually exists alongside ER 
positive breast cancer. HER2 positive breast cancer is caused by overexpression of 
HER2 receptor resulting in dysregulated HER2 signalling and target gene expression, 
again leading to increased proliferation of the cells. It is not uncommon to find patients 
exhibiting both PR and ER positive breast cancer and/or HER2 negative or positive 
receptor expression, however, a patient can develop breast cancer that is not related 
to these three receptors resulting in a triple negative breast cancer, giving rise to a 
disease with a complex genetic background (Eroles et al., 2012). Based on this, it is 
clear that not all breast cancers evolve in the same way and some types of breast 
cancer are more aggressive than others. So understanding the histopathological 
alterations and the different characteristics of breast cancer is important to develop 




1.4 Breast cancer risk factors 
Although the majority of breast cancers are sporadic and multifactorial, numerous 
breast cancer risk factors have been identified. Mutation in BRCA1 and BRCA2 genes 
are the most common factors that are strongly associated with a family history for 
developing breast cancer. These factors are involved in repair of DNA damage and 
when they are mutated increased mutations in the breast DNA result in the 
development of cancer (Balmana et al., 2011). Breast cancer is also attributed to other 
risk factors including reproductive factors, which are associated with the ER status. 
These factors included late menopause, early menarche, nulliparity and late age at 
first pregnancy, all of which increase the length of exposure to oestrogen (Sun et al., 
2017). Furthermore, environmental and lifestyle factors also contribute to the 
incidence of breast cancer. For example, alcohol consumption can increase the risk 
of breast cancer by increasing the level of oestrogen-related hormones in the blood 
and stimulate the oestrogen receptor pathways (Jung et al., 2016). Obesity and too 
much dietary fat intake, smoking and environmental contaminations can also enhance 
the risk of DNA mutations and therefore increase the risk of breast cancer (Sun et al., 
2017). 
1.5 Epidemiology of breast cancer 
Breast cancer is the most common form of cancer in the UK, even though it is rare in 
men due to smaller amounts of breast tissue. It therefore highly affects women, with a 
total of 55,122 cases reported in 2015, which accounts for about 30% of all recently 
diagnosed cancer cases (CRUK, 2015). Breast cancer is considered the second most 
common cause of cancer death in females in the UK with about 11,500 deaths in 2016, 
while in males with breast cancer there were 80 deaths in the same year (CRUK,2018). 
It is considered the leading cause of death among women globally. According to the 
world health organization, in 2018, the worldwide estimation of the number of breast 
cancer cases is about 11.6% of all cancers with breast cancer causing 6.6% of all 
deaths worldwide (WHO, 2019). Despite the fact that there are a large variety of 
different treatment measures, if not detected early, the prognosis of breast cancer 
remains poor and correlates with tumour metastasis (Rakha et al., 2007). That said, 
there has been an improvement in breast cancer mortality, which is attributable to a 
combination of improved screening programmes that facilitate early detection and 
availability of effective systemic adjuvant therapy. Recent improvement in the 
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knowledge of the molecular pathogenesis of breast cancer and its progression have 
led to the understanding of novel molecular pathways involved in the development of 
breast cancer resulting in development of target specific therapeutics. Since each 
patient has a varying genetic background, this necessitates the development of patient 
specific treatment and that could help to aid further reduction in breast cancer 
mortality.  
1.6 Breast cancer histopathologic classification 
Normal breast epithelial cells are surrounded by different proteins in the extracellular 
matrix which consists of proteins such as glycoproteins and collagen, which regulate 
cell-cell adhesion. Several factors, such as those described earlier in section 1.4, could 
directly or indirectly derail the normal processes and result in increased cell production 
of the normal breast epithelia resulting in hyperplasia (Koukoulis et al., 1991). As 
stated earlier, hyperplasia has been graded histologically into two types; usual 
hyperplasia (UH) which the duct filled with proliferating epithelial cells but with no 
atypia present and the cells look normal, and atypical ductal hyperplasia (ADH) which 
could become localized in the duct with distorted, abnormal cells. There is no evidence 
of neoplasia detected in UH (Page and Dupont, 1990). However, ADH is characterized 
by increasing nuclear pleomorphism, hyperchromatism and a uniformity arrangement 
and organization of cells within the breast duct, and some studies have suggested this 
could be considered as an indicator for developing breast cancer in the future (Page 
and Dupont, 1990). Indeed, one study found that patients with ADH had 5.3 times 
increased relative risk for developing breast cancer than patients with non-proliferative 
lesions. In addition, the family history and other risk factors may contribute to the 
development of breast cancer (Dupont and Page, 1985). 
In a stepwise manner, ADH also have the potential to become ductal carcinoma in situ 
(DCIS), which is a non-invasive but premalignant type of breast cancer. DCIS can 
occur due to an abnormal proliferation of neoplastic epithelial cells. These cells are 
contained within the breast ducts and have not yet spread beyond the basement 
membrane (Simpson, 2009). DCIS may exhibit some tumour characteristics such as 
nuclear atypia and is also found to have carcinoma precursor cells which share similar 
genetic features with invasive carcinoma (Carraro et al., 2014). These could enhance 
the development of pre-invasive and pre-malignant lesions with subsequent 
progression of invasive breast cancer potential (Wellings and Jensen, 1973). ADH is 
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sometimes difficult to differentiate from DCIS. DCIS is characterised by a high nuclear 
grade with necrosis and debris. However, ADH can sometimes be distinguished from 
DCIS by cellular variability or clonality and nuclear overlap as ADH is usually made up 
of cells with low grade nuclei which are uniform and small (Lakhani et al., 1995, Pinder 
and Ellis, 2003).  
The alteration in growth regulating pathways leading to an imbalance of proliferation 
and therefore increased cell growth are the major causes of developing DCIS and 
subsequently invasive breast cancer. The level of ER is found to be higher in many 
DCIS cells suggesting a role for this growth factor in breast cancer progression (Arpino 
et al., 2005). In addition to DCIS, other in situ carcinomas are also found such as 
lobular carcinoma in situ (LCIS), which refers to cancerous epithelial cells that 
accumulate within the lobules, and are contained within the lobular basement 
membrane. Importantly, when DCIS develops it can increase the risk of progression 
to invasive breast cancer, as one study found that 43% of the invasive breast cancers 
studied had been diagnosed earlier as DCIS by mammography (Leonard and Swain, 
2004). Therefore, strategies to control DCIS by surgery or selective oestrogen 
modulation by Tamoxifen are used and can work effectively to prevent the subsequent 
development of aggressive breast cancer. However, not all DCIS cases will progress 
to invasive breast cancer leading to possible over treatment of patients, something 
that has become a major concern nowadays. 
Invasive ductal carcinoma (IDC) accounts for about 86% of breast cancer cases, which 
is the highest percentage of all breast cancers and in this form, the cancer cells have 
developed in the milk ducts (as DCIS) and progressed  to invade through the basement 
membrane into nearby tissues to become IDC (Arpino et al., 2004). It is characterized 
by the dissemination of cancer cells beyond the basement membrane of the ducts. In 
addition to IDC, invasive lobular carcinoma (ILC) accounts about 10% of invasive 
breast tumours (Arpino et al., 2004). ILC formation is often predicted by its risk factors, 
lobular neoplasia, which is comprised of LCIS, a monomorphic population of non-
adhesive cells in the lobular duct and atypical lobular hyperplasia, in which there is 
accumulation of abnormal cells that can develop to form cancer cells.  
Clinical investigations have illustrated that there are major differences between IDC 
and ILC. ILC are known to have a “single-file” growth pattern rather than forming a 
mass, are larger in size and less aggressive compared to IDC, and often ER and PR 
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positive (Tazaki et al., 2013, Engels et al., 2014). However, treatment modalities 
employed in both cases are similar with respect to systemic adjuvant therapy that 
considers histological grade, size of tumour, and hormone and growth factor receptor 
status (Engels et al., 2014). Thus, understanding the molecular pathways involved in 
breast cancer progression may be of more importance than histopathological studies, 








































Figure 1.2: Model of breast cancer stages. The drawing shows a schematic 
illustration of the model of breast cancer evolution and cell-lines that reflect the 
different breast cancer stages. The terminal normal duct epithelium (MCF-10A 
represent the normal cells in this project) enlarges to form hyperplastic epithelial 
lobular units which alter to more complex lesions including ADH (MCF-10AT 
represents the ADH stage). ADH lesions may then progress and differentiate into 
DCIS (DCIS.com cells represent the DCIS stage). The DCIS can then progress and 
break through the basement membrane to become invasive breast cancer (MCF-7 
and T47D cells represent the invasive cell lines with variable receptor status) and 
MDA-MB-231 cells represent metastatic cells. The invasive cells then metastasise and 
one of the most common sites for breast cancer metastasis is the bone; this stage is 
represented by the fully bone-homed cells called MDA-MB-231-(BM). Elements of this 





1.7 Breast cancer molecular subtypes  
Multiple molecular changes occur during the progression of breast cancer including 
the oestrogen and progesterone receptors, proliferation markers, and the HER2 
receptor expression. The expression of these markers differs between different breast 
cancer subtypes including luminal A, luminal B, HER2 positive, basal-like and claudin-
low. Knowing the receptor status of the breast cancer is very important in determining 
the best strategies for treating and targeting the disease. For example, high levels of 
Ki-67, which is a nuclear antigen detected in cells in the proliferative phases of the cell 
cycle (G1, S, G2, and M) and helps in maintaining the growth rate, has been 
associated with increased risk of breast cancer recurrence (Rivenbark et al., 2013). 
Luminal A subtype is characterized as hormone receptor positive ER and/or PR 
positive and HER-2 negative with low Ki-67 expression. The proliferation rate and the 
histological grade of luminal A are low. This subtype accounts for 50%-60% of the 
cases and considered the most common type of breast cancer. Luminal A subtype 
shows a good prognosis in response to chemotherapy (Yersal and Barutca, 2014). 
Luminal B subtype is characterized as hormone receptor positive ER and/or PR 
positive in addition to a positive HER-2 expression. The expression of Ki-67 is high 
and the proliferation rate of this type is slightly faster than the luminal A cancer with 
poorer prognosis compared to luminal A. However, both luminal subtypes have an 
excellent long-term survival of about 80% to 85% at 5-years. The luminal B cancer 
represents about 15% to 20% of all breast cancers. Both luminal A and B can be 
treated by hormonal therapy as both showed ER-dependent growth phenotype with a 
varying response (Rivenbark et al., 2013, Yersal and Barutca, 2014).  
HER2 positive cancer represents 15-20% of breast cancer subtypes. It is 
characterized by high expression of HER2 gene with negative ER and PR. The 
expression of Ki-67 is usually high in HER2 positive cancer. The proliferation rate of 
HER-2 positive is faster than luminal cancers and therefore it has a slightly lower 
prognosis which about 71% 5-year survival but the HER2 can be targeted and the 
cells are responsive to Herceptin (an antibody to HER2), which is a common treatment 
for this subtype (Dias et al., 2017). 
Basal-like cancer is characterized by cancers that do not express ER, PR and HER-2 
hence it is often referred to as triple-negative causes. It is more common in patients 
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with BRCA1 gene mutation and accounts for 15% of all breast cancers. Triple negative 
cancer has a high rate of cell proliferation with an extremely poor prognosis. The Ki-
67 level is high in triple negative cancers and this type of cancer is positive for EGFR 
(Rivenbark et al., 2013). It has a survival rate of 73% at 5-years survival (Dias et al., 
2017). Claudin-low breast cancer is somewhat similar to the triple negative type. It 
accounts for 10% of all breast cancers. As in triple negative, claudin-low is receptor 
negative for ER, PR and HER-2. It is enriched in epithelial-to-mesenchymal transition 
and has reduced expression of Claudin with a survival rate of 79% at 5-years (Prat et 
al., 2010, Yersal and Barutca, 2014, Dias et al., 2017). 
Normal breast-like cancer is poorly characterized and is usually classified as a 
fibroadenoma. It represents 5-10% of all breast cancer and does not express any of 
ER, PR and HER-2 receptors and has an intermediate prognosis between luminal and 
basal-like. It expresses gene characteristics of adipose tissues and it does not respond 
to neoadjuvant chemotherapy. Normal breast-like cancer are not characterised as 
basal-like as they are negative for basal myoepithelial markers such as CK5 and 
epidermal growth factor receptor which make it different from triple negative cancer 
(Yersal and Barutca, 2014).  
Despite the differences between the molecular subtypes of breast cancer, the 
development and pattern of metastasis is considered the most important risk factor for 
cancer prognosis, and has important implications for the clinical management of the 
disease (Gupta and Massague, 2006). The ability of aggressive malignant cells to 
spread beyond the breast and nearby lymph nodes to distant organs is known as 
tumour metastasis, and occurs as a late event in tumour progression. Tumour cells 
may travel into blood vessels, lymphatic vessels, or spread within body cavities. The 
distant metastatic spread is the most common cause of death among patients with 
breast cancer. Depending on the breast cancer subtypes, it primarily metastasizes to 
bone, lung, liver and brain; the last two sites occur less frequently but are seen more 
in triple negative tumours. Overall bone is considered the main site for breast cancer 
metastasis especially for oestrogen receptor positive tumours (Scully et al., 2012, Jin 
and Mu, 2015).  
In order for cancer cells to be able to metastasize they must have some fundamental 
properties and gain certain tumorigenic features and functions to complete the 
multistep metastatic cascade. The metastatic cascade can be divided into different 
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steps (Scully et al., 2012) including invasion and intravasation, dissemination into the 
circulation, arrest and extravasation at the distant site, and micrometastasis and 
colonization of target organs (Hunter et al., 2008). 
Tumour invasion is one of the first steps that cells must fulfil in order to be able to 
metastasise. Malignant cells undergo the process of epithelial-to-mesenchymal 
transition (EMT) by down-regulation of E-cadherin and up-regulation of vimentin giving 
them a migratory phenotype. This enables them to move through the extracellular 
matrix (ECM) and basement membrane of the vasculature and intravasate into blood 
or lymphatic vessels (Hunter et al., 2008). Invasion is preceded by break down of the 
ECM to allow the penetration of tissue boundaries. This degradation is carried out via 
the release of metalloproteinases (MMPs) which are a family of endopeptidases that 
are able to break down most known extracellular matrix components. Cells squeeze 
through spaces in the matrix and move into the circulation. Once in the circulation they 
have to survive a hostile environment, which they do via aggregation in clumps with 
each other and platelets. The cells travel to the secondary sites, mainly bone in breast 
cancer, where they arrest in the microvessels and extravasate out again. The cells 
then initiate growth in the secondary site which is directly enhanced by the recruitment 
of the tumour metastasis-associated macrophages, and over time, cancer cells can 
establish full colonization of secondary organs (Hunter et al., 2008, Scully et al., 2012). 
Therefore, the development and progression of breast cancer is regulated by a variety 
of different genetic factors resulting in changing expression of different proteins. There 
are a number of proteins that are considered to be tumour suppressor proteins that 
are down-regulated or switched off in breast cancer and these include the 
semaphorins.  
1.8 Breast cancer and semaphorins 
The development and pathogenesis of breast cancer is not fully elucidated due to 
diversity and complex genetic background. However, emerging evidence suggests 
that semaphorins have an important role in some tumours types by affecting their 
progression either by activation or inhibition (Nasarre et al., 2005, Segarra et al., 
2012). The differences in gene and protein expression of semaphorins among normal 
and different grades of breast cancer suggest their role as important prognostic factors 
for evaluating breast cancer progress (Butti et al., 2018), and therefore could be useful 
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for the diagnosis and prognosis of breast cancer and indeed for targeted therapy to 
prevent cancer in the early stages of the disease. 
1.8.1 Semaphorins 
Semaphorins (collapsins) are a family of secreted and transmembrane proteins, which 
have a substantial impact on axon guidance, the development of the renal, respiratory 
systems and on the immune system. In recent years, they have been shown to play 
an important role in angiogenesis, regulation of cell-cell interactions and cell 
differentiation, immune responses and tumour progression, where some semaphorins 
are thought to act as tumour suppressors (Luo et al., 1993, Yazdani and Terman, 
2006, Capparuccia and Tamagnone, 2009). Importantly, some semaphorins are 
overexpressed and others are under expressed in different cancers (Rehman and 
Tamagnone, 2013). Semaphorins are mostly expressed during nervous system 
development, however, this is not exclusive with expression in many organ systems 
including the cardiovascular, endocrine, gastrointestinal, hepatic, immune, renal, 
reproductive, and respiratory systems. Notably, the expression of semaphorins has 
been shown to be reduced with cellular maturity in neuronal tissue. During adulthood 
the expression of semaphorins was notably altered during tissue damage associated 
with certain pathological conditions. One of the common functions of semaphorins is 
their direct effect on of tissue morphogenesis and the other critical cellular processes. 
The alteration of semaphorin function has been associated with some neural disorders 
such as epilepsy, Alzheimer’s and Parkinson’s disease (Eastwood et al., 2003). The 
proteolytic processing of semaphorins by cleavage of furin-like proprotein convertases 
helps to activate the function of some semaphorins and therefore mediate axon 
guidance, migration, invasiveness and metastasis of cancer cells (Adams et al., 1997).  
One of the cancer hallmarks is that cancer cells must gain some tumorigenic features 
in order to metastasize and persist (Seyfried and Huysentruyt, 2013). The metastatic 
tumour cells must be supplied with nutrients to enhance the growth of tumours and 
this is via the process of developing new blood vessels called angiogenesis. 
Angiogenesis is one of the multisteps in the development of human cancers and 
directly contributes to tumour progression. Semaphorins play critical roles in 
angiogenesis by regulating vascular endothelial growth factor VEGF/VEGFR, 
considered to be the main player in this scenario (Castro-Rivera et al., 2004). A 
previous study suggests that semaphorins regulate angiogenesis by competing with 
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VEGF for neuropilin binding which acts as a co-receptor for some types of 
semaphorins as well as for the VEGF family of proteins (Castro-Rivera et al., 2004). 
Other semaphorin members promote tumour function by enhancing cell proliferation 
and migration in breast cancer. However, some members function as suppressor 
genes and anti-angiogenic factors that lead to decrease of metastatic ability and 
reduced aggressiveness of breast tumours (Varshavsky et al., 2008). It has been 
reported that breast cancer development and progression is associated with 
inactivation of SEMA3F as the knockdown of SEMA3F promotes tumour invasion 
(Xiong et al., 2012). Based on the evident relationship between semaphorin 
expression and cancer, attention has focused on the possibility of targeting 
semaphorin expression as a potential strategy for treating breast cancer, as some 
members have been shown to be effective in some types of cancer (Joseph et al., 
2010, Loginov et al., 2015). This evidence strongly suggests a critical role of 
semaphorins in breast cancer and highlight the importance of their expression on 
cancer progression, which needs to be thoroughly investigated to clarify how 
modification of the semaphorin family could be used in cancer therapeutics as novel 
factors to regulate tumour development. 
1.8.2 Classification of semaphorins 
Based on their structure and the phylogenetic characteristics, semaphorins are 
classified into eight subclasses. Class 1 and 2 are found in invertebrates only, whereas 
classes 3 to 7 are expressed in vertebrates, class 5 is found in both vertebrates and 
invertebrates, and class 8 is only found in viruses. Each subclass consists of several 
individual semaphorin proteins; each assigned a different letter (table 1.1). The 
structure of semaphorins consists of a highly conserved region of 500 amino acids at 
the amino-terminal end –the sema domain– which contains 17 highly conserved 
cysteine residues folded into a seven blade β-propeller structure. In addition, 
semaphorins comprise of at least one plexin, semaphorin and integrin (PSI) domain 
which is a cysteine-rich domain. Other aspects of semaphorins differ from each other. 
For example, SEMA4 and SEMA6 commonly have PDZ binding motifs at the C-
terminal of their intracellular domain, which can be cleaved proteolytically to generate 
soluble proteins (Artigiani et al., 2003, Kruger et al., 2005). In contrast, SEMA7 
proteins have a ghycophosphatidylinositol anchor (GPI) in their structure to help them 
remain linked to the plasma membrane and therefore they can interact with β integrins 
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in order to mediate the inflammatory response (Suzuki et al., 2007). Some classes of 
semaphorins, including SEMA 2, 3, 4, 7 also have a single immunoglobulin IG-like 
domain in their structure, while SEMA5 has seven thrombospondin domains (figure. 
1.3).  
Table 1.1: Semaphorins receptors and their locations (Law and Lee, 2012, Sabag 
et al., 2014). 
  
Semaphorin Receptor Location 
 
Class 1   Invertebrate 
    SEMA1A PlexinA 
    SEMA1B PlexinA 
Class 2   Invertebrate 
    SEMA2A PlexinB 




    SEMA3A NP1; Plexin-A4 
    SEMA3B NP1, -2, Plexin-A1, -A2, -A4 
    SEMA3C NP1, -2; Plexin-A2, -D1 
    SEMA3D NP1 
    SEMA3E Plexin-D1 
    SEMA3F NP1, -2; Plexin-A1, -A2 
    SEMA3G NP2 
Class 4    
 
Vertebrate 
    SEMA4A Plexin-B1, -B2, -B3, -D1 
    SEMA4B Plexin-B1 
    SEMA4C Plexin-B2 
    SEMA4D Plexin-B1, -B2 
    SEMA4G Plexin-B2 
Class 5    
Vertebrate and Invertebrate 
    SEMA5A Plexin-B3, -A1, -A3 
    SEMA5B Plexin-A1, -A3 
Class 6    
 
Vertebrate 
    SEMA6A Plexin-A4 
    SEMA6B Plexin-A4 
    SEMA6C Plexin-A1 
    SEMA6D Plexin-A1 
Class 7   Vertebrate 
    SEMA7A Plexin-C1 
























Figure 1.3: Vertebrate semaphorin structure and their binding partners, plexins 
and neuropilins. Semaphorin protein family members are classified into 8 classes 
based on their domain structure. Class 3 semaphorins are secreted, semaphorins of 
other classes are attached to the membrane. Class 3 semaphorin members are 
grouped into 7 classes including 3A, 3B, 3C, 3D, 3E, 3F and 3G. Class 3 semas are 
found in vertebrates. Plexin receptors, the main receptors for semas, are classified into 
4 classes (3A–G), (B1-3), (C1) and D1. Each plexin receptor class interacts with a 
certain semaphorin class to initiate signaling. Neuropilins receptors (NP1 and NP2) act 
as ligand binding co-receptors. Reproduced from (Worzfeld and Offermanns, 2014). 
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1.8.3 Semaphorin signalling and biological implications 
The plexins, a group of transmembrane receptors, are utilized by semaphorins for their 
signalling and these receptors are expressed in a wide range of cell types such as in 
the bone marrow progenitors, endothelial cells and cancer cells. For instance, plexin 
A, a neuronal semaphorin receptor, controls axon guidance through binding to class 
1 semaphorins (Winberg et al., 1998). Plexin receptors play a critical role in the 
recognition and mediation of semaphorins as the majority of semaphorins work 
through these receptors (Tamagnone et al., 1999). However, some classes of 
semaphorins, including SEMA3s, also utilize co-receptors such as the neuropilins 
(NP1& NP2), which exist in a complex with plexin for plexin activation and cell 
signalling to occur (Takahashi et al., 1999). The affinities of the binding between class 
3 semaphorins and neuropilin-plexin complexes are variable depending on each 
specific SEMA3 protein (Gaur et al., 2009). The plexin-semaphorin ligand binding 
results in activation of downstream signalling pathways and this is known to have a 
significant function in many disorders including the development of inflammation, lung 
and renal disorders and most importantly, cancer development or regression 
(Capparuccia and Tamagnone, 2009). Different members of the semaphorin family 
have different signalling pathways and interactions in cancer in general, and in breast 
cancer in particular. However, the signal transduction cascades of each semaphorin 
are not yet clearly identified (Butti et al., 2018).  
Class 3 semaphorins are secreted proteins that in general, with SEMA3B and 
SEMA3F specifically, are thought to play an important role in cancer development as 
they act as tumour inhibitors and potential anti-angiogenic factors in some lung and 
breast cancers (Neufeld et al., 2005, Gaur et al., 2009, Staton et al., 2011). In fact, 
SEMA3B and SEMA3F are both regarded as tumour suppressors as the expression 
of both genes are found to be lost in some lung cancers (Xiang et al., 1996), and re-
expression of these genes in a mesothelioma cell-line inhibited lung cancer cell growth 
(Tomizawa et al., 2001).  
In contrast, other classes of semaphorins could aid cancer development by stimulating 
crosstalk between intracellular and extracellular signals, enhancing cell migration and 
invasion into adjacent tissues, both of which are hallmarks of cancer. Indeed, 
semaphorins act as pleiotropic factors by controlling multiple signalling pathways 
involving cell survival and apoptosis. Semaphorins may be released in the tumour 
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microenvironment by infiltrating leukocytes or cancer cells where they can exhibit an 
autocrine regulatory loop (Rehman and Tamagnone, 2013). Hence, changes in 
expression pattern of semaphorins may be responsible for their different functions in 
varying pathological conditions. For instance, loss of heterozygosity of SEMA3B and 
SEMA3F has been observed in different cancers and mRNA overexpression of these 
proteins induces apoptosis and inhibits cell proliferation (Castro-Rivera et al., 2004). 
In contrast, expression of SEMA3B has been correlated with poor prognosis for cases 
of glioblastoma because even though it inhibits tumour growth, the cancer cells were 
found to retain their metastatic potential in a number of cases, which is consistent with 
p38-MAPK dependent activation of p21 and induction of interleukin 8 (Rolny et al., 
2008).  
1.9 Class 3 semaphorins 
Class 3 semaphorins are a subfamily of semaphorins, and are secreted proteins which 
are expressed in numerous cells including neurons, epithelial cells and some tumour 
cells (Worzfeld and Offermanns, 2014). They consist of seven soluble proteins (A, B, 
C, D, E, F and G) and are found in vertebrates. Like most semaphorins, Class 3 
semaphorins consist of a 500 amino acid sema domain and PSI domain, in addition 
to an immunoglobulin-like domain, and a C-terminal basic-rich domain (Yazdani and 
Terman, 2006, Staton, 2011, Nasarre et al., 2014). As previously stated, SEMA3 
signalling is activated through binding to plexin receptors in the presence of NP1 and 
NP2 which act as co-receptors. The main receptors for the class 3 semaphorins are 
the Plexin A subgroup, however, additional receptors/co-receptors are also known to 
contribute to class 3 semaphorin signalling such as L1cam, Nrcam, Plexin B1 and 
PlexinD1 (Takahashi et al., 1999, Gu et al., 2005, Julien et al., 2005).  
Neuropilin co-receptors are essential to stimulate cell signalling and to stabilize the 
semaphorin–plexin interactions. The resultant signalling is dependent on the affinity of 
class 3 semaphorins to these co-receptors, which varies between members of the 
class, with SEMA3A binding to NP1 while SEMA3F and SEMA3G bind to NP2. Some, 
like SEMA3B, SEMA3C and SEMA3D bind to both NP1 and NP2, whereas SEMA3E 
is the exception as it binds directly to Plexin D1 without the need for a neuropilin co-
receptor (Nasarre et al., 2014). It has been shown previously that class 3 semaphorins 
play an important role in axon guidance and cell-cell signalling. They are also known 
to reduce endothelial cell adhesion and migration, thereby acting as anti-angiogenic 
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agents preventing vascularization of tumours. The majority of SEMA3 members 
including SEMA3A, 3B, 3D, 3F and 3G all act as anti-angiogenic factors, however, 
SEMA3C and SEMA3E have the potential to activate angiogenesis and tumour growth 
(Martín‐Satué and Blanco, 1999). Class 3 semaphorins are also thought to act as 
tumour suppressors by inhibiting tumour growth in some types of cancers, in addition 
to inducing programmed cell death (Rolny et al., 2008). 
1.9.1 Class 3 semaphorin receptors and their cell signalling 
1.9.1.1 Plexins 
Plexins are large transmembrane cell surface receptors that act as the main receptors 
for semaphorins. They are expressed in both embryonic and adult tissues and act as 
signal transduction molecules. They are classified into four classes, namely plexin A, 
B, C and D, and each class has a number of different subclasses consisting of plexin 
A1-4, B1-3, C1 and D1 (Tamagnone et al., 1999, Shim et al., 2012). The extracellular 
structure of plexins consists of a 500 amino acid sema domain, which does not 
dimerize, a PSI domain and Immunoglobulin-plexin-transcription factor (IPT)/glycine-
proline (G-P), which are proline rich motifs that interact with the sema domain of 
semaphorins. The intracellular portion of plexins contains a split GTPase activity 
protein (GAP) domain which comprises of C1 and C2 domains separated by Rho-
GTPase binding domain (RBD). However, not all plexins are identical in their structure. 
For instance, plexin class B1-3 contain intracellular PDZ binding motifs and 
extracellular convertase cleavage sites whereas plexin D1 contains SEA motifs 
composed of the amino acids Ser, Glu and Ala in their extracellular region (Worzfeld 
and Offermanns, 2014).  
Plexins are known to have a role in the regulation of Rho-family GTPases and in 
stimulation of R-Ras/M-Ras family, which are involved in semaphorin signaling 
(Nasarre et al., 2014). To be activated, plexin receptors are bound to semaphorins 
after which they are phosphorylated on a tyrosine residue in the cytoplasmic domain. 
Otherwise, they remain in their inactive forms. Semaphorin binding to plexins 
stimulates different intracellular signaling cascades that eventually effect semaphorin 
biological function. For instance, the GAP domain of plexins are activated in the 
presence of Rho-GTPase binding domain, which interact with the Rnd family of 
proteins, a multidrug efflux pump. Rnd proteins are a distinct subclass of Rho-
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GTPases and the interaction with plexin GAP domain requires GDP-GTP exchange in 
a reaction that also require Ras-related proteins RRas and MRas to form RRas-GAP 
or MRas-GAP (Saito et al., 2009, Worzfeld and Offermanns, 2014). 
Dependent upon their location plexins function as axon guidance receptors, although 
they also have a significant role in cellular migration, tumour growth, metastasis and 
angiogenesis whether by overexpression or downregulation dependent on the plexin 
class and cancer types (Hota and Buck, 2012). It has been shown that plexin A1-4 are 
the main receptors for SEMA3s, when they form complexes with neuropilins in 
initiating SEMAs biological function (Worzfeld and Offermanns, 2014) (figure 1.4). 
Class A plexins regulate tyrosine kinases Fes and Fyn which modify the interaction of 
SEMA3A with plexin A1. Plexin A1 is phosphorylated by Fes, collapse response 
mediator protein (CRMP) and CRMP associated protein (CRAM) (Mitsui et al., 2002). 
In this way, Fes promotes collapse of growth cones of COS-7 cells by SEMA3A and 
this kinase activity of Fes on plexin A1 is required for collapse of dorsal root ganglion 
neuronal cells (Mitsui et al., 2002). In addition, an upregulated expression of plexinA1 
is observed in some cancers, such as colorectal carcinoma and gastric cancer, where 
the upregulation correlates with increased vascularisation through angiogenesis (Zhao 
et al., 2007, Carrer et al., 2008). However, in invasive breast cancer, the expression 
of plexin A1 and A3, in addition to class 3 semaphorins has been shown to be 
downregulated and this correlates with an increase in angiogenesis (Staton et al., 
2011). This suggests that plexin As are important contributors in cancer development. 
Although Plexin A1-4 are the main receptors for SEMA3 proteins, there is a suggestion 
that Plexin D1 may interact with one member of the family. Indeed, in many cancer 
cells where there is elevated expression of SEMA3E, elevated levels of plexinD1 are 
also observed and this correlates with the aggressiveness of the tumour. It is therefore 
not surprising that knockdown of plexinD1 and/or SEMA3E inhibited metastasis in a 
xenograft mouse model (Tseng et al., 2011, Luchino et al., 2013) suggesting an 




























Figure 1.4: Class 3 semaphorins and their interaction with neuropilin and plexin. 
Class 3 semaphorins such as SEMA3B signal through neuropilins like NP1 or NP2 in 
the presence of a receptor known as plexin (Plexins A1, A2 and A4 in case of 
SEMA3B). This interaction results in a cytoplasmic signaling cascade, in some 
oncogenic pathways through the GAP domain of plexinA for instance. SEMA3B is 
characterized by a large sema domain, one PSI domain and a C-terminal basic that is 
required for neuropilin binding. Neuropilins receptors are transmembrane receptors 
that act as a co-receptor for SEMA3B and consisting of CUB (a1 and a2) domains, 
two coagulation factor V/VIII domains (b1/b2) and a MAM domain (c domain). Plexins 
receptors are transmembrane receptors consisting of sema domain, three PSI 
domains, three Ig-like folds in their extracellular portion, and GAP domain in their 





Neuropilins are transmembrane glycoproteins with a molecular mass of 120 to 130 
kDa and classified into NP1 and NP2, which are encoded by genes located at 10p12 
and 2q34, respectively (Nakamura and Goshima, 2002, Ellis, 2006). They are 
expressed by different cells including neuronal, dendritic, inflammatory, endothelial, 
vascular smooth muscle, and tumour cells (Herzog et al., 2001). NP1 and NP2 have 
a similar protein structure but NP2 shares only about 44% sequence homology with 
NP1. The extracellular part of the neuropilins consists of five domains; two N-terminal 
CUB (a1 and a2) domains, Bone Morphogenetic Protein 1 (BMP1), and Tolloid 
proteins. Neuropilins also have two coagulation factor V/VIII domains (b1/b2) which 
bind to several ligands including VEGF and a MAM domain (meprin, A-5 protein, and 
receptor protein-tyrosine phosphatase mu), which is found in many receptors and 
mediates the dimerization of neuropilins. However, the intracellular part of neuropilins 
is only 20 amino acids in length and consists of SEA motifs which bind to different 
proteins, one of which is the PDZ synectin known to confer the VEGFR specific 
interaction to NP1 (figure 1.4). This interaction is essential for VEGF-dependent 
migration of endothelial cells (Wang et al., 2003, Worzfeld and Offermanns, 2014). 
Despite this ability to bind intracellular proteins, the small cytoplasmic domain of 
neuropilins leads them to mostly depend on molecules like plexins to transduce signals 
(Rohm et al., 2000, Prahst et al., 2008).  
Neuropilins comprise of a small family of co-receptors, which form a complex formation 
with plexins in the presence of semaphorins, by providing a high affinity-binding site 
for the semaphorin ligand. Neuropilins also bind to VEGF, thus playing an important 
role in angiogenesis (Gaur et al., 2009). Interestingly, neuropilins have been implicated 
in vascularization within the tumour microenvironment, due to their interactions with 
semaphorins and VEGFs affecting cell proliferation, migration and survival (Rizzolio 
and Tamagnone, 2011). NP1 is observed to be mainly expressed in carcinomas while 
NP2 is found to be expressed in tumour cells derived from neural crest cells (Ellis, 
2006). Increased expression of NP1 often correlates with poor prognosis due to 
accelerated cancer progression. Interestingly, growth factors such as epidermal 
growth factor (EGF) can induce NP1 expression (Akagi et al., 2003).  
Neuropilin binding to VEGF is important for vascularisation in tumour cells by forming 
receptor complexes (Gluzman-Poltorak et al., 2000). NP1 appears to bind specifically 
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to VEGF165 while NP2 binds both VEGF145 and VEGF165, and both NP1 and NP2 can 
bind additional VEGF family members such as VEGFB, VEGFE or Placental Growth 
Factor (PlGF2) (Migdal et al., 1998, Makinen et al., 1999). NP1 has been shown to 
enhance VEGFR2 signaling and it has been proposed that enhanced ligand binding 
to VEGFR2 in the presence of NP1 is responsible for enhanced potency of VEGF 
(Whitaker et al., 2001). It is worth noting that binding of VEGFR2 to NP1 occurs 
through the PDZ domain and this domain is known to confer angiogenic properties to 
neuropilins. This was confirmed in PDZ deficient cells which showed reduced 
NP1/VEGFR2 complex formation (Prahst et al., 2008). 
The activity of VEGF is inhibited by semaphorins which was originally thought to be 
due to the competition between VEGF and semaphorins for the neuropilin binding site 
(Appleton et al., 2007). This fact was strengthened by the study carried out by Pan et 
al. (2007) where blocking of the NP1 VEGF binding motif resulted in additional 
inhibition of NP1 angiogenic properties. However a new line of evidence from a 
mutagenesis study has shown that even though both VEGF165 and SEMA3 proteins 
bind to the b1b2 subdomain of NP1, the amino acids of NP1 that bind VEGF165 are 
different from those binding the SEMA3 proteins (Geretti et al., 2008), thus suggesting 
the possibility of another mechanism of angiogenesis inhibition rather than competitive 
binding. For example, Geretti et al (2008) found that VEGF165 can bind to the B (b1b2) 
domain of NP2, and this interaction can be altered by the reduction of the 
electronegative potential of B-NP2 which can decrease the affinity of binding between 
VEGF165 and NP2 without affecting SEMA3F affinity (Geretti et al., 2008). Thereby, 
this knowledge could play a potential role in developing effective anti-angiogenic 
therapies. 
1.10 Semaphorin 3B (SEMA3B) 
Semaphorin 3B (SEMA3B) is an 83 kDa protein member of the class 3 semaphorins, 
and its gene is located on the 3p21.3 LUCA region, which is found to exhibit a high 
loss of heterozygosity in lung and ovarian cancers (Tse et al., 2002). In fact, up to 40% 
of SEMA3B allele losses on chromosome 3 contribute to the progression of some 
types of cancers like lung, renal, breast and cervical carcinomas. These allele losses 
of SEMAB gene impaired different cellular processes such as stimulation of apoptosis 
and inhibition of angiogenesis (Senchenko et al., 2004). SEMA3B shares the same 
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structure as all semaphorins including the NH2-terminal highly conserved sema 
domain and has a basic domain at the COOH terminal (Roskies, 1998).  
SEMA3B has a recognition site for pro-protein convertases (PPCs) which is 
susceptible to cleavage by proteolytic activity. Cleavage at this site generates a 51-60 
kDa of SEMA3B protein which has been suggested to be an inactive form of SEMA3B 
(Varshavsky et al., 2008).  
1.10.1 SEMA3B receptors and signaling 
The main receptors for SEMA3B are plexins A1, A2 and A4, and neuropilins (NP1 and 
NP2), which serve as mediators for its biological function through receptor complex 
formation (Gaur et al., 2009, Sabag et al., 2014). NP1 and NP2 both interact with 
SEMA3B by providing a binding site for the semaphorin while plexins are required for 
enhancement of signal transduction such as stimulating kinase activities (Nakamura 
and Goshima, 2002). By forming a receptor complex with neuropilins, SEMA3B is able 
to induce apoptosis in cancer cells, and is thought to be able to regulate their survival, 
migration and cell proliferation (Castro-Rivera et al., 2008). This is thought to be 
through inhibiting P13K and therefore inactivating AKT signaling leading to decrease 
cell survival and cell proliferation (Butti et al., 2018). SEMA3B also inhibits VEGF165 
angiogenic activity, although whether it is through competition for NP1/2 binding or 
through stimulating different signalling pathways remains to be elucidated. NP1 also 
serves as a co-receptor for SEMA3B for axonal guidance during development of 
embryos (Tse et al., 2002, Bielenberg et al., 2006). 
However, the role of specific plexins in SEMA3B signalling is not fully understood. 
Previous studies have shown that plexin A1 is required alongside NRCAM, an 
adhesion molecule, for the transduction of SEMA3B signals for commissural axon 
guidance in vertebrates during nervous system development (Nawabi et al., 2010). 
Interestingly there is now some data suggesting plexin A4 is required for SEMA3B 
complexes and inhibition of plexin A4 expression nullifies SEMA3B signalling in 
endothelial and glioblastoma cells (Sabag et al., 2014). Unlike SEMA3A that signals 
through NP1 alone, SEMA3B signals through NP2 as well and this interaction appears 
to require plexin A2 (Sabag et al., 2014). Interestingly, a transcription factor of GATA3, 
which can be used as a marker of breast cancer as it helps to increase the maturation 
of precursor cells into breast epithelial cells, was found to be targeted by SEMA3B 
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resulting in suppression of breast cancer metastasis by phosphorylation and activation 
of LIMK1 and LIMK2 kinases (Shahi et al., 2017). Therefore, although the signaling 
pathways are not entirely clear it is evident that the specific plexin involved confers the 
specificity of the resultant SEMA3B signaling pathway. 
1.10.2 Regulation of SEMA3B 
Regulation of SEMA3B gene expression occurs in many different ways. Several 
studies have found that in different types of cancer such as neuroblastoma, lung 
cancer, renal cell carcinoma and oral squamous cell carcinoma there is methylation or 
hypermethylation of the CpG island/promoter region of SEMA3B resulting in loss of 
function of the gene (Grote et al., 2005, Nair et al., 2007, Loginov et al., 2009, Wang 
et al., 2013). Indeed, Nair et al.,2007 discovered that CpG islands in the promoter 
region of SEMA3B were highly methylated in neuroblastoma cell-lines that exhibit a 
3q loss (about 95%) or in tumours without 3q loss (52%), suggesting a two hit 
mechanism for loss of function i.e. deletion and hypermethylation. Loss of function due 
to methylation was confirmed by treating the neuroblastoma cells with demethylating 
agents which resulted in some level of SEMA3B expression (Nair et al., 2007). Loginov 
et al. (2009) also discovered a high frequency of methylation in the SEMA3B CpG 
island which inversely correlates with the expression level of SEMA3B mRNA in clear 
cell renal cell carcinoma.  
In addition to 3q deletion and hypermethylation which both lead to loss of function or 
inactivation, SEMA3B is also regulated through cleavage by furin, a pro-protein 
convertase which is a calcium-dependent serine endoprotease (Ito et al., 2005, 
Varshavsky et al., 2008). Importantly, processing of some SEMA3 proteins, namely 
SEMA3A and SEMA3E, by furin resulted in about a 40% reduction in their 
effectiveness to inhibit VEGF function (Parker et al., 2013) and therefore reduced their 
functional activity. Normally furin as a pro-protein convertase facilitates the conversion 
of inactive proteins such as some metalloproteinases to the active form (Tellier et al., 
2007), however, it appears that here furin generally converts active SEMA proteins to 
inactive forms depending on the cleavage site, thereby suggesting an alternative 
pathway for regulation of semaphorins by furin. Furin and the family of furin-like pro-
protein convertases will be discussed in more detail later in this chapter. 
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1.10.3 SEMA3B effect on normal cells  
Semaphorins such as SEMA3B are expressed in many normal cells such as 
endothelial and neuronal cells, as well as cancer cells as previously stated. The 
ubiquitous expression of this protein suggests it plays a cellular role that is critical to 
the survival of certain normal cells. Indeed, SEMA3B is implicated in physiological 
functions including endothelial development and control of the immune system (Kruger 
et al., 2005). SEMA3B is expressed by endothelial cells, suggesting that SEMA3B can 
regulate endothelial cell functions in an autocrine manner by transducing signals that 
compromise endothelial cell survival (Kruger et al., 2005, Guttmann-Raviv et al., 2007, 
Staton et al., 2011). Moreover, the expression of SEMA3B is high in normal breast 
epithelium compared to invasive breast cancer (Staton et al., 2011). It remains unclear 
whether or not SEMA3B is maintaining mammary gland homeostasis in these 
circumstances. However, SEMA3B has a potential autocrine function by promoting 
luminal epithelial cell differentiation and could therefore function as a safeguard for 
cellular function (Shahi et al., 2017). 
In addition, SEMA3B is expressed in the floor plate region of the spinal cord in rat 
embryos and it has been found to play a critical role in commissural axon directional 
growth (Zou et al., 2000). Because of the lack of decussated commissural axons in 
the floor plate at the embryo stage, it was suggested that SEMA3B could be playing a 
role in directing axons into appropriate tracts. In fact, in vitro explant assays have 
shown that commissural axons become sensitive to floor plate secreted factors as 
mimicked by COS7 cells secreting SEMA3B (Zou et al., 2000). Recently it has been 
demonstrated that mice lacking SEMA3B presents commissural defects where the 
axons fail to cross the midline and turn prematurely, further reinforcing its role in axon 
guidance (Nawabi et al., 2010).  
Villous cytotrophoblasts (CTBs) are present in the placenta and they differentiate to 
establish the maternal interface. They also differentiate into aggressive endothelial–
like cells invading the uterus and surrounding vasculature so as to re-route a blood 
supply to the placenta (Zhou et al., 2013). CTBs have been found to express high 
levels of SEMA3B in pre-eclampsia and  this has been corroborated in a study by Zhou 
et al. (2013) where they discovered that adding exogenous SEMA3B to CTB reduces 
the invasiveness of the cells to create a pre-eclampsic phenotype. In addition to this, 
they discovered downregulation of VEGF signaling via PI3K/AKT signaling as 
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discussed earlier. Like endothelial cells, CTBs express VEGFRs and other cell surface 
receptors and the downregulation of VEGF signaling by SEMA3B could result in 
SEMA3B-neuropillin mediated internalization of VEGFR resulting in reduced vascular 
processes that cause pre-eclampsia. Here, SEMA3B expression seems to play a 
negative role thereby causing the development of preeclampsia and a reduced 
expression may be required for normal VEGF signaling to prevent pre-eclampsia. 
1.10.4 Cellular and tissue expression of SEMA3B and its effect in cancer 
Expression of SEMA3B mRNA in different cancer cells and tissues have been 
analyzed. Chen et al. (2014) demonstrated that the expression level of SEMA3B 
mRNA was higher and the methylation status was lower in normal gastric cells than in 
gastric tumour cells. Interestingly, of all the semaphorins, only SEMA3B is 
predominantly expressed in normal ovarian tissue and this expression goes down in 
invasive ovarian cancer (Sekido et al., 1996, Joseph et al., 2010). In addition to this, it 
was found that the majority of SEMA3B expression in breast cancer is high in the duct 
of normal breast tissues but significantly reduced in invasive breast cancer (Staton, 
2011). Likewise, similar studies have found that SEMA3B expression was higher in 
normal lung tissue compared to invasive forms of lung cancer (Castro-Rivera et al., 
2004). SEMA3B mRNA levels are decreased in many cancer cell-lines, for instance in 
small and non-small cell lung cancer (NSCLC) and it has been shown that SEMA3B 
suppresses the growth of a NSCLC cell-line and tumour development in an 
immunodeficient mouse model (Pronina et al., 2009). An in vitro study carried out on 
four different gastric cancer cell-lines showed that mRNA expression of SEMA3B was 
lower than in the normal cell-lines utilized (Chen et al., 2014). This low expression 
level may be linked to the high methylation of SEMA3B promoter found through 
bisulphite sequencing in the same study, since high methylation of promoters results 
in low mRNA expression. From all indications, expression of SEMA3B seem to be 
significantly reduced in cancer cells when compared with normal cells.  
1.10.5 SEMA3B in breast cancer  
There are relatively few studies investigating the role and expression of SEMA3B in 
breast cancer. Staton et al.,(2011) found a significantly higher cytoplasmic expression 
of SEMA3B protein in normal breast epithelial cells compared to invasive breast 
cancer cells. This is supported by the findings of the study by Pronina et al.,(2009), 
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where they found reduced SEMA3B mRNA expression in breast cancer cell-lines and 
primary breast tumour cells. However, comparing SEMA3B mRNA expression in 
normal cells and six different breast cancer cell-lines used in their study, shows 
SEMA3B mRNA level was significantly decreased in breast cancer cell lines by 10-
250 fold compared to normal cells (Pronina et al., 2009).  
In a study by Castro-Rivera et al. (2004), using conditioned medium containing full 
length SEMA3B, growth inhibition of a breast cancer cell-line was observed. They also 
demonstrated that SEMA3B inhibits VEGF-dependent cell growth in a VEGFR-
independent manner using an MDA-MB-231 breast cancer cell-line that does not 
express VEGFR. This pattern is in agreement with a recent study that demonstrated 
an angiogenic signature of low expression of SEMA3B with high expression of VEGFA 
in MDA-MB-231 cells, suggesting an important role of the angiogenic factors in the 
triple negative breast cancer cell-line (Bender and Mac Gabhann, 2013). Given that 
SEMA3B may compete with VEGF for binding to NP co-receptors, this pattern of gene 
expression may promote tumour progression. Indeed, patients that exhibit this type of 
VEGF-SEMA3B signature have poor prognosis irrespective of their triple negative 
status (Bender and Mac Gabhann, 2013). 
Akt is a critical factor in the regulation of phosphatidyl inositol 3-kinase (PI3K) pathway 
of cell survival in cancer cells. Recent evidence showed that the Akt signaling pathway 
which promotes tumour cell proliferation in lung and breast cancers is inactivated by 
SEMA3B through NP1 (Castro-Rivera et al., 2008). In this study, breast cancer cell-
lines knocked down in NP1 and expressing active Akt were found to be insensitive to 
SEMA3B while they became sensitive to SEMA3B when NP1 was exogenously 
expressed. This suggests that the NP1-SEMA3B complex formation is essential for 
SEMA3B activity in inhibiting Akt signaling pathway to induce apoptosis in cancer cells. 
These findings also highlight the role of SEMA3B in tumour-inhibitory function and 
inhibition of proliferation. 
However, in contrast to this, another study found that even though SEMA3B could 
suppress tumour growth, it could trigger prometastatic signaling by releasing 
interleukin 8 (IL8) via the activation of p38-MAPK pathway on NP1-dependent manner 
in breast cancer cell-lines (Rolny et al., 2008). As such if SEMA3B is expressed in 




A role for SEMA3B in the p53-dependent apoptotic pathway has also been highlighted 
as SEMA3B seems to function as a tumour growth suppressor by inducing apoptosis 
of premalignant and malignant cells via Akt inhibition. A study showed increased 
SEMA3B expression in breast cancer cells deficient in p53 when the cells were treated 
with UV and doxorubicin (Ochi et al., 2002). These studies suggest SEMA3B may be 
mediating a p53 independent DNA damage response since p53 is normally 
upregulated during DNA damage. Even though most of these studies were descriptive 
analysing expression of SEMA3B without investigating the in-depth mechanism, 
evidence from these studies further suggests that SEMA3B may be involved in breast 
cancer pathogenesis. 
1.10.6 SEMA3B regulation in breast cancer pathogenesis 
One of the first lines of evidence that SEMA3B may play a crucial role in the 
pathogenesis of breast cancer is the detection of frequent deletion of the 3p21.3 
chromosomal location through genetic mapping of breast tumours, premalignant 
lesions and breast cancer cell-lines (Lerman and Minna, 2000). In a later study using 
genetic mapping with polymorphic microsatellites that are specific to the 3p location, 
there was allelic imbalance due to loss of a section of the chromosome that may likely 
house some tumour suppressors (Ingvarsson et al., 2015). Several earlier studies 
confirmed this observation (Ji et al., 2002, Hesson et al., 2004, Senchenko et al., 
2004). In addition to allele deletion, hypermethylation of the SEMA3B promoter 
correlates with the progression of different cancers (da Costa Prando et al., 2011) and 
this may also be the case for breast cancer. Promoter methylation in breast cancer 
has not been widely studied but one in vitro methylation study using seventeen 
different breast cancer cell-lines and three other non-tumourigenic breast cell-lines 
including 184A1, 184B5 and MCF-10A, showed that hypermethylation of CpG Island 
gene cluster containing SEMA3B results in reduced expression of SEMA3B (da Costa 
Prando et al., 2011). As a consequence of this, the hypermethylation of the CpG Island 
is regarded as a potential factor for altering SEMA3B expression, and hence, a cancer 
progression marker in breast cancer. These data suggest that SEMA3B expression is 
down-regulated in breast cancer via two mechanisms, allelic loss and promoter 
hyermethylation. Despite this some breast cancers do express SEMA3B (Staton et al., 
2011). However, other work has suggested that SEMA3B can also be cleaved by furin 
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(Varshavsky et al., 2008), and potentially other proteases and it is not clear whether, 
when SEMA3B is expressed in breast cancer, it is cleaved and therefore inactive. 
1.11 Proteases 
Proteases, commonly called peptidases, are a family of enzymes that regulate 
proteolytic events in cellular mechanisms. They have an important role in the post-
translational processing of various inactive proteins to bioactive molecules by 
hydrolysis of peptide bonds producing new, active, protein products. Proteases are 
categorised based on the mechanism of catalysis and the nucleophilic amino acid in 
the active site involved in proteolysis, into six main families including serine, cysteine, 
threonine, aspartic, glutamic and metallo-proteases (Lopez-Otin and Bond, 2008). 
Serine proteases contain a serine residue in the active site and this plays the 
nucleophilic role of attacking the bound peptide/protein thereby catalysing the 
hydrolysis reaction. Similarly, cysteine proteases have cysteine residues in their active 
site and have been known to be involved in programmed cell death and immunity. 
Aspartic proteases have a pair of aspartic acids in the active site that work together to 
catalyse the cleavage of peptide bonds. Examples of aspartic proteases are renin, 
which is known to control blood pressure, and pepsin that is found in the digestive 
system. Metallo-proteases have metal residue in their active site, which are 
responsible for increasing the nucleophilic capability of the enzyme. Importantly, most 
proteases are synthesised as an inactive form (zymogen) and by the mechanism of 
proteolysis they are activated through removal of a small peptide (Lopez-Otin and 



























Figure 1.5: Classification of proteases. Proteases are classified based on the 
chemical structure of their active site. Each class has a chemical structure of the core 
residue in their active site. Six known distinct classes are described: serine, cysteine, 
threonine, aspartic and metallo proteases. Serine proteases are grouped into five 
classes, Trypsin-like, Chymotrypsin-like, Elastase-like, Thrombin-like and Subtilisin-
like proteases. Subtilisin-like proteases are also classified into three main groups, 
Kexin-like, including PCSK1, PCSK2, Furin, PCSK4, PCSK5, PCSK6 and PCSK7, 




1.11.1 Proteases mechanism of action  
Serine proteases are included in biological processes such as digestion, blood 
coagulation and immunity and are the most common type of protease. They are 
characterised based on their substrate specificity into different classes including 
trypsin-like proteases, chymotrypsin-like, thrombin-like, elastase-like and subtilisin-like 
etc. All of these classes cleave peptides by a similar mechanism of action but their 
differences are in their regulation and specificity (Lopez-Otin and Bond, 2008, Page 
and Di Cera, 2008).  
Serine protease enzymes are able to cleave peptide bonds in a protein to activate it, 
to increase the rate of chemical reactions without being consumed by the reaction, as 
well as helping to breakdown large proteins into small fragments. The active site of the 
enzyme contains three different residues that act together to promote and catalyse the 
cleavage of peptide bonds, and this collection of three amino acids is known as a 
catalytic triad. The catalytic triad is considered the main player in the serine proteases 
catalytic mechanism and consists of serine 195, histidine 57 and aspartate 102 that 
are essential for the active site of enzyme (Polgar, 2005). These amino acids are 
located distant from each other on the sequence but due to protein folding are held in 
close proximity; this closeness and the flexibility of the enzyme play an important role 
in the catalytic action (figure 1.6, step 1 and 2). The binding of the substrate to the 
enzyme occurs in the S1 pocket of the enzyme, which is known to give enzyme 
specificity and is responsible for holding the protein that is going to be cut (figure 1.6, 
step 3). There are two different phases taking place in this action, first is the positioning 
step in which a polypeptide chain aligns itself in the active site of the enzyme that 
contains serine, histidine and aspartic acid. By this binding, the structure of the 
enzyme will slightly change altering the proximity of the aspartic acid and histidine side 
chains (Polgar, 2005) (figure 1.6, step 4). The negative charge on oxygen molecule of 
aspartic acid will make it closely move to histidine, changing the electron configuration 
of nitrogen molecule of histidine and grabbing the hydrogen from serine, enabling the 
catalytic mechanism to start. Consequently, the –OH proton of serine is binding to 
nitrogen molecules of histidine ring, leading the oxygen of serine to have a negative 
charge and that called alkoxide ion (figure 1.6, step 5). Alkoxide ion is generating 
nuclephilic attack on carbonyl carbon of peptide bond, leading to rearrangement of 
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molecules, which make these molecules unstable due to having a single bond 
between carbon and oxygen molecules (figure 1.6, step 6). 
In order to deal with this instability, the oxyanion hole in the enzyme helps the 
molecules to fall apart easily (figure 1.6, step 7). At this stage, the hydrogen of histidine 
will take the nitrogen of the substrate, yielding a tetrahedral intermediate resulting in 
the bond between the carbon and nitrogen of the substrate breaking, and therefore 
part of this protein will be free to do its business while the other part will be attached 
to serine by a covalent bond (figure 1,6, step 8). The covalent bond then has to be 
broken in order for the original protein to be released. In order to do this, H2O comes 
into the active site and the nitrogen of histidine will attack the proton of the water, 
leading to activated hydroxide which will attack carbonyl carbon and rearrange the 
electronic environment generating tetrahedral intermediate again (figure 1.6, step 9). 
This results in breaking bonds between the protein and serine and completing the 
process (Polgar, 2005, Page and Di Cera, 2008). 
Most protease classes such as cysteine, asparatic acid and metallo-protease function 
in a similar way with slightly different nucleophilic agents present in the active site. 
Cysteine proteases use cysteine as a nucleophilic residue to cleave the peptide bond. 
As the cysteine nucleophile is not strong enough on its own, it is activated by the action 
of histidine. On the other hand, aspartic acid proteases contain a highly conserved 
pair of aspartic acid residues that work together to transform the water into a good 
nucleophilic agent that can hydrolyse peptide bonds. Metallo-proteinases have a metal 
atom in the active site to bind the water and transform it into a more capable 
nucleophile so the water can hydrolyse the peptide bonds. Importantly, metallo-
proteinases and asparatic acid proteases use water as the nucleophile to break 
peptide bonds while the others use their own collection of amino acids to hydrolyze 
peptide bonds (Page and Di Cera, 2008).  
As serine proteases are the most abundant proteases and furin, which is thought to 
cleave SEMA3B is a serine protease, this project will focus on the family of serine 

































Figure 1.6: Catalytic mechanism. Steps of the catalytic reaction by the catalytic 
triad of serine protease. The nucleophile residues Ser, His and Asp are shown in 
step 1 where folding of polypepties chain of enzyme takes place. The initial step of 
activation of catalytic triad is shown in step 2. During the catalytic reaction process, S 
pocket is holding on a substrate to be cut is shown in step 3. Binding of substrate to 
enzyme, leading electronic configuration of His as shown in step 4. These changes 
creating alkoxide ion on Ser, resulting in negatively charged oxygen ion of the 
tetrahedral intermediate generated in steps 5, 6 and 7, which are stabilized by the 
oxyanion hole, releasing half of polypeptide shown in step 8. The other half link to Ser 




1.11.2 Subtilisin-like pro-protein convertases  
The subtilisin-like pro-protein convertases are a family of calcium and pH-dependent 
serine endoproteases that are responsible for protein cleavage and maturation. 
Subtilisin-like pro-protein convertases function via autocatalytic cleavage of their N-
terminal region, which they activate to mediate their functionality. The abnormal 
activation and production of pro-protein convertases has been associated with tumour 
progression. PPCs are inhibited by some inhibitors that can bind to the active site of 
enzymes and this is usually an irreversible inhibition. Several strategies aiming at 
inhibiting the activity of pro-protein convertase rely on competitive inhibition of PPCs 
activity using various protein-based inhibitors. α1-PDX, CMK, and the pro‐segments 
are some examples of these inhibitors (Basak, 2005). Most of the precursor proteins 
bind and cleave at a general consensus motif at paired basic residues Lys(K)-Arg(R) 
or Arg(R)-Arg(R) to generate a mature form such as growth factors, certain receptors, 
bacterial toxins and viral surface glycoproteins such as gp160 (Seidah et al., 1998).  
The Pro-protein convertase (PPC) family comprises nine members that were identified 
according to their structure and cleavage motifs (Seidah and Chrétien, 1999). Seven 
of these PPCs have been identified to cleave their substrates at single or paired basic 
residues at (RK)-(X)n-(KR)↓, where X= any amino acids and n = the number of amino 
acids 0,1,2,4 or 6 and the downward arrow emphasises the cleavage position. These 
seven PPCs are PCSK1 (also known as PC1/3), PCSK2 (also referred to as PC2), 
Furin (also known as PC3), PCSK4 (also referred to as PC4), PCSK5 (also known as 
PC5/6), PCSK6 (also called PACE4) and PCSK7 (also called PC7). PCSK8 (also 
called subtilisin kexin isoenzyme-1 “SKI-1” and also known as site-1 proteases “SIP”) 
is a pyrolysin-like protease and cleaves its substrate at a non–basic residue sequence 
(R/K)X(V/L/I)Z↓, where Z is any amino acid except Val, Pro, Cys, Glu, or Asp, and the 
spacer X is often a basic residue (Seidah et al., 2013). The final family member is 
PCSK9, which also belongs to the proteinase K family (also known as neura 
apoptosis-regulated convertase-1 NARC-1). This protein cleaves itself once in the 
endoplasmic reticulum at the sequence Val-Phe-Ala-Gln152↓ (VFAQ152↓) within its 
pro-segment (Seidah et al., 2014). Importantly, all of these PPCs are responsible for 
orchestration of a series of events involving proteolytic cleavage that is a crucial step 
in the activation of many secreted proteins (Seidah and Chrétien, 1999, Seidah et al., 
2008, Seidah et al., 2013). 
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1.11.3 Tissue distribution and cellular localisation of pro-protein convertases 
PPCs are expressed in most mammalian cells where they play an important role in 
cleavage of their substrates within the constitutive or regulated pathways (Seidah and 
Prat, 2012) (table 1.2). 












PCSK1 Neuroendocrine Secretion granules   Implicated in diabetes and obesity 
(Creemers et al., 2012). 
PCSK2 Neuroendocrine Secretion granules   Diabetes (Leak et al., 2007). 
Furin Ubiquitous in 
many tissues  
TGN, cell surface & 
endosomes 
Responsible for activation of some 
viral infections e.g. HIV 
(Hallenberger et al., 1992) and has 
a role in tumour progression (Jaaks 
and Bernasconi, 2017). 
PCSK4 Expressed in 
germ cells, testis, 
placenta, and 
ovary 
Cell surface Linked with infertility in male and 
has a role in fertilization, and 
embryonic development (Gyamera-





PCSK5 a: secreted through 
the regulated secretory 
pathway. 
PCSK5 b: active at cell 
surface and extracellular 
matrix 
Implicated in cancer including lung, 
head and neck cancer and viral 






Cell surface and 
extracellular matrix 
Implicated in arthritis pain (Malfait 
et al., 2012) and cancer (Couture 
et al., 2017). 
PCSK7 Ubiquitous TGN, cell surface, 
endosomes 
Implicated in cancer (Demidyuk et 
al., 2013) and in iron metabolism 
(Guillemot et al., 2013). 
PCSK8 Ubiquitous cis- and medial-Golgi Implicated in viral infection and 
cholesterol metabolism (Seidah et 
al., 2013). 
PCSK9 Liver, intestine, 
kidney 
TGN, extracellular Implicated in lipid and cholesterol 
metabolism (Dubuc et al., 2004) 




1.11.4 Pro-protein convertases structure  
All PPCs have multiple domains and share a similar N-terminal structure with a slightly 
variable C-terminal resulting in differing biological function. Each protease has an N-
terminal pro-peptide that consists of a signal peptide that is necessary to direct the 
precursors to the appropriate cellular compartment, and for entry of PPCs into the 
endoplasmic reticulum where these enzymes are processed for releasing within the 
secretory pathway. This signal peptide is followed by a pro-domain or pro-segment 
domain consisting of 80-90 residues, which acts to mediate correct folding of the 
proteins as well as acting as a competitive inhibitor for the enzymatic activity until it is 
released by cleavage (Artenstein and Opal, 2011). Subsequently the first cleavage is 
usually after the pro-domain. Downstream of the pro-domain, the catalytic domain is 
located including the catalytic triad of serine, histidine and aspartic acid. Following the 
catalytic domain, all the PPCs, except for PCSK9, have a P-domain that helps the 
correct folding and stability of the enzyme in the endoplasmic reticulum and regulates 
Ca+ and pH. Following these largely conserved domains, the carboxyl terminal (C-
terminal) of each PPC is less conserved and they have unique sequences controlling 
their subcellular routing and trafficking, in addition to its role in substrate binding (figure 
1.7) (Gensberg et al., 1998, Page and Di Cera, 2008).  
Some PPCs like furin, PCSK5 and PCSK6 contain a cysteine rich domain (CRD) 
consisting of repeats of a cysteine rich domain containing multiple cysteine residues. 
which is involved in regulating the activity of the PPCs. Moreover, furin, PCSK5, 
PCSK7 and PCSK8 have a transmembrane domain and cytosolic domain which both 
are involved in directing PPCs sorting and transit control within cell compartments in 
addition to direct cell surface tethering, while some PPCs such as PCSK1, PCSK2, 
PCSK4 and PCSK7 contain a ser/thr rich region, which is highly glycosylated and this 
domain is important for cell surface exposure, instead of the CRD. PCSK9 is unique 
as it possesses a cysteine-histidine rich domain (CHRD), which was found to be 
important for binding of the protein to low-density lipoprotein receptor (LDLR) and the 


























Figure 1.7: Schematic representation of the pro-protein convertases structure. 
All PPCs are kexin-like basic amino acid (aa) except PCSK8, which is pyrolysin-like 
and PCSK9, which is proteinase-like. The presence of a signal peptide, a pro-domain 
and catalytic domain is conserved in all convertases that display where the catalytic 
triad occurs. The C-terminal domain of each PPC has unique sequences regulating 
their cellular localization and trafficking. CHRD = Cys-His-rich domain. Reproduced 




1.11.5 Pro-protein convertases activation  
Most proteases are synthesized as an inactive form and these inactive enzyme 
precursors are known as zymogen or proenzymes. These proenzymes are present in 
endoplasmic reticulum (ER) as full-length proteins, and two cleavages need to take 
place in order for the PPCs to be fully activated. The first cleavage occurs between 
the pro-domain and the catalytic domain and takes place in the ER. However, the 
enzyme will not be activated by this event, as the pro-domain will remain attached to 
the catalytic domain thereby acting like an inhibitor. The complex of pro-domain and 
the rest of the molecule then exit the ER moving to the Golgi apparatus to be 
processed by a second cleavage in order to generate the active enzyme. The second 
cleavage is Ca+ and pH dependent, and occurs in the trans Golgi network, completely 
removing the pro-domain thereby activating the catalytic domain (Polgar, 2005, Page 
and Di Cera, 2008). Following this, PPCs transport to either the plasma membrane for 
secretion, lysosomes (for endocytosis) or return to the ER using the KDEL sequence 
(figure 1.8). KDEL sequence contain four amino acids located at the C-terminal of 
proteins that acts as a signal for localization of proteins to the lumen of the ER. Most 
PPCs are activated similarly to each other, but some have slight differences. For 
example, PCSK2 needs 7B2 binding protein as a chaperone for activation, with the 
complex of PCSK2 and 7B2 undergoing an autocatalytic cleavage in the trans-Gogli 
after they exit from ER. Furthermore, PCSK1 and PCSK2 are generated and activated 
late in the secretory granules due to replacement of the oxyanion hole ASN residue 
with ASP in their structure (Seidah et al., 2008). 
PPCs are secreted via two different pathways, and in both types of secretory 
pathways, all proteins exit from the trans-Golgi network and are then secreted via the 
constitutive or regulated pathways. In the constitutive pathway, the protein is contained 
in a vesicle, which will fuse to the cell membrane in order to release the protein 
molecules outside the cells. This pathway is considered to be the default pathway for 
the secretion of proteins (Gensberg et al., 1998). In contrast, the regulated pathway 
usually involves the protein being sorted and held in vesicles until an extracellular 
signal triggers and stimulates their secretion. In the PPC family, PCSK1, PCSK2 and 
PCSK5a are secreted from the cell in a regulated manner whereas furin, PCSK4, 
PCSK5b, PCSK6, PCSK7 and PCSK8 are active in TGN and secreted via constitutive 
vesicles, with the exception of PCSK9 as the inhibitory pro-domain remains attached 
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tightly with the catalytic domain, indicating that the circulating PCSK9 is enzymatically 
inactive due to this association, and only in an acidic compartment, PCSK9 can 
enhance degradation of its substrate (Zhou et al., 1999, Dikeakos et al., 2007, Seidah, 
2017).  
To summarise, the PPC family are serine proteases, which are released from cells to 
cleave proteins at specific sites to activate or inactivate them. Many of them are up-
regulated in cancer and may therefore have a specific role in cancer. Furthermore, 
furin is thought to potentially cleave SEMA3B thereby inhibiting its activity as a tumour 











































Figure 1.8: Activation of pro-protein convertases. Different processes are used by 
the pro-protein convertases to be activated. PPCs are initially synthesised as inactive 
precursors, and specific processing is required to convert these pro-proteins into 
active forms. All the maturation steps of PPCs start in the ER, where the first 
autocatalytic cleavage occurs. The zymogen of PPCs contains a signal peptide, a pro-
domain, a catalytic domain, a P domain and a cytoplasmic tail. After the first cleavage, 
the pro-domain remains attached to the catalytic domain and act as an inhibitor. PPCs 
require proteolytic removal of the inhibitory pro-domain to become proteolytically 
active enzymes. The second cleavage takes place in Golgi in Ca+ and pH-dependent 




1.12 Furin an essential convertase  
Furin is a calcium-dependent serine endoprotease, which needs approximately 1mM 
of calcium for full activity, and it is considered a key member of the pro-protein 
convertase family as it is expressed in many tissues throughout the body in both 
vertebrates and invertebrates. Its name, furin, refers to the encoded gene, which is 
known as fur. It is located on chromosome 15q26.1 and the protein is 794 aa in length  
(Paleyanda et al., 1997) (figure 1.7). Furin is initially synthesised as an immature 
inactive 100 kDa protein, which is cleaved to 98 kDa by removing the pro-domain at 
the Arg-Ala-Lys-Arg site (residues 104–107), and this is inactive due to the remainder 
of the pro-domain attached to the catalytic domain. The second cleavage takes place 
after Leu at the C-terminal of furin, generating two fragments with different molecular 
weights at 84 kDa and 60-70 kDa. Both forms are active, however the 84 kDa fragment 
is considered less active due to the lack  of the transmembrane domain whilst the 
fragment detected at 60-70 kDa arises from additional cleavage(s) in the cysteine-rich 
region and indicates an active mature form of furin (Paleyanda et al., 1997). The way 
furin processes the proteins and cycles between the trans Golgi network and the cell 
surface via the constitutive secretion pathway makes it important and has a role in the 
maturation of bioactive peptides and proteins in both the exocytic and endocytic 
pathways (Plaimauer et al., 2001). 
Several studies have demonstrated high furin activity in different cancers correlating 
with cancer aggressiveness and malignancy (Bassi et al., 2003, Siegfried et al., 2003). 
In addition, furin is expressed at low levels in normal tissues and at higher levels in 
cancers including lung and breast (Cheng et al., 1997). In agreement with a potential 
role of furin in cancer progression, other studies have suggested that inhibition of furin 
expression correlates with reduced cancer growth (Bassi et al., 2001a, Coppola et al., 
2008). Varshavsky et al. (2008) showed that furin cleaves SEMA3B into 61 kDa and 
20 kDa inactive fragments, which resulted in inhibition of the SEMA3B antiangiogenic 
effects. Treating the cancer cells with furin like pro-protein convertase inhibitor resulted 
in restoring the full-length form of SEMA3B (83 kDa-active form). This group 
suggested that furin was responsible for cleavage of SEMA3B (Varshavsky et al., 
2008), however, the inhibitor used could inhibit other PPCs so it may not be furin that 




 1.13 Pro-protein convertase 1 (PCSK1)  
PCSK1 which is also called prohormone convertase PC1/3, is encoded by the Pcsk1 
gene which is located on chromosome 5q15 and is expressed as a 753 aa zymogen. 
PCSK1 undergoes cleavage in the ER like other PPCs to become active. It is released 
to the cell surface via the regulated secretory pathway and stored in secretory 
granules. PCSK1 is expressed in most of the neuroendocrine tissues and has a role 
in the activation of brain functions as it has been demonstrated that the expression of 
PCSK1 mRNA is high in the anterior subdivisions of the thalamus (Seidah and 
Chrétien, 1999, Podvin et al., 2018). However, it is mostly found in endocrine and 
neural tissue as well as in pituitary (Seidah and Chrétien, 1999). 
In addition to the normal structure of PPCs, PCSK1 has Serine/Threonine-rich region 
at its C-terminal, which helps in sorting of PCSK1 into secretory granules (figure 1.7). 
The cleavage of the 94 kDa proPCSK1 generates two forms of proteins, 87 kDa which 
represents an enzymatically active form and a more completely cleaved 74-66 kDa 
form, which is much more functionally active than the 87 kDa form, but is less stable 
(Zhou and Lindberg, 1994, Seidah and Chrétien, 1999). PCSK1 is known to cleave 
several important substrates like pro-insulin, pro-opiomelanocortin, pro-renin, pro-
enkephalin, so it is not surprising that it is linked to various human diseases. For 
example, the expression of PCSK1 has been associated with early onset of obesity, 
as a PCSK1 mutation resulting in loss of PCSK1 activity increases the risk of obesity 
(Creemers et al., 2012).  
High expression of PCSK1 mRNA was found in small cell lung carcinoma (SCLC) with 
no expression found in non-SCLCs and normal lung (Creemers et al., 1992), 
suggesting a role in SCLC progression. Similarly, another study demonstrated 
increased PCSK1 protein expression in colon cancer and liver metastasis compared 
to the normal liver (Tzimas et al., 2005). As of yet the expression of PCSK1 has not 




1.14 Pro-protein convertase 2 (PCSK2)  
PCSK2 (also known as prohormone convertases PC2) is localized on chromosome 
20p12.1. The PCSK2 mRNA is translated into 619 aa and undergoes autocatalytic 
cleavage steps before it becomes fully active. PCSK2 is initially synthesised as an 
immature 75 kDa protein, which is then cleaved to mature PCSK2 (64-68 kDa) (Mbikay 
et al., 1997, Tzimas et al., 2005). However, this maturation process is extremely slow 
compared with other member of PPCs. For the intercellular maturation of PCSK2, it 
needs to bind to another protein namely 7B2 to be activated and is considered the 
only one member of PPCs that requires the presence of this protein for proper folding 
and maturation (Zhu and Lindberg, 1995). Despite the need for 7B2 for the activation 
of proPCSK2, 7B2 has also an inhibitory effect on PCSK2 function. Removal of the C-
terminal peptide of 7B2 leads to disable the PCSK2 processing and therefore inhibition 
of activity (Zhu and Lindberg, 1995). 
The expression of PCSK2 is largely limited to neuroendocrine tissues including the 
pancreatic islets (Mbikay et al., 1997). Since this protein is found mostly expressed in 
neuronal and endocrine cells, it is not surprising that it is associated with a 
neuroendocrine phenotype in some cancers. For example, PCSK2 mRNA was 
detected at high level in SCLCs, which show neuroendocrine features, more than in 
adenocarcinoma and squamous cell carcinoma (Mbikay et al., 1997). PCSK2 is also 
known to influence glucose homeostasis, and it has been involved in the cleavage of 
proinsulin to insulin. Any defect in this pro-hormone processing could lead to metabolic 
disorders and obesity, so it is not surprising the PCSK2 is linked to obesity (Anini et 
al., 2010, Leak et al., 2007). 
PCSK2 protein expression also was detected in much higher levels in 85% of 
pheochromocytomas tumours, a neuroendocrine tumour of the medulla of the adrenal 
glands, than in normal adrenal human tissue (Konoshita et al., 1994). However, in 
contrast, one previous study has shown that PCSK2 mRNA is not present in human 




1.15 Pro-protein convertase 4 (PCSK4)  
PCSK4 also known as PC4, SPC5 is located on human chromosome 19 and is 
translated into 755 aa. The lack of the secondary cleavage site in the pro-domain of 
PCSK4 makes it unclear how this protein becomes fully activated. Like other PPCs, 
PCSK4 cleaves its substrate at paired basic residues at (KR↓ and RR↓), however, it 
appears to cleave better at a monobasic site usually at a single R↓ residue (Gyamera-
Acheampong and Mbikay, 2009). PCSK4 is synthesised as a proPCSK4 82 kDa, 
which is then cleaved to different fragments ∼62 and 38 kDa. The fragment of 62 kDa 
is an enzymatically active protein with a high degree of efficiency. The fragment of 38 
kDa is also active but with less stability (Basak et al., 2008). The PCSK4 substrates 
are limited with only two substrates that have been shown to be processed by PCSK4. 
One of these is pituitary adenylate cyclase activating polypeptide (PACAP) which is 
produced during spermiogenesis and has a role in the reproductive system, where 
PCSK4 is known to be most highly expressed (Thomas et al., 2013). The other is 
proinsulin like growth factor (proIGFs-I and II), which is also thought to be processed 
by PCSK4, in part due to its role in localization in the testis (Basak et al., 1999).  
PCSK4 expression has been linked to fertility as its expression is limited to testicular 
cells in males, and ovarian and placenta cells in females (Gyamera-Acheampong and 
Mbikay, 2009). Indeed, a decrease in its expression in mice has been found to interfere 
with the ability of sperm to fertilize oocytes by reducing its ability to bind to the zone 
pellucide. Also in female mice, decreases in PCSK4 expression resulted in impaired 
folliculogenesis. All these findings suggest a role in reproductive physiology and in 
embryonic development. In contrast, the role of PCSK4 in the pathogenesis of cancer 
has not been clearly identified. To our knowledge there is only one study investigating 
this, which demonstrated that a defect in PCSK4 expression could be responsible for 
unprocessed insulin-like-growth factor II which is secreted from the tumour in a case 
of pleural solitary fibrous tumour. This, caused non-islet tumour hypoglycaemia, so it 
is possible that the low expression of PCSK4 could enhance pleural solitary fibrous 




1.16 Pro-protein convertase 5 (PCSK5) 
PCSK5 also known as PC5/6 is ubiquitously expressed in adrenal gland, uterus, brain, 
intestine, liver and lung and it is important for mammalian development. It is located 
on chromosome 9q21.13 and is translated into a 1860 aa protein. It has two identified 
alternatively spliced forms that are soluble PC5/6A (1860 aa) which is thought to 
regulate secretory granules, and membrane-bound PC5/6B (913 aa) which moves 
between the trans-Golgi network and the cell surface. Both transcripts share similar 
structures they both have a signal peptide, pro-segment, catalytic domain, P-domain 
and a cysteine rich domain (figure 1.7). In addition, PC5/6B has also a transmembrane 
domain and cytosolic domain that are important for sorting and direct cell surface 
tethering. PCSK5 is mainly active at the cell surface after the second auto-cleavage 
event in the Golgi apparatus (Artenstein and Opal, 2011). 
However, the role of PCSK5 in cancer has not been fully investigated. In colon cancer, 
the expression of PCSK5 was detected in three different colon cancer cell-lines HCT8, 
LS174T and ColoDM320 suggesting it may have a role in colon cancer (Rovere et al., 
1998). The study suggests that this role is via processing pro-neurotensin/neuromedin 
N (proNT/NN) which is a regulatory peptide known to promote carcinogenesis and 
stimulate the growth of human colon cancer cell-lines (Rovere et al., 1998). Moreover, 
high PCSK5 expression was also found in very aggressive lung cancer cell-lines as 
well as in head and neck cancer cells suggesting that PCSK5 might have a role in 
cancer development as its expression correlated with the aggressiveness of the 
cancer (Bassi et al., 2005). In contrast, one study showed that expression of PCSK5 
was decreased in endometrial cancer, perhaps suggesting that the role of PCSK5 in 
cancer progression is dependent on the cancer type (Singh et al., 2012). However, 
only one study has investigated the expression of PCSK5 in breast cancer where its 









1.17 Pro-protein convertase 6 (PCSK6) 
PCSK6, also called paired basic amino acid-cleaving enzyme 4 (PACE4) is the only 
member of the pro-protein convertase family to share a chromosome with furin as they 
are both located on chromosome 15. PCSK6 is highly expressed in the anterior 
pituitary, liver, kidney and pancreas (Nour et al., 2005). PCSK6 is a 969 aa protein, 
which is made up of a single peptide followed by pro-domain, the subtilisin-like 
catalytic domain, p-domain and cysteine-rich domain (figure 1.7). Its activity is found 
at the cell surface and it is constitutively secreted into the extracellular milieu (Nour et 
al., 2005). As most of PPCs, PCSK6 is initially synthesised as inactive zymogen (106 
KDa) that undergoes autocatalytic processing in the ER. Then, it undergoes a second 
cleavage to be active in the TGN at the cell surface as approximately 97 kDa (Mains 
et al., 1997, Nour et al., 2005). The mature protein of PCSK6 is found in a monomer 
form while in ER, it is found as a dimer suggesting an association between its cleavage 
and the tertiary or quaternary structure of the protein (Nagahama et al., 1998). PSCK6 
was shown to be overexpressed in non-small cell lung cancer (NSCLC) and their 
expression correlates with disease prognosis (Lin et al., 2015). Interestingly, the 
expression of PCSK6 was also shown to be involved in increasing invasiveness in 
breast and prostate cancer (Lapierre et al., 2007). Silencing of PCSK6 gene reduced 
proliferation of prostate cancer cells indicating the importance of this gene in the 
progression of this cancer (D'Anjou et al., 2011). Similarly, knockdown of PCSK6 in 
MDA-MB-231 breast cancer cells was associated with decreasing proliferation, 
migration and invasion of these cells suggesting its role in cancer progression (Wang 
et al., 2015). Furthermore, in oestrogen-receptor-positive breast cancer, inhibition of 
PCSK6 showed delayed tumour progression with a decrease in cell proliferation 
(Panet et al., 2017). 
PCSK6 can play an opposing role to furin in cancer development depending on the 
expression of other factors. For instance, expression of PCSK6 in a breast cancer cell-
line resulted in increased expression of matrix metalloproteinase 9 (MM9), a member 
of a group of proteins responsible for the turnover of protein in the extracellular matrix, 
and subsequent increase in the metastatic potential of the cell-lines. The effect of 
PCSK6 was abolished in the presence of furin expression in the same breast cancer 
cell-line (Lapierre et al., 2007, Seidah and Prat, 2012). The expression of PCSK6 
mRNA was detected in MCF-7, T47D and MDA-MB-231 cell-lines in similar 
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concentrations but undetectable in normal breast tissues suggesting the role that 
PCSK6 may have in inducing the pathobiology and progression of breast cancer 
(Cheng et al., 1997). 
1.18 Pro-protein convertase 7 (PCSK7) 
PCSK7 is a type‐I membrane‐bound protease, which is ubiquitously expressed in 
various tissues including neuroendocrine, liver and brain. It is located on chromosome 
11 and is translated into 785 aa. As with all other PPCs, the protein sequence has 
different domains including signal peptide, predomain, catalytic domain, P-domain and 
in addition to that, PCSK7 has a Ser/Thr rich region, transmembrane domain and 
cytosolic tail (figure 1.7). PCSK7 is activated in the trans-Golgi network and it reaches 
the cell surface by the constitutive pathway (Rousselet et al., 2011). PCSK7 plays an 
important role in in iron homeostasis and metabolism which may influence its 
regulation (Guillemot et al., 2013). PCSK7 has multiple physiological functions as it 
has the ability to process certain precursor proteins by activating growth factors such 
as EGF which suggests that PCSK7 may have implications in cancer growth by 
enhancing the activity of EGF receptor. The role of PCSK7 has been also identified in 
prostate cancer, knockdown of PCSK7 in the prostate cancer DU145 cell-line resulted 
in decreased tumour cell proliferation in vitro (Couture et al., 2012). Moreover, the 
inhibition of PCSK7 resulted in decreased progression of hepatocellular carcinoma 
(Declercq et al., 2015). In contrast, PCSK7 mRNA expression was decreased in 
human lung cancer suggesting different pathways of tumour development and 
progression could be involved (Demidyuk et al., 2013). In breast cancer, PCSK7 
mRNA was higher in cancer cell-lines than in normal breast tissues (Cheng et al., 
1997). Similarly, the expression of PCSK7 mRNA in MDA-MB-231 breast cancer cells 
was increased compared to an oestrogen-receptor-positive breast cancer cell-line 








1.19 Pro-protein convertase 8 (PCSK8)  
PCSK8 is called subtilisin/kexin-isozyme-1 (SKI-1) and also known as membrane-
bound transcription factor site-1 protease (MBTPS1), or site-1 protease (S1P) and it 
belongs to pyrolysin-like of subtilisin-like proteases. PCSK8 is encoded by the 
MBTPS1 gene, located on16q23.3 and translated into 1052 amino acids. PCSK8 is 
synthesised as a 148 kDa zymogen that is processed into a 120 kDa (inactive form) 
and 106 kDa protein form in the ER and then secreted as a 98 kDa form (active form) 
(Seidah et al., 1999). It is widely expressed and found abundantly in the anterior 
pituitary, thyroid, and adrenal glands (Seidah et al., 1999). PCSK8 is the only member 
of pro-protein convertases known to cleave its substrates at non-basic residues in the 
Golgi. The PCSK8 protein sequence shares the same conserved domain structure of 
other pro-protein convertases members. It comprises of a signal peptide, pro-domain, 
and a catalytic domain that contains Arg-Arg-Gly-Ser-Leu which differs to other 
members. In addition, the PCSK8 has no p-domain however, its C-terminal has a 
transmembrane domain and a cytosolic tail (Seidah et al., 1999). PCSK8 undergoes 
initial autocatalytic processing in the ER, and then a second autocatalytic event for 
maturation in the Golgi, where the catalytic activity takes place (Seidah et al., 1999). 
It has been implicated in viral infections and cholesterol and lipid metabolism. 
However, in vivo, the loss of PCSK8 expression is associated with embryonic 
development, as deficiency of PCSK8 enhanced early embryonic death by reducing 
axonal growth (Seidah et al., 2013). 
A previous study revealed that in lung tumour tissue, the expression of PCSK8 mRNA 
is decreased compared to furin, which was increased, suggesting different pathways 
of different pro-protein convertases members may contribute differently in tumour 
progression and development (Demidyuk et al., 2013). However, in human metastatic 
melanoma there was a significant increase of PCSK8 mRNA compared to normal skin 
signifying the crucial role that PCSK8 might have on melanoma cell (Weiss et al., 







1.20 Pro-protein convertase 9 (PCSK9) 
PCSK9 is also known as neural apoptosis-regulated convertase 1 (NARC-1), it is the 
most recently discovered pro-protein convertase. It belongs to the proteinase K-like 
subfamily of subtilisin-like proteases. It cleaves itself at VFAQ152↓motif and it has only 
one substrate, which is the low-density lipoprotein receptor. It is located on 
chromosome 1p32.3 and translated into 692 amino acids. It is synthesised as a 74 
kDa zymogen which is inactive and this processed to 62 kDa (active form) (Wicinski 
et al., 2017). PCSK9 is highly expressed in liver, kidney, cerebellum, and small 
intestine (Seidah et al., 2003). The protein sequence of PCSK9 shares similar domains 
as other PPCs members, in addition, it has a CHRD in its C-terminal that helps for the 
internalization and lysosomal trafficking of the PCSK9 (figure 1.7). However, PCSK9 
is the only member of protein convertases that does not undergo a second cleavage. 
It is secreted as an inactive form in complex with the inhibitory prosegment which does 
not release from it (Seidah et al., 2003). PCSK9 has a role in regulating cellular 
apoptosis and proliferation. In some tissues such as in primary cerebellar neurons, 
PCSK9 induces an apoptotic effect (Dubuc et al., 2004). PCSK9 also acts as a key 
regulator for lipid metabolism which has been associated with cholesterol homeostasis 
and hypercholesterolemia (Schulz and Schlüter, 2017). The new strategy to reduce 
the high cholesterol level is by inhibiting the function of protein PCSK9 which disrupts 
binding to the LDL receptor, leading to a decrease in the cholesterol level. Moreover, 
in melanoma, PCSK9 decreased liver metastasis progression by sustaining high 
cholesterol levels (Sun et al., 2012). PCSK9 has been positively correlated with some 
cancers such as brain cancer, colon cancer and prostate cancer (Sun et al., 2012). 
However, surprisingly, the expression of PCSK9 was significantly decreased in 
hepatocellular carcinoma, with PCSK9 mRNA expression released compared with the 
normal liver cells (Bhat et al., 2015). As it has been shown that the elevation of 
cholesterol levels is strongly associated with an increase risk of breast cancer (Nelson 
et al., 2014), this could suggest a link between PCSK9 expression and breast cancer 
progression. However, its role in breast cancer is not yet been elucidated. 
Based on the above studies, each member of pro protein convertases has a unique 
function, some of them have shared similar functions whilst others do not, and are 
























1.21 Inhibition of pro-protein convertases as a potential treatment for cancer 
Many cancers appear to progress when there is an overproduction of one of the PPCs 
resulting in activation of their substrates or cleavage of a tumour suppressor (Basak, 
2005, Bassi et al., 2005). Therefore suppression of PPCs activity may result in 
decreasing tumour growth. As a result, several approaches have been established to 
inhibit the activity of PPCs. These methods include silencing gene expression, which 
has been implemented for targeting the PPCs activity, or by using small molecules 
inhibitors that are directed against the proteases by blocking their active site from 
being occupied by substrates (Basak, 2005, Klein-Szanto and Bassi, 2017). The most 
attractive method as a potential therapy is using the small molecule compounds 
because of their metabolic and proteolytic stability. Various PPCs inhibitors have been 
reported in the literature, with differences in these inhibitors dependent on their 
chemical structure and their competitive binding for inhibition of PPCs activity (Basak, 
2005). As furin is the most commonly studied PPCs most studies have attempted to 
inhibit this PPC using a peptidyl chloromethyl ketone called decanoyl-RVKR-cmk 
(CMK) (Basak, 2005) and/or a protein-based inhibitor called α1-antitrypsin Portland 
(α1-PDX). However, both of these inhibitors are limited as they do not demonstrate 
good selectivity between PPCs.  
CMK is an irreversible competitive inhibitor of furin and other pro-protein convertases, 
but is a pan-PPC inhibitor (Basak, 2005). The drawback of using this inhibitor is its 
cytotoxicity and instability. CMK has been shown to successfully inhibit PPC-
mediated cleavage of MT1-MMP, which is associated with the invasive and metastatic 
potential of tumour cells, thereby resulting in decreased MT1-MMP maturation, and a 
decreased invasive ability of the cells (Maquoi et al., 1998). Another study, showed 
that treating head and neck squamous carcinoma cells with CMK reduced their 
proliferation rate and invasive potential, suggesting a key role of the PPC family in 
these processes at least in vivo, although which PCC family member is not clear as it 
is a pan-inhibitor (Bassi et al., 2003). A previous study found that CMK-dependent 
blockage of furin-like pro-protein convertase activity in breast cancer cell-lines resulted 
in impaired SEMA3B cleavage, diminished the activity of PPCs, and therefore restored 
the suppression ability of SEMA3B, suggesting a key role of the PPC family in these 
processes, although which PPC family member is not clear due to pan-inhibition 
(Varshavsky et al., 2008). 
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In contrast, α1-PDX has been shown to be a potent inhibitor of furin and it contains a 
single minimal furin consensus motif in its reactive site Arg-Ile-Pro-Arg (Tsuji et al., 
1999). Despite evidence of furin selectivity, some studies argue that α1-PDX is a 
general inhibitor of PPCs family members (Benjannet et al., 1997). α1-PDX showed 
potent inhibition of the processing of the furin substrates HIV-1 gp160 and gp120 by 
inhibiting the catalytic activity of PPCs. The study demonstrated that furin is the most 
efficient convertase and to a lesser extent PCSK6, PCK5-B and PCSK1 are involved 
in the intracellular processing of gp160 into gp120/gp41 in addition to the capability of 
furin to produce gp70 gp50-like proteins, suggesting that these are the most likely 
candidates to be involved in this process. However, this study found that α1-PDX is a 
potent inhibitor for both furin and PCSK6 (PACE4)-mediated processing of gp160 and 
gp120 (Vollenweider et al., 1996). In vitro experiments showed that the inhibition by 
α1-PDX of furin-expressing invasive HNSCC cell-lines also resulted in decreased the 
invasion of head and neck squamous cell carcinoma cells (Bassi et al., 2001a). 
Moreover, α1-PDX decreased the cell growth, proliferation and invasive ability of two 
transfected tumorigenic astrocytoma cell-lines of brain tumours by blocking furin 
function. The inhibition effect of α1-PDX on furin was confirmed by studying the effect 
of α1-PDX on a specific furin substrate called insulin-like growth factor which was not 
activated in PDX-expressing astrocytoma cells (Mercapide et al., 2002). In vivo 
experiments using animals injected with HT-29 cells and the α1-PDX inhibitor 
demonstrated reduced tumour growth (Khatib et al., 2001). Although there is limited 
evidence of using these inhibitors in breast cancer, it is clear that PPCs actively 
contribute to the malignant phenotypes of some cancers, so inhibiting their activity by 





1.22 Aim and hypothesis 
In conclusion, previous studies suggest that SEMA3B acts as a tumour suppressor 
and that SEMA3B can be cleaved and rendered inactive by PPCs. However, there has 
been little investigation into the active role of SEMA3B and its relationship with other 
factors in the development of breast cancer. Furthermore, it is not clear whether 
SEMA3B inactivation by furin or other pro-protein convertase family members is 
responsible for cancer cells invasiveness or progression. 
Thus, we hypothesize that PPC cleavage of SEMA3B results in inactivation of 
SEMA3B in invasive breast cancer (figure 1. 10) 
To test our hypothesis, this project aimed to determine whether or not cleavage by 
furin-like pro-protein convertase leads to inactivation of SEMA3B in a spectrum of 
normal to metastatic breast cell-lines by assessing both mRNA and protein expression 
of SEMA3B and Furin like pro-protein convertases using qPCR, western blot and 
immunohistochemistry. 
1.22.1 objectives  
1- To establish and characterise an in vitro model of breast cancer progression. 
 Proliferation, migration and invasion of different cell-lines representing the 
stages of breast cancer  
 Investigate the expression of SEMA3B in breast cancer cell-lines and tissues 
representing various stages of breast cancer development. 
2-  To assess whether any factors/proteins are produced by the cells which cleave the 
full-length SEMA3B, and then determine the effect of full-length SEMA3B on 
proliferation, migration and invasion of the normal breast and cancer cell-lines. 
3- To investigate furin-like pro-protein convertase gene and protein expression in the 
model. 
4- To assess the expression of furin-like pro-protein convertases in human tissue 
samples. 






















Figure 1.10: Hypothesis of the project. In normal breast cells, the expression of full-
length SEMA3B (83 kDa, active fragment) is increased whilst in breast cancer cells, 
the expression of SEMA3B is decreased with tumour progression as SEMA3B 
undergoes proteolytic cleavage by PPCs at KRRFRR cleavage site present in the 
SEMA3B protein sequence by generating a 51 kDa SEMA3B (inactive fragment) with 




Chapter 2: Materials and Methods 
 




1,4-Dithiothreitol (DTT) NP0009 4 °C Sigma-Aldrich, UK 
1.5M Tris-HCL /PH8.8 EC-892 RT Sigma-Aldrich, UK 
10 % SDS 101685031 RT Sigma-Aldrich, UK 
100% isopropyl alcohol - RT Fisher Scientific, UK 
3,3-Diaminobenzidine substrate (DAB)  4 °C Vector Laboratories, 
Peterborough, UK 
30% acrylamide EC-890 RT Sigma-Aldrich, UK 
70% ethanol  RT Fisher Scientific, UK 
Ammonium Persulfate (APS) A3678-25G RT Sigma-Aldrich, UK 
Antigen Retrieval Solution  4 °C Dako, Spain 
Breast common disease array of 102 
cases 
ab178113 4 °C Abcam ,UK 
Casein  4 °C Vector Laboratories, 
Peterborough, UK 
Chemiluminescent substrate 34077 RT ThermoFisher scientific, 
UK 
Corning matrigel basement membrane 
matrix growth factor reduced 5 ml. 
(cat.356230) -20 °C Corning ,USA 
Deionised Water (dH2O) - RT Millipore-QTM Water 
Purification system 
Developing Solution  RT AGFA, Mortsel, Belgium 
Dimethyl Sulphoxide (DMSO) D5879-
500ML 
RT Sigma-Aldrich, UK 
Films Hyperfilm™ ECL  RT Sigma-Aldrich, UK 
Filter Paper  RT Sigma-Aldrich, UK 
Fixing Solution  RT AGFA, Mortsel, Belgium 
Goat serum  4 °C Vector Laboratories, 
Peterborough, UK 
Haematoxylin  RT Fisher Scientific, 
Loughborough, UK 
Invasive breast tissues slides - RT Obtained from patients 
attending the Royal 
Hallamshire Hospital from 
1995-2003 (Research 
Ethics: SSREC 98/137). 
Laemmli Sample Buffer NP0007 4 °C Sigma-Aldrich, UK 
Marvel dried skimmed milk  RT UK 
Methanol  RT Fisher Scientific, 
Loughborough, UK 
Mitomycin C  4 °C Sigma-Aldrich, UK 
Phosphate Buffer Saline (PBS) BE17-512F RT Lonza, Slough, UK 
Pierce™ 20X TBST 28358 RT ThermoFisher scientific, 
UK 
Polyvinylidene fluoride (PVDF) membrane 1620177 RT BIO-RAD,UK 
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Precision Plus ProteinTM Standard 1610374 -20 °C Bio-Rad Laboratories Ltd., 
UK 
Pre-invasive (DCIS.com) breast tissues 
slides 
- RT Obtained from patients 
attending the Royal 
Hallamshire Hospital from 
1995-2003 (Research 
Ethics: SSREC 98/137). 
Protease Phosphatase Inhibitor Cocktail 1862209 4 °C Sigma-Aldrich, UK 
Rabbit serum  4 °C Vector Laboratories, 
Peterborough, UK 
RIPA Buffer, Cell Lysis Buffer 89900 4 °C Fisher Scientific, UK 
Running Buffer EC-870 RT Flowgen bioscience, UK 
Stripping Buffer 21059 RT Fisher Scientific, UK 
TBS-Tween 20x 28360 RT Fisher Scientific, UK 
TEMED 101199677 RT Sigma-Aldrich, UK 
Transfer buffer EC-880 RT Sigma-Aldrich, UK 
Trypan Blue  RT Life Technologies, UK 
Trypsin (0.05%)/EDTA (0.02%)  4 °C  Sigma-Aldrich, UK 
Tween20  RT Sigma-Aldrich, UK 
Wax pen -  Vector 
Xylene 470045-580 RT VWR,UK 
 











348 PCR Plate Z374911-
1PAK 
RT Sigma-Aldrich,UK 






96 well cell culture 3595 RT Life science ,USA 
ABI Prism 7900HT Sequence Detection 
System 
- - Applied Biosystems, 
Life Technologies, UK 
Cell culture inserts, Falcon® 734-0038 RT VWR International 
Ltd.UK 
Centrifuges - Harrier 18/80 - - Sanyo , Electric 
Biomedical Co, Japan 
CO2 incubator - - SANYO Electric 
Biomedical Co, Japan 
Counting slides dual chambers 1450003 RT Bio-Rad, UK 
CryoPure Tube 1.8 ml 72.379 RT Sarstedt, Leicester, UK 
Disposable pipets 10 ml  RT Thermo fisher scientific, 
Denmark 
Falcon® 24 Well Treated Cell Polystyrene 
Permeable Support Companion Plate 
353504 RT Corning ,USA 
FLUOstar® Galaxy microplate reader - - BMG LABTECH, 
London, UK 
Freezer (-20 °C and -80 °C) - - Sanyo , Electric 
Biomedical Co, Japan 
Grant JB Series Water Bath - - Wolflabs, UK 
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Heat Block - - Hybride Thermal 
Reactor, UK 
Laminar Flow Hood (Class II) - - Walker Safety Cabinet 
Ltd., UK 
Mr. Frosty™ Freezing Container 5100-0001 -80 °C ThermoFisher 
Scientific, Denmark 
Nanodrop©Lite Spectrophotometer - - Nanodrop 
Technologies, USA 
Nikon Eclipse TS 100 Inverted 
Microscope 
- - Nikon UK Ltd, UK 
Pipettes Tips (P2-P1000)  RT Sarstedt, Leicester, UK 
Shaker - - Stuart, Staffordshire, 
UK 
TC20™ Automated Cell Counter - - Bio-Rad, UK 
Trans-Blot® Turbo™ Transfer System - - BIO-RAD, UK 
Tubes 50 ml 352070 RT Sarstedt, Leicester, UK 
Universal tubes 25-50 ml  RT Sarstedt, Leicester, UK 
Vortex - - VWR , Lutterworth, UK 
 
2.1.2 Commercial kits and suppliers 
Commercial Kits Catalogue 
number 
Storage suppliers 
CellTiter96 Aqueous One Solution cell 
viability assay 
G3582 -20 °C Promega, UK 
Ez-PCR Mycoplasma Test Kit 1721460 -20 °C Geneflow Ltd, Litchfield, 
UK 
High Capacity RNA-To-cDNA Kit 4368814 -20 °C Applied Biosystems, 
Life Technologies, UK 
Micro BCA Protein Assay Kit-500 ml) 23235 RT Thermo-Scientific, UK 
Nuclease-Free Water AM9937 RT AmbionTM,  
Qiagen RNeasy mini kit 74104  Qiagen, Germany 
SYBR® Green qPCR Mastermix 
(Precision 2X q-PCR Mastermix) 
PP00508 -20 °C PrimerDesign, UK 
 
2.1.3 Cell culture media 
All media were stored at 4 °C. 
Cell culture media Supplier 
Dulbecco’s Modified Eagle’s Medium (DMEM) Lonza, Slough, UK 
Roswell Park Memorial Institute 1640 (RPMI 1640) 
Medium without L-Glutamine (1x) 
Lonza, Slough, UK 
Supplements for cell culture media of DMEM and RPMI 1640: 
 
Component  Growth medium Storage  Suppliers 
Foetal Bovine Serum 
(FBS) 
50 ml (10% final) Aliquoted and stored at -
20 °C until required 
Biosera, 
Ringmer, UK 
Glutamine (G) 5 ml (2 mM final) Aliquoted and stored at -
20 °C until required 
Sigma-
Aldrich,UK 
Penicillin/Streptomycin 5 ml (100 IU/ml penicillin 
and 
100 μg/ml streptomycin) 
Aliquoted and stored at -
20 °C until required 
Invitrogen, 
Paisley, UK 
Dulbecco's Modified Eagle Medium; Nutrient Mixture 
F-12 (DMEM/F12) 
Lonza, Slough, UK 
Supplements for cell culture media of DMEM/F12: 
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Cholera Toxin 50 μl (100 ng/ml final) Aliquoted and stored at 




Bovine Insulin  500 μl (10 μg/ml final) Aliquoted and stored at -






100 μl (20 ng/ml final)  Aliquoted and stored at -




Horse Serum  25 ml (5% final) Aliquoted and stored at -




Hydrocortisone  250 μl (0.5 μg/ml final) Re-suspended in 
absolute ethanol and 
aliquoted and stored at -






5 ml (100 IU/ml penicillin 
and 100 μg/ml 
streptomycin) 
Aliquoted and stored at -
20 °C until required 
Invitrogen, 
Paisley, UK 
Human endothelial cell growth medium (C-22010) Promocell, UK 
 





2.1.4 Quantitative polymerase chain reaction (qPCR) primers 
Primers 
Forward Reverse Suppliers 
SEMA3B primer (cat .HQP070437) 
GCGGCAAGACGTAAGGAATG CTGGAAAGTCCACTCCACGC GeneCopoeia, USA 
Furin primer (cat. HQP012121) 
GCATTGTGGTCTCCATTCTG CGTGCCTGTTGTCATTCATC GeneCopoeia, USA 
GAPDH primer (housekeeping gene ) 
TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG GeneCopoeia, USA 
PCSK1 primer (cat.HQP012539) 
TCACACATGGGGAGAGAACC GGCTGCTTCATATGCTCTGG GeneCopoeia, USA 
PCSK2 primer (Accession No.NM_00120152) 
CCTGTACGACGAGAGCTGC CCCAGAATGCCTCAGAGTGC Primer design ,UK 
PCSK4 primer (cat.HQP013677) 
GACCTGGAGATCTCGCTCAC GGTTCTCATCCCAGAAGTGG GeneCopoeia, USA 
PCSK5 primer (cat.HQP059944-01) 
CCTGCCCCATGACAAGGATT ACTTCCTTGGCATCTCTGGC GeneCopoeia, USA 
PCSK6 primer (cat.HQP070611) 
CGCAGGCCCTTTACTTCAAC   CGGCAGCGACTGTTCTTGT GeneCopoeia, USA 
PCSK7 primer (cat.HQP02211) 
CTTCAGCCATAGCCACCAG CGGAATCGCCTTGTTTTC GeneCopoeia, USA 
PCSK8 primer (cat.no. SY-hu-600) 
TGCCACAGAACGGAGACAAC GCCGCTTTCTTGGTCACAGA Primer design ,UK 
PCSK9 primer (Cat.no. SY-hu-600) 
AAGTTGCCCCATGTGGAGTA AGCGGTCTTCCTCTGTCTG Primer design ,UK 





2.1.5 Western blot primary antibodies  




SEMA3B antibody (Rabbit polyclonal) ab48197 1:1000 Abcam ,UK 
Furin antibody (Rabbit polyclonal) H-220-20801 1:1000 Santa Cruz,UK 
PCSK1 antibody (Rabbit polyclonal) Ab55543 1:1000 Abcam, UK 
PCSK2 antibody (Rabbit polyclonal) ab135808 1:1000 Abcam, UK 
PCSK4 antibody (mouse polyclonal,) ab169708 1:1000 Abcam, UK 
PCSK5 antibody (Rabbit polyclonal) LS-C408843 1:500 Lifespan BioSciencesInc, 
 UK 
PCSK6 antibody (Rabbit monoclonal) ab151562 1:1000 Abcam, UK 
PCSK7 antibody (rabbit polyclonal) ab116567 1:1000 Abcam, UK 
PCSK8 antibody (Rabbit polyclonal) .ab140592 1:500 Abcam, UK 
PCSK9 antibody (Rabbit polyclonal) ab135647 1:1000 Abcam, UK 
Anti-beta actin (Rabbit polyclonal). ab16039 1:2000 Abcam, UK 
Recombinant protein 
Recombinant Human Semaphorin 3B Fc 
Chimera Protein, CF 




Decanoyl-RVKR-CMK inhibitor  3501 135 and 
200 µM 
Biotechne 
Human alpha-1 PDX Recombinant Protein RP-070 8.0-20µM Thermo Fisher Scientific  
 
2.1.6 Commercial human tissue slides for IHC 
Tissue slides Storage  Supplier 
 
Breast common disease array of 102 
cases (cat.ab178113) 





2.1.7 Immunohistochemistry primary antibodies  
Primary Antibodies Catalogue 
number  
Suppliers 
SEMA3B antibody (Rabbit polyclonal) ab48197 Abcam,UK 
Furin antibody (Rabbit polyclonal) H-220-20801 Santa Cruz,UK 
PCSK1 antibody (Rabbit polyclonal)  ab55543 Abcam,UK 
PCSK2 antibody (Rabbit polyclonal) ab135808 Abcam,UK 
PCSK4 antibody (Rabbit polyclonal) HPA005572 Sigma-Aldrich, UK 
PCSK5 antibody (Rabbit polyclonal) LS-C408843 Lifespan Bioscience,UK 
PCSK6 antibody (Rabbit monoclonal) ab151562 Abcam,UK 
PCSK7 antibody (Rabbit polyclonal) 12044-1-AP Proteintech, UK 
PCSK8 antibody (SKI-1 Antibody mouse monoclonal) A-11-sc-271916 Santa Cruz,UK 
PCSK9 antibody (Rabbit polyclonal) ab135647 Abcam,UK 
 
2.1.8 Secondary antibodies 
Secondary antibodies  Catalogue 
number 
Dilution Technique  Suppliers 
Polyclonal anti-mouse 
Immunoglobulins 
P0260 1/2000 WB Dako 
Polyclonal anti-mouse biotinylated 
IgM 
NA931V 1/2000 IHC GE Healthcare 
Polyclonal anti-rabbit IgG-
horseradish Peroxidase (HRP) 
P0448 1/2000 WB Dako 
Polyclonal anti-rabbit biotinylated 
IgM 
BA-1000 1/2000 IHC Vector Labs 
Polyclonal anti-goat biotinylated 
secondary antibody 



















2.2. Cell-lines and cell culture 
2.2.1. Cell-lines 
Cell-lines were selected to represent a range of breast cancer subtypes and 
aggressiveness. Human breast cell-lines: MCF-10A, MCF-10AT, DCIS.com, MCF-7, 
T47D and MDA-MB-231 and MDA-MB-231-BM were used in all the experiments. 
Table 32.1: Cell Lines 
Cell-lines Catalogue number and suppliers 
MCF-10A Epithelial cells derived from a 
patient with fibrocystic disease 
(ATCC® CRL­10317™). 
MCF-10AT Atypical ductal hyperplasia cell 
-line 
Obtained from Ann Arbor institute. USA 
DCIS.com Ductal carcinoma in situ cell-
line 
Provided by Karmanos Cancer Institute, 
USA. 
MCF-7 Invasive ductal carcinoma with 
low metastatic potential 
(ATCC® HTB-22™). 
T47D Invasive ductal carcinoma with 
low metastatic potential 
(ATCC® HTB-133™). 
MDA-MB-231 Metastatic adenocarcinoma 
with pleural effusion 
(ATCC® HTB-26™). 
MDA-MB-231-BM Bone homing metastatic cell-
line 
Obtained from Professor Janet Brown. 
University of Sheffield 
Hep-G2 Hepatocellular carcinoma cell- 
line 
Obtained from Dr Karen Sisley. University 
of Sheffield 
HUVEC HUVE-c pooled -Human 
Umbilical Vein Endothelial 
Cells 
C-12203, Promocell, UK 
 
The MCF-10A cell-line was derived from a patient with fibrocystic disease and is a 
non-tumorigenic normal breast epithelial cell. It is used as a model for the in vitro study 
of normal breast cell function and transformation. These cells do not express the 
oestrogen receptor. Cells were immortalised after proliferating for more than four years 
and maintained in a medium with low calcium concentration so as to increase their 
longevity (Soule et al., 1990).  
The MCF-10AT cell-line is an atypical ductal hyperplasia that represents the pre-
malignant stage of breast cancer. These cells were implanted in mice for a 12-16 week 
period which generated lesions similar to ductal hyperplasia. MCF-10A was 
transfected by T24 c-Ha-ras oncogene for a period of one year, during which time the 
cells sporadically transformed into carcinomas. These cells are therefore used as a 
model for the conversion of normal breast ductal epithelial cells into malignant cells 
(Dawson et al., 1996).  
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The Ductal carcinoma in situ (DCIS) cell-line is a non-invasive model that originated 
from premalignant MCF10AT cells. MCF-10AT cells were injected as xenografts into 
severe combined immune deficient mice in order to generate DCIS (Miller et al., 2000).  
The MCF-7 cell-line is derived from a metastatic adenoma patient with a pleural 
effusion. It is a widely studied model for a hormone-dependent human breast cancer. 
It represents an invasive ductal carcinoma with low metastatic potential, is luminal type 
A, oestrogen and progesterone receptor positive and HER2 negative, with a wild type 
p53 (Lim et al., 2009).  
The T47D cell-line is derived from a metastatic ductal carcinoma patient with pleural 
effusion. It represents an invasive breast carcinoma with low metastatic potential, and 
is classified as luminal type A, oestrogen receptor positive, progesterone receptor 
negative and HER2 negative, with a mutant p53 (Lim et al., 2009). 
The MDA-MB-231 cell-line is derived from a metastatic patient with metastatic 
adenocarcinoma with pleural effusion. It represents an invasive breast carcinoma with 
high metastatic potential. It is classified as basal type, claudin-low, triple negative 
receptor (ER, PR and HER2) and has mutant p53 (Lim et al., 2009) 
The MDA-MB-231-BM cell-line is a specific bone homing metastatic cell-line. In order 
to establish bone metastatic cell-lines, MDA-MB-231 cells were injected into the tail 
vein of nude mice and then the cells were collected, cultured and re-injected several 
times into the mice. The cells were passaged seven times and, once injected into the 
tail, they were able to make their way to the bone (Nutter et al., 2014).  
The Hep-G2 cell-line was isolated from a patient with hepatocellular carcinoma. It 
was used as a positive control for pro-protein convertases since it known that the 
expression of furin-like pro-protein convertases is abundant in these types of cells 
(Nutter et al., 2014). 
Human umbilical vascular endothelial (HUVEC) cell-lines are isolated from large 
umbilical veins. The cells were supplied from pooled donors and each cryovial 
contained more than 500,000 viable cells after thawing. HUVEC were used as a 
positive control as it has previously been known that SEMA3B inhibits migration and 
angiogenesis of HUVEC cells.  
All cell culture work was carried out in a class II safety cabinet under sterile conditions. 
MCF-10A cells were cultured in Dulbecco's Modified Eagle Medium (DMEM-F12), 
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which is a mixture of DMEM medium and Ham’s F-12 medium, containing a high 
amount of glucose, amino acids and vitamins. It is supplemented with horse serum, 
penicillin and streptomycin, insulin, hydrocortisone, EGF and cholera toxin (in order to 
promote cell growth by increasing the intracellular cAMP level in the mammary 
epithelial cells) to a total volume of 500 ml, and at the concentrations stated in table 
2.1.3. 
MCF-10AT and DCIS.com cell-lines were used to culture in the same medium as 
MCF-10A. Following advice from internal examiners of the initial stages of this project, 
however, the same culture medium was used for all cell-lines in order to minimise the 
variables and ensure that comparisons could be made based on the same conditions. 
Accordingly, cells were re-cultured in RPMI-1640 and both MCF-10AT and DCIS.com 
cells grew normally, except for MCF-10A cells which died. Since it was evident that 
these could not survive in RPMI medium they were kept in their normal culture 
medium. The MCF-10AT, DCIS.com, MCF7, T47D and MDA-MB-231 cell-lines were 
cultured in supplemented RPMI-1640 as stated in table 2.1.3. The MDA-MB-231-BM 
cell-line was cultured in supplemented DMEM medium (table 2.1.3). All cells were 
incubated at 37 °C with 5% CO2 until use, and all the prepared media were stored at 
4 °C. The cells were kept in exponential growth by re-culturing of stock cultures two to 
three times a week. The morphology of the cells used throughout this thesis is shown 
in figure 2.1. 
HUVEC cell-line was cultured in supplemented human endothelial cell growth 
medium, containing a low foetal calf serum (2% v/v), EGF, hydrocortisone and 
endothelial cell growth Supplement/ Heparin (ECGS/H) to a total volume of 500 ml. 






























































































































2.2.2 Cell culture  
All the culture work was done in a sterile class II laminar flow hood using aseptic 
techniques. The cabinet was switched on and left for 30 minutes before use to allow 
the air to circulate. The cabinet and all the equipment was cleaned with industrial 
methylated spirit (IMS) before use. All cell-lines were grown in T75 or T25 flasks in 
complete medium and incubated in a humidified atmosphere at 37 °C and 5% CO2. 
The cells were monitored daily to make sure that they were growing well and were free 
of contamination. They were fed with the full growth medium every 48 hours until they 
reached 70-80% confluence and were ready for sub-culturing.  
2.2.2.1 Passaging of mammalian cells  
All cell-lines were grown in T75 flasks in complete medium as described above in 
section 2.2.2. After reaching 70% confluency, cells were washed twice with 10 ml 
Dulbecco's Phosphate Buffered Saline (DPBS) without calcium and magnesium in 
order to remove any residual serum that could interfere with the trypsin action. The 
cells were then trypsinised with 0.05% (v/v) trypsin in 0.02% EDTA solution and 
incubated at 37 °C and 5% CO2 for about 2-5 minutes to allow complete detachment 
from the surface of the flask. This mixture of trypsin and EDTA was added in order to 
remove the calcium and magnesium from the cell surface, which allows trypsin to 
hydrolyse specific peptide bonds and therefore release the cells adhering to the culture 
vessel. Cells that are difficult to detach may be left longer at 37 °C in order to facilitate 
dispersal. Some cells, like MCF-10A, DCIS.com and T47D, were incubated for up to 
ten minutes in the trypsin to ensure that they had all detached from the surface of the 
flask. The flask was checked under the microscope and tapped sharply to release the 
cells. Long exposure to trypsin, leads to cell death, which can often be recognised by 
aberrant morphology. The trypsin was deactivated by adding 7.5 ml of complete 
medium containing 10% FBS serum, in addition to protease inhibitors, particularly α1-
antitrypsin, which inhibits the trypsin activity. This step was followed by extensive 
pipetting up and down and then centrifugation at 1000 x g for five minutes. The 
supernatant was removed, and the cell pellet was re-suspended in 5 ml of the 
appropriate complete medium. Depending on the growth rate of each cell-line, 0.5-1 
ml of the cell suspension was added to 10 ml of complete medium in a T75 flask so 
as to generate a split ratio of 1:2 - 1:10 (table 2.2.). When it was important to generate 
cells at 70% confluent by a specific date, however, they were seeded at a particular 
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number per flask rather than using the split ratio depends on the set up of the 
experiment. 
For HUVEC cells, an appropriate volume of growth medium was filled in T25 cell 
culture flask and placed in an incubator (37°C, 5% CO2) for 30 minutes to adjust the 
temperature of the medium. HUVEC cells were grown in T25 flask in complete medium 
as described above in section 2.1.3 and 2.2.1. After reaching 70% confluency, cells 
were washed twice with 5 ml DPBS to wash the cells and the flask was agitated 
carefully for 15 seconds. The DPBS was aspirated from the flask and trypsin/EDTA 
was added and the flask was kept at room temperature for 2-3 minutes, allowing cell 
detaching. The cells were examined under a microscope and when they started to 
detach, the flask was tapped gently to loosen the remaining cells. Medium containing 
10% serum was added for neutralization and the flask was gently agitated. The cell 
suspension was aspirated and transferred to a centrifugation tube and then 
centrifuged at 220 x g for three minutes. The supernatant was discarded and the cell 
pellet was re-suspended in 1 ml of the appropriate HUVEC complete growth medium 
in new cell culture flask containing prewarmed growth medium. The flask was then 
placed in an incubator (37°C, 5% CO2) and the media was changed every two to three 
days (table 2.2.). The cells were used between passages 2 to 6. 
Table 42.2: Split ratio for the cell used: 
Cell-lines Split ratio Medium Renewal 
MCF-10A 1:3 to 1:4 2 to 3 times/week 
MCF-10AT 1:4 2 to 3 times/week 
DCIS.com 1:4 2 to 3 times/week 
MCF-7 1:3 to 1:6 2 to 3 times/week 
T47D 1:3 to 1:5 2 to 3 times/week 
MDA-MB-231 1:2 to 1:4 2 to 3 times/week 
MDA-MB-231-BM 1:10 2 to 3 times/week 





2.2.2.2 Cryopreservation and retrieval of cells  
In order to keep the cells for a long period of time, they were cryopreserved and kept 
in liquid nitrogen until use. Cells were re-suspended at 1x106 cells/ml in medium 
containing 90% FBS and 10% dimethyl sulphoxide (DMSO) so as to prevent the 
formation of ice crystals during the freezing process. Then, the cryovials containing 1 
ml cells were placed in cell freezing containers (Mr Frosty) to allow the cells to be 
slowly frozen at -80 °C for 24 hours before transfer to liquid nitrogen. When it was 
necessary to retrieve these cells from liquid nitrogen, the cryovials were defrosted 
rapidly in a 37 °C water bath, and the cells were then spun down at 1000 x g for five 
minutes to remove DMSO from the media. The cells were re-suspended in 5 ml of 
fresh growth medium that had been warmed to 37 °C and transferred into a T25 flask 
and incubated at 37 °C with 5% CO2. The following day, the media was changed to 
fresh growth medium and the cells were monitored as they grew to confluence before 
passaging as required. 
2.2.2.3 Mycoplasma testing of cell-lines 
A regular mycoplasma testing schedule across the department was carried out shortly 
after the cell-lines arrival into the laboratory. The cells were checked every six months 
to ensure that the used cells were free of mycoplasma, especially after reviving the 
cells from frozen stocks. 5 ml of conditioned medium of the samples was collected and 
placed in a universal container for testing. The EZ PCR Mycoplasma Detection Kit was 
used to perform this test. The screening was carried out by the laboratory technicians 


























2.2.2.4 Cell counting  
In order to seed the correct number of cells, they were counted using a TC20™ 
automated cell counter by mixing 10 µl of re-suspended cells with 0.4% (v/v) of trypan 
blue (1:1) and then adding 10 µl of the mixture onto a counting slide. The cell counter 
machine detects the viability, the number of viable cells and the total number of cells. 
The principle for this is based on the fact that live cells possess intact cell membranes 
that exclude certain dyes, whereas dead cells do not, and this allows dead cells to 
take up trypan blue. This trypan blue cell exclusion assay is widely used with an 
automated cell counter, since this approach is more rapid, reliable and accurate. The 
potential weaknesses of this assay, however, are that the dye can be fused by live 
cells after a short exposure time (Avelar-Freitas et al., 2014). 
2.3 Assessment of cell proliferation and survival 
Cell proliferation was assessed by two different methods, cell counting, including 
viability, and measuring the cellular metabolic activity using the MTS assay (Kroemer 
and Pouyssegur, 2008).  
Figure 2.2: Example of mycoplasma test results. Lane 1 = 100 bp ladder, samples 
from lane 2 to 10, lane 2 and 3 unrelated samples, lane 4 (MCF-10A), lane 5 (MCF-
10AT), lane 6 (DCIS.com), lane 7 (MCF-7), lane 8 (T47D), lane 9 (MDA-MB-231) and 
lane 10 (MDA-MB-231-BM) represent the related samples. Lane 11 = In-house 
positive control for mycoplasma test, Lane 12 = Gap, Lane 13 = Kit Positive Control, 
Lane 14 = Gap and Lane 15 = Negative control (sterile endotoxin-free water). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
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2.3.1 Cell counting 
Initially, cell counting was used in order to generate a growth curve for each cell-line. 
The seeding density of this experiment was optimised to avoid any cellular over-
confluence during the assay. Initially, all cell-lines were seeded at different densities 
(5x103, 1x104 and 2x104 cell/well) in a 12-well plate in order to determine the most 
appropriate seeding density for the experiment to ensure that there was a change in 
the number of cells across the duration of the experiment and that the cells did not 
become too confluent with slow of growth during this time.  
At 5x103 and 1x104 cell/well, counting the number of cells led to large errors in some 
cell types, especially for those with a low growth rate e.g T47D and DCIS.com. At 
2x104 cell/well the growth rate was steady and appropriate for all cell-lines. This was 
important to minimise the variability between cells. Cells were therefore seeded at 2 x 
104 cells into 12-well plates and then incubated at 37 °C before monitoring proliferation 
at 24, 48, 72 and 96-hour time points using trypsinisation and cell counting as follows. 
At the relevant time point, all conditioned media were collected and then cells were 
washed with 1 ml of DPBS (without calcium and magnesium) and the washes were 
added to the conditioned media. This ensures that all dead cells were collected. Cells 
were then trypsinised by adding 500 µl of trypsin and incubated for 2 to10 minutes at 
37 °C. Then, 1.5 ml of medium was added to the cells and all cell suspensions were 
collected and added to the wash and conditioned medium to ensure that all cells within 
each well were collected. The cells were then centrifuged at 1000 x g for five minutes 
and then cell counting was carried out as described previously in section 2.2.2. For 
each individual experiment, there were three wells/time point and the experiment was 
repeated as three independent experiments.  
The length of time that cells took to double in number was measured using a doubling 
time computing tool (available from http://www.doubling-time.com/compute.php) 
(Roth, 2006) in order to assess the difference in growth rate between the cell-lines. 
The doubling time was calculated using the following equation: 
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒=                                  duration× log 2 
                  ____________________________________________________ 
                                 Log (Final concentration) – log (Initial concentration) 
 * "log" is the logarithm to base 10 (as automatically calculated). 
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2.3.2 Cell counting in response to Semaphorin 3B treatment 
In order to assess the effect of recombinant semaphorin 3B on cell growth and 
proliferation, DCIS.com and MDA-MB-231 cells were seeded at 2 x 104 cells in 12-well 
plates. The recombinant semaphorin 3B was added at different concentrations 0, 0.5, 
1 and 2 µg at the same time as the cells were seeded in media containing 1% serum. 
The cells were incubated at 37 °C before monitoring proliferation at 24, 48 and 72 hour 
time points using trypsinisation and cell counting as previously described in 2.2.2. 
2.3.3 MTS cell proliferation/ viability 
The MTS assay was performed in order to measure the metabolic activity and the 
viability of the cells over a 96h period using the CellTiter96 AQueous One Solution cell 
viability assay. MTS is a colorimetric assay which is based on the ability of viable cells 
to reduce the MTS tetrazolium salt (3-(4,5-dimethyl-2-yl)-5-(3- carboxymethoxyphenyl)          
-2-(4-sulfophenyl)-2H-tetrazolium) to a formazan product, a process mediated by 
NAD(P)H-dependent dehydrogenase enzymes and therefore measuring the 
mitochondrial function (Dunigan et al., 1995). The amount of the formazan product is 
measured by reading the absorbance of the solution at 490 nm. In order to perform 
the experiment, when cells reached 70% confluent they were trypsinised, counted and 
seeded into four 96-well plates at a seeding density of 5x103 cells in 100 µl of culture 
medium/ well. Optimisation of the assay was previously performed by other members 
of our group. 
DPBS (100 µl) was added to wells at the edges of the 96-well plate to avoid 
evaporation of the medium over the duration of the assay. At each time point (24, 48, 
72 and 96 hour), a plate was removed from the incubator and 20 µl of CellTiter  
Aqueous One solution reagent was added into each well. The plates were incubated 
for an additional three hours in the dark at 37 °C. Then, the absorbance was measured 
at 490 nm using a microtitre plate reader. The experiments were repeated three times 
for each cell-line, with six wells per cell-line per repeat. Wells seeded with media alone 
were used as the absorbance control. The background absorbance of the media was 




2.3.4 Effect of recombinant Semaphorin 3B (rSEMA3B) on metabolic activity of 
the cells 
In order to assess the potential effect of recombinant SEMA3B on actively proliferating 
cells, the cell-lines of interest, DCIS.com and MDA-MB-231 cells, were seeded into a 
96-well plate and incubated overnight. The following day, the media was removed and 
replaced with media containing 1% serum and a range of rSEMA3B concentrations 
(0, 0.5, 1, 2 µg/ml) in the total volume 100 µl in each corresponding well. Plates were 
incubated at 37 °C for 24, 48, 72 hours and the protocol followed as described in 
section 2.3.3. 
2.4 Scratch (wound healing) assay 
The scratch assay was carried out to assess the ability of cells to migrate, since this 
assay can mimic the behaviour of tumour cells during migration in vivo. This is a 
straightforward, convenient and cost-effective method for analysis of cell migration in 
vitro. The limitation of this method, however, is that it takes longer to perform since 
the cells need to be confluent and the scratch should be done by wounding the 
surface of a confluent monolayer of cells which can lead to damage of the extracellular 
matrix components of cells (Liang et al., 2007). The gap closure is measured over 
time, thereby quantifying both the migration and proliferation of the cells. In order to 
reduce the proliferation and ensure that only the migration is measured, mitomycin C 
was used in this experiment, as described below in 2.4.1.3. 
2.4.1 Optimisation of the scratch assay 
2.4.1.1 Seeding densities 
Different seeding densities were used to optimise a consistent migration assay (2x104, 
5x104 and 1X105 cells/well) (figure 2.3). This experiment was intended to choose an 
appropriate seeding density at which the cells became confluent having formed a 
monolayer of cells. This was achieved at cell density of 1x105 in 24-well plates after 
48 hours. 
2.4.1.2 Starvation period 
Cell serum starvation is a necessary step in this assay in order to minimise the cell 
proliferation by synchronising the cells to arrest at the G0 phase of the cell cycle. The 
period of serum starvation was established and the cells were starved for 48 hours 
prior to the scratch, at which point they were compared to the cells without serum 
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starvation. Adherent cells were not affected after this time. To ensure that cells were 
not actively proliferating at the start of the experiment, cells were starved for 48 hours. 
2.4.1.3 Mitomycin C optimisation 
Mitomycin C is a DNA synthesis inhibitor which is known to inhibit proliferation and this 
was therefore used to prevent proliferation in the migration assay and to ensure that 
the gap closure measured is due to cell migration only. Studies have shown, however, 
that mitomycin C can cause cell death and disruption of the cell monolayer (Verweij 
and Pinedo, 1990). Therefore it was necessary to establish an appropriate 
concentration of mitomycin C, sufficient to stop proliferation but not so much as to kill 
the cells or disrupt the cell monolayer. In order to identify a mitomycin C concentration 
that would inhibit cell proliferation without killing the cells, the MTS assay was 
performed. Previous studies in the lab have shown that breast cancer cell-lines are 
sensitive to mitomycin C so a low dose range was tested (from 0.5 to 10 µg/ml). As 
previously described in section 2.3.3, cells were seeded at 5x103 in 96-well plates and 
incubated overnight at 37 °C. The following day, the cells were treated with different 
concentrations of mitomycin C (0, 0.5, 1, 2, 5 and 10 µg/ml) for one hour (figure 2.4) 
and then cells were washed and the cell proliferation was assessed at different time 
points (24, 48 and 72 hours). The cellular proliferation was measured by MTS assay 
(section 2.3.3) and the absorbance was measured at 490 nm (figure 2. 5.). As seen in 
figure 2.4, after one hour of adding the higher doses of mitomycin C into the cells (5 
and 10 µg), some cells had detached from the flask and died. The lower doses (1 and 
2 µg/ml) showed less cytotoxic effect on cells with no cell detachment. 
Nonetheless, proliferation was initially measured by MTS so as to confirm the 
effectiveness of the above process. The results showed that the mitomycin C-treated 
cells did not proliferate over the course of the assay (72 hours) compared to the 
untreated cells and that proliferation reduced in a dose-dependent manner (figure 2.5). 
Accordingly, the scratch assay was performed using 2 µg/ml to ensure that the 
confluent monolayer would not be disrupted and to guarantee that the majority of the 












































Figure 2.4: A representative image of the effect of different doses of mitomycin 
C on MDA-MB-231 monolayers. Cells were treated with different doses of mitomycin 
C (0,1, 2, 5 and 10 μg/ml). Cells were less confluent and cell death occurred after 1 
hour with increased doses of mitomycin C. Scale bar = 100 µm. 
 
Figure 2.3: Examples of optimisation of different seeding densities. Scale bar = 
























Figure 2.5: The effect of different doses of mitomycin C on cell viability of 
MDA-MB-231. Cells were seeded into 96-well plates and treated with different 
doses of mitomycin C (0, 0.5, 1, 2, 5 and 10 μg/ml) for an hour and then washed. 
The cell viability was then measured at different time points (24, 48 and 72 hours) 
using the MTS assay and expressed as absorbance at 490 nm. The viability of the 
MDA-MB-231 cells decreased with increased doses after 72 hours (n=1). 
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2.4.2 Protocol  
All cell-lines were seeded into a 24-well plate (1x105 cells/well) to a final volume of 500 
µl in full medium and incubated for 48 hours to obtain a confluent monolayer, and then 
the media was replaced with serum free medium so as to starve the cells for a further 
48 hours. Mitomycin C was then added to the medium for an hour prior to making a 
straight line scratch using a p200 pipette tip. Cells were washed once with 500 µl 
DPBS in order to remove debris and floating cells, and the wells were then filled with 
500 µl serum free medium and the plate incubated for a further 30 minutes to allow 
the stressed cells to equilibrate. After that, the medium was aspirated off and replaced 
with 500 µl of medium containing 1% serum. Images were taken under a microscope 
at 10x magnification for each well before and after scratching. The plates were placed 
in a tissue culture incubator at 37 °C and images were captured after 0, 24, 36 hours. 
ImageJ software was used to measure the gap closure and to calculate the remaining 
clear area after each time point compared to the control time zero hour. About 20 
horizontal lines were drawn across the edge of the scratch, the measurements of the 
length of the drawn lines were obtained and the percentage of the closed area was 
calculated (figure 2.6). These steps were repeated for each cell-line. The percentage 
of wound closure was calculated using the following equation: 
Wound closure (%) = (width of initial scratch - width of scratch at 0, 24 or 36h) × 100 
                                                    width of initial scratch  
The experiments were repeated three times for each cell-line, with three wells per cell-































































Figure 2.6: Analysis of cell migration by scratch assay using ImageJ software. 
Twenty lines were drawn randomly across the entire length of the scratch in the well 
and quantified using Image J. The percentage of the closed area was calculated for 
each scratch. Scale bar = 100 μm. 
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2.5 Effect of recombinant Semaphorin 3B on cell migration 
In order to assess the potential effect of recombinant SEMA3B on cells migration, the 
cell-lines of interest, MDA-MB-231 and HUVEC cells, were seeded into a 24-well plate 
and incubated for 48 hours to obtain a confluent monolayer as described in section 
2.4.2. HUVEC cells were used as a positive control in this assay. Then, the medium 
was removed and replaced with serum free medium and cells were starved for 48 
hours except for HUVEC cells which could not survive in the absence of serum 
therefore they were kept in 2% serum. The cells were treated with Mitomycin C as 
described in section 2.4.2 and then a straight line scratch was applied using a p200 
pipette tip. Cells were washed and then the media containing 1% serum and differing 
concentrations of rSEMA3B (0, 0.5, 1, 2 µg/ml) in the total volume 500 µl was added 
in each corresponding well. Plates were incubated at 37 °C for 24, 36 hours and the 
protocol followed as described in section 2.4.2. The results were analysed by drawing 
twenty horizontal lines across the edge of the scratch, the measurements of the length 
of the drawn lines were obtained and the percentage of the closed area was calculated 
as decribed in section 2.4.2. 
2.6 Invasion assay  
One of the major characteristics of tumour metastasis is the ability of tumour cells to 
invade through the basement membrane. An invasion assay was therefore performed 
in order to study this characteristic of each cell-line toward a chemoattractant gradient 
(10% FBS as chemoattractant in medium). Matrigel is a solubilised basement 
membrane protein mixture extracted from Engelbreth-Holm-Swarm (EHS) mouse 
sarcomas that represents the basement membrane found in many tissues, and can 
therefore be used to study the invasion of cells. 
2.6.1 Preparation of Matrigel for membrane coating  
Matrigel was aliquoted upon receipt and thawed on ice at 4 °C overnight before use. 
Then, it was swirled gently to ensure homogeneity and kept on ice continually until 
use, at which point it was dissolved in pre-cooled serum-free medium to 9.5 mg/ml 
(protein concentration).  
2.6.2 Preparation of transwell invasion assay plates 
The required number of transwell inserts were placed into a 24-well cluster plate using 
sterile tweezers. 20 µl of Matrigel (30 µg/insert) was applied to coat each transwell 
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insert, making sure that the entire surface was evenly coated. The plate was then 
incubated for two hours at 37 °C to allow the Matrigel to set. 
2.6.3 Principle of invasion assay 
Two chambers were used in this assay, separated by a filter coated with Matrigel 
components. The cell suspension containing serum free medium was placed in the 
top chamber and incubated for a specific time in the presence of medium containing 
chemoattractants (10% FBS in medium) in the bottom chamber. The invasive cells 
migrate from the top chamber through the coated filter pores to the bottom underside 





















2.6.4 Optimisation of seeding density and time for invasion  
In order to optimise the assay, MCF-10A, MCF-10AT, DCIS.com, MCF-7, T47D, MDA-
MB-231 and MDA-MB-231-BM cells were seeded at 1x104, 2x104 and 3x104  cell/well 
in the appropriate assay media (figure 2.8). MCF-10A, MCF-10AT, DCIS.com cells did 
not invade over the course of the 72 hours experiment and so were excluded from 
further experimentation.  
To establish how long the cells took to penetrate through the Matrigel-coated cell 
culture insert the extent of invasion at a range of time points was investigated, and 
cells were seeded at different densities for 48 and 72 hours. MCF-10A, MCF-10AT 
and DCIS.com cells did not invade over a period of three days. MCF-7, T47D, MDA-
MB-231 and MDA-MB-231-BM did invade, but the number of invaded cells were few 
after 48 hours, although after 72 hours the cells did have better invasion (figure 2.8). 
Based on this investigation, a cell density of 3x104 and a duration of 72 hours were 


































Figure 2.8: Optimisation of the 
seeding density and the time-
period of the invasion assay. 
Images were taken after 48 and 72 
hours of untreated cells. The 
number of invaded cells were 
measured/10 fields of view at x20 
magnification. Pre-invasive, pre-
malignant and invasive cell-lines 
were optimised at different 
concentrations. The representative 
images show examples of seeding 
densities at (a) 1x104 cells/insert for 
48 hour. (b) 2x104 cells/insert for 72 






2.6.5 Protocol of the invasion assay 
The cells were starved overnight by replacing the complete medium with serum free 
medium. The media was removed, and the cells were washed twice with 1X PBS and 
trypsinised, re-suspended in serum-free medium, counted and seeded at 2x104 
cell/200 µl medium /insert in 24-well plates (figure 2.8). Cells were seeded onto coated 
inserts in triplicate under sterile conditions. The outer wells were filled with 500 µl of 
complete growth medium containing 10% FBS and the plate was incubated for 72 
hours at 37 °C. After incubation, each insert was fixed by being placed into 100% 
ethanol for ten minutes followed by washing with PBS for two minutes. The coated 
chambers were stained with haematoxylin (300 µl) for 30 minutes and then the inserts 
were washed twice with distilled water (500 µl) in order to remove excess stain. They 
were then allowed to dry at room temperature. The following day, the non-invading 
cells were removed by repeatedly “scrubbing” the membrane with a cotton swab 
(moistened with PBS) inside the bottom of the membrane, applying firm pressure to 
rub the top surface. This was repeated twice. Then, the membrane was cut and 
mounted onto glass slides. It was expected that the invasive cells would penetrate 
through the Matrigel basement membrane while the non-invasive cells remain in the 
upper filter on the top of the Matrigel and hence removed with the swab. Images were 
taken in ten random fields by phase contrast and the number of invaded cells were 
quantified using a 20X objective. The number of cells was counted, both by eye and 
using the cell counter in ImageJ software, which allows cells to be counted by clicking 
on the cell image and thus provides the total number of cells in the field 
2.7 The effect of recombinant SEMA3B on cell invasion   
In order to assess the effect of rSEMA3B on invasion, cells were seeded at 2x104 in 
200 μl of total serum free medium into the upper chamber of the 24-well transwell 
plate. Various concentrations of rSEMA3B (0, 0.5, 1, 2 μg/ml) were added to the 
medium containing full serum in the lower chamber. After incubation for 72 hours at 
37 °C under 5% CO2, each insert was fixed and stained as previously described in 
2.6.5. Images were taken and the invaded cells counted in ten random fields/slide by 
phase contrast microscopy and the number of invaded cells quantified by using a 20X 
objective. Then the cell number was counted by both eye and ImageJ software. The 
number of invaded cells in the presence of rSEMA3B was compared to the negative 
control (untreated cells). 
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2.8 Cytometric Bead Array assay 
The aim of this experiment was to identify which cytokines are released by the different 
cell-lines and to assess their expression levels by a Cytometric Bead Array assay 
(CBA). This assay works by coating multiplex beads with antibodies to specific 
cytokines. The antibodies then bind to and pull out the cytokines from the cell 
supernatants. The amount of cytokine in each sample can then be quantified using an 
Attune Autosampler to measure the concentration of cytokines in the samples. 
Cells were seeded at 2x106 cells/ml in T75 flask in medium containing full serum as 
described in section 2.2.2. After reaching 70-80 % confluency, the media was replaced 
with serum free medium and after 24 hours the medium was collected and centrifuged 
at 1000 x g for five minutes. The supernatants were then collected to be investigated 
by CBA. Different cytokines were purchased from BD Biosciences, including IL-8, IL-
11, G-CSF, GM-CSF, IFN-Y and IL-10. The BD CBA Flex set used the range of 
fluorescence detection offered by the Attune Autosampler and antibody-coated beads 
to capture analytes. The CBA Flex Set contained two vials of standard and one vial 
each of Capture Bead and PE Detection Reagent (reporter). The standard component 
was reconstituted in 4.0 ml assay diluent, the standard contained a protein 
concentration of 10,000 pg/ml. The prepared components were stored at 4 °C in order 
to protect them from exposure to light. The binding complex between antibody and 
cytokine provides a fluorescent signal which reflects the concentration of the analyte 
in the test matrix. Standard curves were generated to determine the concentration of 
each analyte in the test sample (figure 2.9). The CBA assay was performed by staff of 
















2.9 RNA extraction and quantitative real-time reverse transcription PCR 
Quantitative real-time PCR (q-RT-PCR) was performed to determine the gene 
expression levels of SEMA3B and furin-like pro-protein convertases in all the breast 
tumour and non-tumour cell-lines. The mRNA expression of all genes of interest were 
analysed by q-RT-PCR. The qRT-PCR assay is based on measuring the fluorescence 
using SYBR Green as a fluorescent reporter molecule. In this technique, RNA is 
transcribed into complementary DNA (cDNA) by reverse transcriptase from mRNA and 
then used as the template for the q-RT-PCR reaction.  
2.9.1 RNA extraction 
Total RNA was isolated from cultured cells using the Qiagen RNeasy mini kit and 
following the manufacturer’s instructions. Once cells reached 80-90% confluence, they 
were detached from the bottom of the flask using trypsin, centrifuged, and then the 
cell pellet was re-suspended in 1 ml of fresh media and counted as described in 2.2.2. 
A minimum of 1 x 106 cells/ml were then lysed as follows. 350 µl of RLT buffer was 
added to the pellet, containing guanidine isothiocycanate and lysis buffer, which 
deactivated RNAses and bind RNA to the silica membrane in order to extract cell 




nucleic acid. The sample was then homogenised using a 21-gauge needle and a 1 ml 
syringe. Then, 350 µl of 70% (v/v) ethanol was added and mixed thoroughly to provide 
optimal RNA-binding conditions, and the lysate was transferred to a silica-based 
RNeasy Mini spin column. The silica membrane selectively helps to exclude short RNA 
molecules of <200 nucleotides, enriching the mRNA. The column was centrifuged at 
8000 x g for 15 seconds. After centrifugation, 700 µl of a guanidine salt-containing 
buffer (RW1) was added to the spin column and used as a washing buffer in order to 
remove proteins and debris, and the column was again centrifuged at 8000 x g for 15 
seconds. The flow through from the column was discarded and 500 µl of RPE buffer 
was added to the top of the column to remove any excess traces of salts, and the 
centrifugation step was repeated. This step was performed twice to ensure thorough 
washing. The spin-column containing sample was then transferred into new collection 
tubes and 50 µl of RNase-free water was loaded directly into the spin column, which 
was then centrifuged for one minute at 8000 x g, releasing the RNA into the water. 
The eluted RNA was collected and was stored at -80 °C until required. 
In order to remove unwanted DNA from the cell lysate, and to treat RNA samples with 
DNase in order to minimise genomic DNA carryover, which has the potential to affect 
the result, an RNAse-free DNAse kit was used. 50 μl of RNA sample was incubated 
with 1 μl DNAse I and 5 μl of the RNAse-free DNAse 10x reaction buffer for 30 minutes 
at 37 °C. The DNAse reaction was terminated by the addition of 5 μl of the stop solution 
(inactivation enzyme) and left for 5-10 minutes at room temperature to be centrifuged 
for two minutes at 14000 x g, at which point the supernatant was collected. 
2.9.2. Assessment of RNA yield and quality 
The purity and the quantity of nucleic acid were measured using the NanoDrop 
spectrophotometer machine. 1 µl of RNase-free water was placed into the NanoDrop 
machine for the blank measurement and stored as a reference spectrum; then, 1 µl of 
sample was added and the ratio of absorbance measured at 260 and 280 nm, used to 
calculate the purity of the extracted RNA, determined from the ratio 260/280 and the 
concentration of the RNA. A ratio of ~1.9 - 2.1 is considered to be pure RNA. As 
determined from the NanoDrop measurement, the concentration of the extracted 
nucleic acid was calculated and 100 ng/µl was used for all cell-lines. 
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2.9.3 Reverse transcription polymerase chain reaction (RT-PCR) 
cDNA was synthesised from the extracted RNA using a High-Capacity cDNA Reverse 
Transcription Kit and following the supplier’s instructions. cDNA was prepared 
according to the table 2.3, No-RT control (no reverse transcriptase) was included in 
each experiment to ensure that the run had no contamination. The RNA template (50 
ng in 10 μl) was add to a 20 μl reaction mixture of MultiScribe reverse transcriptase, 
reverse transcriptase buffer, random hexamer primers and dNTP mix, as described in 
table 2.3. The mixtures were added into 0.5 ml reaction tubes on ice. The tubes were 
then placed in a thermal cycler and the RT-PCR programme started using the following 
conditions listed in table 2.4 to generate complementary DNA. 
Table 52.3: Component of Reverse Transcription Master Mix 
Reagents Final volume 
(Per 20-μL reaction) 
Description 
Nuclease-free H2O 4.2 μl For dilutions 
MultiScribe™ Reverse 
Transcriptase, 50 U/μL 
1 μl RNA–dependent DNA polymerase 
which uses single-stranded RNA as 
a template to generate a cDNA 
strand 
10✕RT Buffer, 1.0mL 2 μl Obtains higher yield of cDNA 




Produces short cDNA fragments 
that would convert mRNA to cDNA 
25✕dNTP Mix (100mM) 0.8 μl 
(0.5 μg/μl) 
Contains premixed aqueous 
solutions of dATP, dCTP, dGTP 
and dTTP 
Extracted RNA X µl - 
Total 20 μl 
 
Table 62.4: Thermocycler parameters for cDNA synthesis 
Step Temperature Time 
Pre-denaturation 25 °C 10 minutes 
Primer extension 37 °C 120 minutes 
cDNA synthesis 85 °C 5 minutes 







2.9.4 Quantitative polymerase chain reaction (qPCR) 
Quantitative real-time PCR was performed using the SYBR® Green qPCR Master Mix 
and following the manufacturer’s instructions. The components of the Master Mix are 
described in table 2.5, a total volume of 9 µl containing SYBR green mastermix, 
nuclease-free H2O, and the primers for the gene of interest (section 2.1.4) were loaded 
into each well of the qPCR 384 well plates and 1 µl of cDNA was added to the 
corresponding wells. Each sample was run in triplicate. Glyceraldehyde-3-phosphate 
dehydrogenase gene GAPDH (a reference housekeeping gene) was used as an 
endogenous control in each run. The qPCR plate was sealed with an optical adhesive 
film and then centrifuged at 2000 x g for two minutes using a Sorvall Legend X1 
centrifuge before being placed into the PCR machine. 
 Table 72.5: Components of qPCR Master Mix 
 
Then, the plate was placed into the 7900HT Applied Biosystem and the machine was 
set up according to the supplier’s protocol, as in the following table 2.6: 
Table 82.6: Parameters for qPCR 
 
All the primers used (All-in-One™ qPCR Primers) were experimentally validated by 
the manufacturer and a single amplification curve of the correct size for the targeted 
gene was generated. The primers were therefore not further validated. 
Reagents Final volume (per 10μl reaction) 
Nuclease-free H2O 3 μl 
SYBR Green 5 μl 
Gene of interest primer/ reference gene primer 1 μl (0.2 μM) 
cDNA sample 1 μl 
Total 10 μl 
Cycles Reaction Step Cycle length Temperature 
 





x 40 cycles 
Denaturation 
(to separate the DNA 
strands) 
15 seconds 95 °C 
Data Collection 
(annealing step to allow 
the primers to anneal to 
the template of interest 
1 minute 60 °C 
Extension step  15 seconds 72 °C 
 Melt curve 15 seconds 95 °C 
 Cooling 15 seconds 60 °C 
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2.9.5 Data analysis 
The Ct values were retrieved automatically from the PCR system. The first cycle at 
which the amplification curve is generated is called the Ct or threshold cycle, which is 
the first point at which the target amplification is detected. This reflects the amount 
and the concentration of the target in the reaction, where lower Ct values indicate high 
target concentrations. Melting curves were generated for each run in order to verify 
the specificity of each PCR reaction. The GAPDH reference gene was used to 
calculate the relative amount between each target gene and GAPDH. GAPDH was 
used as an endogenous control because its expression does not change between the 
different cell-lines. In order to calculate the change in Ct, relative quantification was 
used to normalise each respective gene to the GAPDH reference. The mean of each 
gene Ct, was subtracted from the mean of the reference gene Ct, according to the 
following equation: ΔCT= Ct [target gene] - Ct [reference gene]. These values were 
compared between the samples being analysed. The experiments were repeated 
three times for each gene, with three wells per gene per repeat. 
2.10 Western blot analysis 
Western blot analysis was carried out to determine the expression of SEMA3B and 
Furin-like pro-protein convertases proteins in all the cell-lines. This technique relies on 
the separation of proteins extracted from cells or in conditioned media, according to 
their molecular weight, on SDS-PAGE. These are then transferred to a membrane and 
the specific proteins of interest detected using specific antibodies. A secondary 
antibody can then identify the primary antibody and in the presence of a soluble 
enzyme substrate, the reaction can be detected by the emitted chemiluminescent light, 


























2.10.1 Sample preparation and extraction 
Once cells reached 80-90% confluence, they were washed twice with 10 ml cold 
DPBS. Then, 1 ml of RIPA lysis buffer, which contains (25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), mixed with 10 µl halt 
protease phosphatase cocktail inhibitors (leupeptin which targets serine and cysteine 
proteases), was added to the cells to extract the proteins. The function of these 
inhibitors is to block or inactivate endogenous proteolytic and phospholytic enzymes 
that are released during cell lysis, so to avoid any protein degradation. It should be 
mentioned that the protease inhibitors were used when lysates were extracted for 
analysis of rSEMA3B stability (see section 2.10.10) to prevent excessive proteolytic 
degradation. Cells were then incubated with the lysis buffer for five minutes, with 
continuous movement and on ice so as to avoid protein degradation, before they were 
scraped and collected into Eppendorf tubes and were passed through a 25-G needle 
ten times to rupture the cell wall and release the proteins into the solution. Lysed cells 
were incubated for 30 minutes on ice to allow full lysis, followed by centrifugation at 
Figure 2.10: Western blotting procedure. The samples are loaded onto the gel and 
separated by SDS-PAGE according to their molecular weights, and then transferred to 
a PVDF membrane. The membrane is blocked and the target protein is incubated with 
a highly selective primary antibody and a secondary antibody. The reaction can be 




13000 ×g for 15 minutes at 4 °C to remove cell debris. The supernatants containing 
the proteins were collected, a small aliquot was used in the protein quantification 
assay, and the remaining sample stored at -80 °C until use.  
2.10.1.1 Collection and concentration of conditioned medium 
Since cells are known to release proteins into the culture medium it was important to 
study the protein expression of SEMA3B and other pro-protein convertases in 
conditioned medium in parallel with protein lysates. Once cells reached 70% 
confluence, the medium was then changed to a serum-free medium for a further 24 
hours and the conditioned medium was then collected and concentrated by 10 or 20 
fold by centrifuging it using a swinging-bucket rotor at 4000 x g for 30 minutes using 
Amicon® Ultra-4 Centrifugal Filter Units. The retained concentrated medium was 
collected and stored at -80 °C until needed. Proteins were quantified in conditioned 
media as described below for cell lysates.  
2.10.2 Protein quantification 
Protein quantification was measured using a Micro™ BCA Protein Assay Kit to ensure 
equal protein loading onto the Western blotting (SDS-PAGE) wells. The principle of 
this assay is that Cu2+ is reduced to Cu1+ by proteins under alkaline conditions and the 
cuprous cation (Cu1+) can be detected by bicinchoninic acid, which is highly sensitive 
and specific. The relationship between absorbance and protein concentration is close 
to linear, allowing determination of unknown protein concentrations from a standard 
curve. That standard curve was generated by diluting bovine serum albumin (BSA) 
stock to a final concentration of 0.2 mg/ml (w/v) (100 µl stock to 900 µl of the sample 
diluent, RIPA buffer), after which standard dilutions, which ranged from (0-20 µg/ml) 
were prepared, as shown in table 2.7. Samples were then prepared at different 
concentrations, 1:50, 1:100, 1:200 (table 2.8), to confirm that the absorbance of 
samples will fall within the range of the prepared BSA standard curve.  
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BSA µl of 0.2mg/ml working stock 
 
µl of dH2O 
 
1 0 0 1000 
2 2.5 12.5 987.5 
3 5 25 975 
4 7.5 37.5 962.5 
5 10 50 950 
6 15 75 925 
7 20 100 900 
 
Table 102.8: Sample preparation for BCA assay 




1:50 20 µl 980 µl 
1:100 10 µl 990 µl 
1:200 5 µl 995 µl 
 
150 µl of the BSA standard, blank and unknown protein samples were pipetted into 
96-well plates in triplicate. The BCA working stock solution contained 25 parts of 
reagent A (containing alkaline tartrate-carbonate buffer) and 24 parts of reagent B 
(containing bicinchoninic acid solution) and 1 part of solution C (copper sulphate 
solution) (2.5 ml, 2.4 ml and 0.1 ml, respectively), mixed until light green in colour. 
Then 150 µl of this working solution was added to each well. The plate was then 
incubated at 37 °C for two hours and the absorbance was measured at 562 nm 
(Fluostar Galaxy Reader). The standard curve was used to calculate the protein 
















2.10.3 SDS-PAGE and gel preparation 
Gels containing 10% sulphate-polyacrylamide, which were 1.5 mm thick, were 
prepared as below (table 2.9). 
Table 112.9: Gel preparation 
Resolving gel Reason Stacking gel 
Reagents Quantity Reagents Quantit
y 
dH2O 8.1ml To make a reagent dilution dH2O 6.1 ml 
1.5M Tris-
HCL /PH8.8 








200µl Sodium dodecyl sulphate is a detergent that 
has been known to denature proteins. It has 
a negative charge so it can apply large 
negative charges to all proteins to help 
them migrate toward the positive pole of an 






6.6ml To complete removal of oxygen from the 






100µl Ammonium Persulfate (APS) is an oxidising 
agent that was used to catalyse the 




TEMED 25µl N,N,N',N'tetramethylethylenediamine is a 
free radical stabiliser which is generally 
included to promote polymerisation by 
catalysing acrylamide. 
TEMED 25 µl 
* 10% (w/v) APS was freshly prepared by dissolving 100 mg of APS in 1 ml of 
dH2O. 
Figure 2.11: BCA standard curve example. The line is the linear regression curve 
for the entire set of standard BSA points. This was generated automatically using 
GraphPad Prism 7 software. 
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After the resolving gel was prepared, it was poured into the gel cast and a small volume 
of ethanol was added to remove air bubbles and generate a flat surface. The gel was 
then left for about 30 minutes to set at room temperature. After which the excess 
ethanol was removed and the gel was washed with deionised water and then dried 
using filter paper. The prepared stacking gel solution was added and the comb was 
placed and left to set for 30 minutes. Both layers of stacking and resolving gels were 
arranged to ensure that all of the proteins reached the running gel at the same time, 
regardless of their molecular weight, allowing them to migrate smoothly as tight bands.  
2.10.4 Sample preparation and loading 
1x volume of cell lysate, diluted to a final concentration of 20-50 μg protein in dH2O, 
was incubated at 95 °C for ten minutes with 1x volume of 2X Laemmli. Laemmli buffer 
contains 4% (w/v) SDS to denature the proteins and make them linear molecules, 10% 
2-mercaptoethanol to reduce disulphide bonds, 20% (v/v) Glycerol to increase the 
density of the sample, 1% (v/v) Bromophonol blue used as a track dye, and 0.125 M 
Tris-HCl (pH 6.8) and dH2O. 
2.10.5 Electrophoresis and protein transfer 
5 µl of precision plus protein dual colour standards (MW range: 10-250 kDa) was 
loaded into the first lane in order to track the molecular weight of each band. Prepared 
cell lysates were loaded into the 10% SDS-PAGE gel and the gel was run in a tank 
containing 1x running buffer (25 mM Tris, 190 mM glycine and 0.01% (w/v) SDS) to 
generate an electric connection between gel and electrodes. Gels were run at 100 V 
for 30 minutes until the samples had passed through the stacking gel. Then the voltage 
was increased until the blue dye ran off the bottom of the gel. The casting plates were 
separated, the stacking gel removed and the proteins were then transferred to 
polyvinylidene fluoride (PVDF) membrane using a semi-dry transfer machine. In order 
to create the transfer sandwich, the PVDF membrane was soaked in methanol for five 
minutes to activate it and then washed with dH2O for five minutes. After that, it was 
placed into 1x transfer buffer (containing 25 Mm Tris, 190 glycine and 20% (v/v) 
methanol) for five minutes. At the same time, filter papers were also soaked in the 
transfer buffer. The transfer sandwich was generated by placing the pre-soaked filter 
paper, then membrane, then gel and then a final layer of pre-soaked filter paper, rolling 
out the layers to ensure removal of air bubbles, which could disturb the transfer of the 
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proteins (Figure 2.12). The transfer machine was run for seven minutes at 1.3 A and 
25 V. After confirming that the proteins were transferred to the membrane successfully, 
by checking the transfer of pre-stained standards visually, the membrane was washed 
once with 1X TBST. This was prepared by mixing 100 ml of 10X TBS with 900 ml of 
dH2O and 500 µl of Tween-20 0.05% (v/v) and mixed well. The membrane was 
incubated in blocking solution (5% (w/v) non-fat milk in 0.05% TBS-Tween) at room 










2.10.6 Antibody probing and blot development  
After blocking, the membrane was incubated with optimised primary antibodies of 
interest. The desired concentrations of antibodies were diluted in the blocking solution 
and were incubated on a shaker overnight at 4 °C. On the following day, the membrane 
was incubated for one hour at room temperature on the shaker and was then washed 
with TBST three times for five minutes each time in order to remove all unbound 
antibodies. Then, 10 ml blocking solution containing an appropriate dilution of the 
relevant horseradish peroxidase (HRP) secondary antibody, was placed on the 
membrane and incubated for one hour on the shaker at room temperature. After the 
incubation, the membrane was again washed with TBST five times for five minutes 
each time.  
Figure 2.12: Semi dry elecroblotting arrangement: The membrane was placed on 
soaked filter papers with the transfer buffer followed by placing the gel on the 
membrane. A further layer of soaked filter was placed on top, as seen in the figure.  
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2.10.7 Chemiluminescence development 
In the dark room under red light, the enhanced chemiluminescence (ECL) substrate 
was added to the membrane and was left for five minutes to react. After removing 
excess substrate from the membrane, it was wrapped in plastic and placed in a 
hypercassette and exposed to X-ray film for a time ranging between 30 seconds and 
one hour depending on the band intensity. Afterwards, the film was placed in a 
developing solution until the bands developed (1-2 minutes), and then was washed 
with tap water before transferring into the fixing solution for 1-2 minutes and then 
washing again with running water and left to dry. The film was then scanned and saved 
for analysis. 
2.10.8 Stripping and re-probing of membranes     
Loading controls were performed in order to check that protein quantities had been 
loaded equally and efficiently, and to compare the expression level between different 
samples. Since ß-actin is involved in the cytoskeletal structure of cells and is therefore 
present in all human cells, its expression level is similar in almost all cells, meaning 
that it can be used as a loading control. In order to assess the levels of ß-actin, the 
initial antibodies needed to be removed from the membrane and this was done using 
a stripping solution. The membrane was washed with TBST for five minutes and then 
5 ml of stripping buffer was added to the membrane and kept for 15 minutes at room 
temperature to allow the release of the first set of probes of the primary and secondary 
antibodies from the membrane. After the incubation, the stripping buffer was removed 
and the membrane was washed with TBST three times for five minutes each and 
incubated in 10 ml of blocking buffer for an hour at room temperature with shaking. 
The blocking buffer was removed and the membrane was washed twice with TBST for 
five minutes each time. The TBST was discarded and 10 ml of the blocking solution 
containing 1:10000 of anti-β-actin antibody was added and incubated overnight at 4 
°C. On the following day, the membrane was incubated for 60 minutes on a shaker at 
room temperature before washing with TBST three times for five minutes each time, 
and then 10 ml of the blocking solution containing 1:2000 -1:10000 of secondary 
antibody was added and incubated for 60 minutes. The membrane was then washed 
five times with 1X TBST before developing in the darkroom, using the technique 
described earlier in 2.10.7. 
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2.10.9 Analysis of Western blot 
In order to compare the level of protein expression in the different cell-lines compared 
to the house-keeping β-actin, the intensity of the detected bands were calculated as a 
proportion of the relevant β-actin band using a densitometer programme in the ImageJ 
software. This ensures that the protein loaded was equal and that any differences 
between the amounts of protein seen are not just due to loading differences. Each of 
the detected protein bands was represented as a peak, the signal of which was 
proportional to the amount of the protein loaded. The exposure time was optimised to 
avoid overexposure which can provide inaccurate quantification, if the Western blot 
bands are overexposed the band density will not be different. 
2.10.10 Analysis of rSEMA3B protein 
Two different protocols were used to examine the stability of rSEMA3B when exposed 
to cells or their conditioned media or cell lysates.  
The first protocol was performed in order to test the effect of cell lysates and cell 
conditioned media on rSEMA3B stability. DCIS.com and MDA-MB-231 cell-lines were 
seeded at 10x105 cells per well in 12-wells plate and incubated for 24 hours. The 
medium was then changed to a serum-free medium for a further 24 hours. Lysates 
were extracted as described in section 2.10.1 and conditioned media were collected 
and concentrated 10 to 20 fold to be transferred into Eppendorf tubes. The lysates and 
conditioned media were treated with rSEMA3B (2 μg/ml) and then incubated for three 
hours at 37°C. After incubation, a BCA protein assay was done and 20 μg of protein 
was used for analysing the samples by Western blot (figure 2.13). The concentration 
of protein started to decrease after three hours so we decided to incubate the treated 
and untreated lysates and conditioned media for no longer than three hours. 
The second protocol was performed to test the effect of intact cells on rSEMA3B. 
DCIS.com and MDA-MB-231 cell-lines were seeded at 10x105 cells per well in 12-
wells plate and incubated for 24 hours as above. The medium was then changed with 
serum-free medium for a further 24 hours. The medium was then changed to medium 
containing 1% FCS and cell cultures were treated for 24 and 48 hours with rSEMA3B 
(2 μg/ml). After the incubation, the conditioned media were collected and the cell 
proteins were extracted and collected,a BCA protein assay was done and 20 μg of 




Figure 2.13: Protocols for Western blot treatment by rSEMA3B protein. 
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2.11 Immunohistochemistry of a breast tissue microarray 
Immunohistochemistry was carried out to assess the expression pattern of SEMA3B 
and furin-like other pro-protein convertases in human tissue breast microarrays 
(TMAs) which included a spectrum of tissue from normal, premalignant and cancer 
tissues (table 2.10). 
This technique is the process of using antibodies to detect specific proteins (antigens) 
in cells in the tissue sections of interest. Briefly, the unlabelled primary antibody binds 
to the antigen of interest and then a labelled reporter secondary antibody will bind to 
the primary one. The antibody-antigen binding can be visualised by using an enzyme 
such as HRP, which is commonly used to catalyse a colour-producing reaction. 
Table 122.10: Human tissue breast microarrays slides 
Tissue type  Number of cases supplier 
Normal Tissue 27  
Abcam Uk Atypical Ductal Hyperplasia (ADH) 8 
Ductal Carcinoma in situ (DCIS) 9 
Invasive Ductal Carcinoma 31 
 
2.11.1 Protocol 
The protocol was optimised on tissue sections of pre-invasive (DCIS) and invasive 
breast tissues which were obtained from patients attending the Royal Hallamshire 
Hospital between 1995 and 2003 (Research Ethics: SSREC 98/137).  
All the TMAs slides were baked at 60 °C for 30 minutes in an oven, deparaffinised in 
order to remove the embedding wax and then rehydrated. They were then dewaxed 
using Xylene for ten minutes and transferred into fresh Xylene to ensure that no 
residue of wax was present on the slides which could interfere with the quality of 
staining. Slides were placed into 100% (v/v) absolute alcohol for five minutes, and then 
into a second bath of 100% absolute alcohol for three minutes, transferred into 95% 
(v/v) absolute alcohol for three minutes before incubating for 30 minutes at room 
temperature in a mixture 30 ml (v/v) of hydrogen peroxide and 270 ml of methanol in 
order to block endogenous peroxidase activity and to avoid background staining. After 
incubation, all slides were washed with gently running water for five minutes. 
Heat-induced target retrieval was performed in order to unmask the antigenic epitope 
and enable an antibody to access the target protein within the tissue and therefore 
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recover the antigen. The target retrieval solution 10x (citrate buffer containing 10 mM 
citric acid, 0.05% (v/v) tween 20, pH 6.1) was diluted in dH2O (1:10) and then was 
heated in a microwave for three minutes on high power. The slides were then 
immersed in the solution and heated for seven minutes on low power to avoid boiling 
and damaging tissues. This step helps to increase the staining intensity as well. Slides 
were left to cool for ten minutes and then were rinsed with phosphate-buffered saline 
with 1% (v/v) tween (PBST) once for a few seconds and then washed three times with 
PBST for ten minutes at room temperature on a rocker. Following that, the slides were 
tapped off and tissue paper was used to remove any excess PBST carefully without 
disturbing the tissue. A wax pen was used to draw a circle to minimise the area and 
ensure that the antibodies cover the entire tissue surface on the slides. 
All slides were then placed on a slide tray and a 10% (v/v) blocking solution containing 
300 µl of goat/rabbit serum and 30 µl of casein in 3 ml of PBS, was added to each 
slide to block non-specific antibody binding. The blocking buffer was incubated for 30 
minutes and then the slides were tapped off and the primary antibodies SEMA3B, furin 
and other pro-protein convertases were diluted at different concentrations in 2% (v/v) 
serum as described in table 2.11 and 200 µl was added to each relevant slide. The 
controls for the experiment were as follows, the negative control was incubated with 
only the 2% (v/v) serum blocking solution not containing any antibodies. Positive 
controls were generated by using tissues that were known to express the protein of 
interest (table 2.12), and isotype controls (IgG or IgM) were used to ensure that the 
antibody was specific (table 2.13). All slides were incubated overnight at 4 °C. 
On the following day, slides were washed once with PBST for a few seconds and then 
washed three times for five minutes each on a rocker, and then the relevant secondary 
antibody was diluted at 1:200 in 2% (v/v) serum and 200 µl added to the slides and 
incubated for one hour. At the same time, avidin-biotinylated enzyme complex (ABC) 
containing 2.5 ml of PBS, one drop of A reagent and one drop of B reagent was 
prepared immediately before use and incubated for one hour. Then, the secondary 
antibody was washed off the slides with PBST twice for five minutes each and then 
ABC was applied to the slides and incubated for 30 minutes at room temperature. ABC 
is commonly used to visualise the antibody-antigen complex. The primary antibody 
binds to the antigen to form the first complex and then a biotin conjugated secondary 
antibody is added that is raised against the species in which the primary antibody was 
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made. The secondary antibody is biotinylated and binds to the primary antibody 
forming a large complex. The ABC contains HRP that has a high affinity for biotin and 
which will therefore bind to the biotin on the secondary antibody. The slides were then 
washed with PBST twice for five minutes each and 3-diaminobenzidene 
tetrahydrochloride (DAB) was added as a substrate. The peroxidase enzyme of ABC 
catalyses a colour change in DAB which results in the formation of an insoluble brown-
coloured product.  
Within ten minutes of adding DAB, the slides were checked under the microscope at 
4x magnification to assess the development of any brown colour. Once the brown 
staining could clearly be seen, slides were washed with running water for five minutes 
and then were stained with Gill’s haematoxylin for one minute to visualise the cell 
nuclei. After that, they were washed with running tap water until the run off was clear, 
before incubating in 70% (v/v) alcohol for three minutes to start the  dehydration 
process. Then, slides were placed into 90% (v/v) alcohol for three minutes, 95% (v/v) 
for three minutes, and then 100% (v/v) for two lots of three minutes. In order to mount 
the slides to allow examination under the microscope, the slides were placed in xylene 
for a further two minutes before adding DPX in order to preserve the stain and tissue. 




Table 132.11: IHC Primary Antibodies 
Antibodies Dilution 
SEMA3B antibody (Rabbit polyclonal) 
1:100  
 
Furin antibody (Rabbit polyclonal) 
1:100 
 
PCSK1 antibody ( Rabbit polyclonal) 
1:100 
 
PCSK2 antibody (Rabbit polyclonal) 
1:50 
 
PCSK4 antibody (Rabbit polyclonal) 
1:50 
 
PCSK5 antibody (Rabbit polyclonal) 
1:100 
 
PCSK6 antibody (Rabbit monoclonal) 
1:100 
 
PCSK7 antibody (Rabbit polyclonal) 
1:50 
 
PCSK8 antibody (SKI-1 Antibody mouse monoclonal) 
1:50 
 




Table 142.12: Positive tissue controls used for optimisation of the IHC assay 
Protein of interest 












PCSK1 Mouse brain 
1:100 
 
PCSK2 Mouse brain 
1:50 
 
PCSK4 Prostate tissue 
1:50 
 






PCSK7 Colon tissue 
1:50 
 
PCSK8 Colon tissue 
1:50 
 








Table 152.13: Isotype controls for IHC 
 
2.11.2 Analysis of immunohistochemical staining 
The quality of the staining was approved by a consultant histopathologist Dr. P. 
Vergani Royal Hallamshire Hospital. The staining was assessed in all breast 
epithelium and tumour tissues and scored using semi-quantitative grading systems.  
 The intensity of staining and the scores were given as follows:  
 0= no staining 
 1= weak staining 
 2= moderate staining 
 3= strong staining 
All sections were grouped according to lesion type including normal, atypical 
hyperplasia, DCIS and invasive cancer. Then the percentage was used to determine 
any changes in expression between each type. Each tissue was compared to the 
intensity of the staining in normal breast tissue, and the positive and negative controls 
were used to confirm the validity of the results. The scoring was double assessed by 




Primary Antibody Clonality Isotype 
SEMA3B antibody Rabbit polyclonal IgG 
Furin antibody Rabbit polyclonal IgG 
PCSK1 antibody Mouse monoclonal IgG 
PCSK2 antibody Rabbit polyclonal IgG 
PCSK4 antibody Rabbit polyclonal IgG 
PCSK5 antibody Rabbit polyclonal IgG 
PCSK6 antibody Rabbit monoclonal IgG 
PCSK7 antibody Rabbit polyclonal IgG 
PCSK8 antibody Mouse monoclonal IgM 




Cytospin is a technique that is used to concentrate cells in a defined area by using a 
special centrifuge in order to deposit cells evenly onto slides. Since some antibodies 
did not work in the Western blots, despite attempts at optimisation, cytospins were 
generated to establish whether the protein expression of these specific proteins could 
be identified in the cell-lines. The cytospins were followed by immunocytochemistry 
for detection of the protein expression. Positive controls of cells known to express the 
protein of interest were included. 
2.12.1 Protocol 
Once cells reached 70% confluence, cells were washed twice with 10 ml DPBS and 
trypsnised as described in 2.2.2. In order to optimise the ideal number of cells that 
would give an even spread in a cytospin, different cell concentrations of 1x104, 2x104, 
5x104 and 1x105 cell/ml were spun with 5x104 cells/ml being identified as the optimal 
concentration where the cells were not too condensed and were distributed evenly on 
the slides when 200 µl of the cell suspension was used (figure 2.14). Labelled slides, 
chambers and blotter for each sample were prepared and 200 µl of each cell 
suspension was added to each slide chamber. Then the slides were centrifuged at 
800 x g for two minutes. The slides were removed from the cytocentrifuge and were 
left to dry prior to staining. All slides were then processed by immunocytochemistry in 
a similar way to immunohistochemistry. 
The slides were fixed with absolute methanol for 30 minutes at room temperature and 
then incubated in permeabilisation solution, which consists of 0.5% (v/v) Triton 100 
and PBS (5 ml Triton 100 in 1 litre PBS) for five minutes in order to permeabilise the 
membranes of cells. The slides were then washed with PBS three times for two 
minutes each, hydrated in 95% (v/v) ethanol for five minutes and 70% (v/v) ethanol for 




2.12.2 Analysis of cytospin slides  
Slides were analysed based on the intensity of staining and the scores were given as 
follows: 0= no staining, 1= weak staining, 2= moderate staining, 3= strong staining. 
Each slide was compared with the normal cell-line slide. The controls for the 
experiment included a negative control, which was incubated with only the 2% serum 
blocking solution not containing any antibodies, and positive controls which was 
generated by using cells that were known to express the protein of interest. The 
































Figure 2.14: an example of the determination of optimal cell density for cytospin 






2.13 Statistical analysis 
Statistical analysis were carried out using GraphPad Prism software 7 for Windows. 
All data are presented as the mean ± standard deviation (SD) in all graphs. The data 
were analysed using one-way ANOVA test followed by Dunnett’s post hoc test for 
multiple comparison/ two way ANOVA to compare the means of data between groups, 
followed by Tukeys test for multiple comparison. All cell-lines and tissue experiments 
were compared with the normal non-tumorigenic cells. The criterion for statistical 







Chapter 3: Development of an in-vitro Breast Cancer Model for Studying 
SEMA3B 
 
3.1 Introduction  
SEMA3B is a secreted protein that has been known to be expressed in many normal 
cells such as endothelial and neuronal cells, but the expression tends to be 
downregulated in cancer cells such as the breast cancer progresses (Yazdani and 
Terman, 2006, Varshavsky et al., 2008). Although a previous study from our laboratory 
has suggested that SEMA3B expression is reduced in human breast cancer compared 
to normal breast tissue (Staton et al., 2011), there are only minimal studies 
investigating the expression of SEMA3B or response to recombinant SEMA3B in a 
few breast cancer cell-lines in vitro such as MDA-MB-231 and MCF-7 cells 
(Varshavsky et al., 2008, Pronina et al., 2009). It has been found previously that 
SEMA3B mRNA is downregulated in breast cancer MDA-MB-321 cells more than 
MCF-7 cells (Pronina et al., 2009). To date, the SEMA3B expression in breast cancer 
cell-lines and its relevance in tumour progression has not been studied in any detail. 
Epigenetic alterations are frequent events in human cancers. Abnormalities in DNA 
methylation and post-translational modifications of histones, which includes some 
modifications like methylation and phosphorylation are examples of some molecular 
defects in cancer that can affect gene expression. Hypermethylation one of the 
common cancer-related disruptions of the DNA methylome, has been observed in 
breast cancer and found likely to be linked with promotors of tumour suppressor 
genes, causing transcriptional silencing (Kuroki et al., 2003, Loginov et al., 2015). 
However, previously published studies have suggested that downregulation of 
SEMA3B mRNA may be due to the methylation of CpG-islands of the SEMA3B gene 
and contributes to the tumour suppressor function of the SEMA3B gene (Pronina et 
al., 2016). 
SEMA3B is deleted in some types of cancer and decreased in the majority of cancer 
cell-lines due to either allele loss or methylation (Ito et al., 2005). However, SEMA3B 
protein is highly susceptible to degradation by pro-protein convertases, upstream of 
C-terminal it is highly conserved and has been shown to be a cleavage site for the pro-
protein convertases, which therefore may also result in inactivation of SEMA3B 
(Varshavsky et al., 2008). Since it has been shown that furin-like pro-protein 
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convertase processing of SEMA3B can inactivate the anti-angiogenic activity of this 
protein, therefore, it is likely that SEMA3B is a tumour suppressor gene which is 
switched off or mutated during breast cancer development. In order to investigate 
these further, a range of breast cancer cell-lines were used representing the different 
malignancy of breast disease, to study the growth-suppressive and the anti-
proliferative effect of SEMA3B in breast cancer. 
Breast cancers arise in different areas of the breast, therefore, distinguishing between 
each subtype is important as each has different diagnoses and treatment options and 
responses. Based on molecular biology and invasiveness, breast cancers are divided 
into three main groups, including non-invasive, invasive, and metastatic breast 
cancers (see section 2.2.1). Breast cancer is initiated in normal breast epithelium, and 
due to some neoplastic evolution, it progresses to atypical ductal hyperplasia which is 
considered as a pre-malignant stage which develops to ductal carcinoma in situ. Whilst 
a cancer is still confined within the breast and not spread beyond the cell membrane 
this known as non-invasive cancer and this reflects a pre-invasive stage. Once cancer 
cells breach the duct or lobule wall and access to the circulation and lymph system 
they are then classified as invasive cancer. Cancers cells with the ability to travel or 
move to other parts of the body may be highly invasive and have the metastatic 
capacity, are classified as metastatic breast cancers (Bombonati and Sgroi, 2011).  
However, there is no guarantee that the progression of breast cancer is likely to 
progress in sequence from pre-malignant or pre-invasive stage to the invasive stage. 
There is evidence that in situ disease is more likely to progress to invasive breast 
cancer if not treated. The DCIS cells may have bipotential progenitor properties, 
generating heterogeneous cell populations with tumour-initiating features (Hu et al., 
2008, Cowell et al., 2013). It has not been yet identified how to predict the most likely 
patients to develop invasive disease following a diagnosis of DCIS. However, it has 
been observed that 20 to 50% of DCIS patients have developed invasive breast cancer 
later. (Cowell et al., 2013). Therefore, in this chapter, a panel of different cell-lines 
were used to represent each stage of breast cancer progression to mimic the 
development and diversity of breast disease. The MCF-10A cell-line was used as an 
example of non-transformed breast ductal epithelial cells, MCF-10AT cells were used 
to represent pre-malignant hyperplastic ductal epithelial cells, and the DCIS.com cells 
was used to represent pre-invasive ductal carcinoma in situ. The invasive breast 
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cancer cell-lines were chosen to represent a diversity of hormone receptors status and 
metastatic potential. MCF7 have wild-type p53, and T47D have mutant p53, and both 
are hormone-dependent breast cancer cell-lines exhibiting luminal A subtypes (ER 
and PR positive) with non-invasive and low to moderate metastatic potential, 
respectively (Aka and Lin, 2012). Interestingly, T47D cells are more responsive to 
progesterone than the MCF-7 cells, suggesting the susceptibility of T47D cell-lines to 
be targeted and treated with specific progesterone therapy (Yu et al., 2017). MDA-MB-
231 cells, which are less differentiated and have a more mesenchymal-like 
appearance, were used to represent triple-negative tumours (ER-, PR-, HER2-) with 
a highly invasive and metastatic potential capacity. Finally, as bone is the most 
common site of metastasis, we used the fully bone homed MDA-MB-231-BM cell-line.  
Hence, this chapter aimed to assess the in vitro behaviour of this model of breast 
cancer development, and then to study the expression of SEMA3B in breast cancer 
progression. Specific aims were to: 
1. Investigate the proliferation and metabolic activity of the normal, pre-malignant, 
pre-invasive, invasive, and fully bone homed breast cell-lines. 
2. Investigate the migration and invasion of the normal, pre-malignant, pre-
invasive, invasive, and fully bone homed breast cell-lines. 
3. To measure the expression of cytokines in all cell-lines. 
4. To measure the expression of SEMA3B mRNA and protein in these cell-lines 
and see whether it correlated with protein expression in human breast tissues 






The cell-lines representing different severities of breast lesion used in this project were 
maintained in sterile culture conditions as previously described in section 2.2.2.  
3.2.1 Cell counting assay  
The assay was used to investigate the growth pattern of cell-lines used and the viability 
and total cell count of the breast cells. The cell number was counted using an 
automated cell counter machine and the proliferation rate was calibrated based on the 
relative increase in cell number versus the number of days. Untreated tumour and non-
tumour cell-lines were seeded at 2x104 in 12-well plates of three replicates and 
incubated over a 96 hour period in their normal growth medium, and the viable cells 
were counted as described in section 2.3.1. 
3.2.2 MTS assay  
The assay was used to assess the metabolic activity of each cell-line. The untreated 
cells were seeded at 5x103 in 96-well plate for 24, 48, 72 and 96 hours and the optical 
densities were measured at the absorbance of 490nm following the protocol described 
in section 2.3.3.  
3.2.3 Scratch (wound healing) assay  
The assay was used to assess the ability of cells to migrate. The images were taken 
at 0, 24 and 36 hours using a cell imaging system microscope (10X phase objective). 
The rate of wound closure was measured as described in section 2.4. 
3.2.4 Invasion assay  
The assay was used to assess the invasive ability of each cell-line using a pre-coated 
Matrigel invasion chamber. Photomicrographs were taken using a microscope and the 
invaded cells were counted as described in section 2.6. 
3.2.5 CBA assay  
The assay was used to measure different cytokines that have been linked to cancer 
progression following the protocol in section 2.8. 
3.2.6 qPCR analysis 
The technique was performed to investigate the mRNA expression of SEMA3B in all 
the cell-lines by extracting mRNA from the cells, converting to cDNA for use in the 
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quantitative real-time PCR as detailed in section 2.9. The validated SEMA3B qPCR 
primer ID and sequence is listed in table 2.1.4. 
3.2.7 Western blot analysis  
The analysis was used to assess SEMA3B protein expression in all cell-lines by 
preparing 20 μg protein samples, which were resolved by SDS-PAGE, transferred to 
a membrane and probed with the corresponding primary and secondary antibodies for 
visualization by chemiluminscence. β-actin was used as a housekeeping protein to 
normalise protein expression and semi-quantification was performed using Image-J 
software as described in section 2.10. 
3.2.8 Immunohistochemical staining  
This method was performed to characterize SEMA3B expression in human tissue 
microarray sections representing a model of breast cancer progression as detailed in 
table 2.10 along with the positive control tissue for SEMA3B, mouse brain tissue. 
Immunohistochemical staining was performed and analysed as described in sections 
2.11. The total sample size of 75 specimens comprised 
 Normal breast (n=27)  
 Pre-malignant atypical ductal hyperplasia (ADH, n=8) 
 Pre-invasive ductal carcinoma in situ (DCIS, n=9)  
 Invasive breast carcinoma (IC, n=31)  
 
All data were analysed using GraphPad Prism 7 software, with all statistical analyses 
performed by comparing each cell-line/tumour tissue to the non-tumorigenic MCF10A 
cells/normal tissue. The tests used were one-way ANOVA test with Dunnett’s multiple 
comparisons test. Data expressed as mean ± SD from at least three independent 









3.3 Results  
3.3.1 Cell growth of breast cell-lines 
Cell growth curves for all breast cells lines were established to compare the growth 
patterns and rates across the spectrum of breast disease. As shown in the figure.3.1, 
the human mammary epithelial cell-line MCF-10A had the highest cell growth 
compared with all other cells. The pre-malignant MCF-10AT and the pre-invasive 
DCIS.com cells had a slower cell growth compared with the invasive cells except with 
T47D cells as they grew at the slowest growth rate. The cell growth of the invasive 
cells MDA-MB-231 (highly metastatic, triple-negative) and MDA-MB-231-BM (highly 
metastatic, triple-negative, bone homing) were much higher than other pre-malignant, 
pre-invasive and invasive cells (figure 3.1). The exception was the MCF-10A cells that 
proliferated very fast. This could be due to the fact that a different growth medium was 
used to sustain the growth of these cells that included insulin, EGF and hydrocortisone 
and cholera toxin 
The doubling times of all cell-lines were determined by counting the viable cells at 
different time points ( 24, 48, 72 and 96 hours) and then the doubling time of each cell-
line was calculated by doubling time computing tool from Roth (2006) used the 
following equation:  
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 =
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 ∗ log 2
log(𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) − log(𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) 
 
 
There are three phases of the growth curve. These include the lag phase which 
represents the first day of the seeding, the exponential phase is the period when the 
cells start proliferating until they reach the plateau phase when the cell growth is 
inhibited. However, MCF-10A cells had the shortest doubling time (20.83 hours) with 
the highest cell growth. The doubling time for the rest of the cell-lines was in the 
following order: MDA-MB-231 (23.22 hours), MDA.MB.231-BM (25.34 hours), MCF-7 
(30.96 hours), MCF-10AT (32.39 hours), DCIS.com (33.05 hours) and T47D (48.10 
hours) which showed the longest doubling time. The differences in cell growth are 
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Figure 3.1: The cellular growth rate and population doubling time for each cell-
line calculated using doubling time computing software. Cells were seeded at 
2x104 in 12- well plates and incubated for 24, 48.72 and 96 hours after which the cells 
were monitored under the microscope to observe the cell growth and measuring the 
cell number using cell counting chamber. These data are presented as mean ± SD 
from three independent experiments. 
Table163.1: The doubling time of the cell-lines  
Cell type Doubling time ATCC datasheet 
MCF-10A 20.83 hour  20 hours 
MCF-10AT 32.39 hour Not available 
DCIS.com 33.05 hour Not available 
MCF-7 30.96 hour 29 hours 
T47D 48.10 hour 32 hours 
MDA-MB-231 23.22 hour 36 hours 



















P re -m a lig n a n t a n d  p re -in v a s iv e  c e lls










M C F -1 0 A
M C F -1 0 A T
D C IS .c o m
112 
 
3.3.2 Metabolic activity of breast epithelial and tumour cell-lines 
Since differences in cellular metabolic activity may contribute to the tumour cell 
phenotype (Kroemer and Pouyssegur, 2008) and targeting the mitochondrial 
metabolism can help to slow or inhibit the growth and proliferation of cancer cells, 
therefore, the metabolic activity and cell viability across the spectrum of breast cell-
lines were investigated by MTS assay. The cells were seeded at 5x103 in 96-well 
plates for 24, 48, 72 and 96 hours, and the optical densities were measured at the 
absorbance of 490 nm as described in section 2.3.3. As shown in figure 3.2, the pre-
malignant MCF-10AT, normal epithelial MCF-10A and pre-invasive DCIS.com cells 
had higher metabolic activity than other cells. In contrast, invasive breast cancer cells 
demonstrated a lower metabolic activity compared to the non-tumour cells. The 
invasive cells showed a different pattern of metabolic activity, with highly metastatic 
cells showing lower metabolic activity than the low metastatic potential cells with the 
exception of T47D, which demonstrated the lowest metabolic activity (figure 3.2). 
However, the deficiency of mitochondrial activity in aggressive tumours may play a 
role in these findings, resulting in dysfunction of the NADH-oxidizing mitochondrial 
enzymes and therefore altered metabolism in tumours (Zancan et al., 2010). There is 
a positive correlation between glycolytic efficiency, and cell aggressiveness 
suggesting that cells with lower glycolytic efficiency compensate with higher 
mitochondrial metabolism. Therefore, the lack of mitochondrial activity in invasive 
MCF-7, MDA-MB-231 and MDA-MB-231-BM cells, make these cells highly dependent 
on glycolytic flux for energy and consequently have high a glycolytic efficiency with a 
lower mitochondrial metabolism which may result in a lower metabolic activity (Zancan 
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Figure 3.2: Metabolic activity of the non-tumour and tumour breast cell-lines. 
Cells were seeded at 5x103 in 96-well plate and incubated for 24, 48, 72 and 96 hours 
after which MTS reagent (20 µl) was added and incubated for three hours before the 
absorbance was measured by spectrophotometer at 490 nm in order to assess the 
metabolic activity of each cell-line. These data are presented as mean ± SD of three 
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3.3.3 Migration of breast epithelial and tumour cell-lines 
A migratory phenotype is required for the development of metastasis, therefore the 
scratch assay was performed to assess the cell migration rates of the different cell-
lines. Cells were seeded at 1x105 in 24-well plate to obtain a confluent monolayer after 
48 hours, then subjected to a scratch, with images captured at 0, 24 and 36 hours post 
wounding as described in section 2.4.2. The cells were treated with mitomycin C to 
inhibit cell proliferation one hour prior to the scratch assay, thus ensuring only 
migration is assessed. The rate of migration was measured by quantifying the total 
distance across the scratch at each time point compared to the zero-hour time point.  
As shown in figure 3.3, the results indicated that the normal, the pre-malignant and the 
pre-invasive cells did not migrate over the 36 hours time point of the assay. However, 
the invasive cell-lines did migrate, the fastest rate of migration by MDA-MB-231-BM > 
MDA-MB-231> MCF-7> T47D at 24 hours (100% ±, 60% ±, 49.34% ±, 30 % ±, 
respectively). By 36 hours, both MDA-MB-231-BM and MDA-MB-231 cells had 100%± 
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Figure 3.3: The migration of breast cancer cells. A) Representative photograph 
images. Scale bar = 100 µm. B) Percentage of wound closure at two time points. Cell 
migration was captured at 0, 24, and 36 hours on the EVOS® Cell Imaging System. 
The data are representative of three independent experiments. Error bars represent 














3.3.4 Invasion of breast epithelial and tumour cell-lines  
As migration and invasion involve different mechanisms, with invasion requiring the 
ability to degrade and migrate through a basement membrane and/or extracellular 
matrix, the invasion assay was carried out to understand the behaviour and the ability 
of normal and cancer cells to invade through Matrigel pre-coated transwell chambers 
representing invasion through the basement membrane. In order to encourage the 
cells to invade a chemo-attractant gradient was established by using complete growth 
medium containing 10% FBS, to measure the capacity of the cells motility and 
invasiveness toward a chemo-attractant gradient as described in section 2.6. 
As shown in figure 3.4, the non-malignant MCF-10A, pre-malignant MCF-10AT or pre-
invasive DCIS.com cell-lines did not invade as demonstrated by the absence of cells 
on the underside of the membrane. However, the invasive tumour cells were able to 
cross the basement chambers. The highest number of invaded cells were observed in 
MDA-MB-231 (246 ±), MDA-MB-231-MB (234.68 ±) then MCF-7 (217.5 ±), whilst 



















Figure 3.4: Invasion of breast epithelial/tumour cell-lines. A) Representative 
image of a randomly selected field of invasion. The cells were stained with 
haematoxylin and the invaded cells were counted by eye and using the cell counter 
in Image J software. The images show no invaded cells in normal, pre-malignant, and 
pre-invasive cells compared to the invasive cells. Scale bar = 100 µm. B) The data 
are representative of three independent experiments. Error bars represented mean ± 




3.3.5 Cytokine expression of breast epithelial and tumour cell conditioned media 
Breast cancer progression is linked to a change in the expression of cytokines, 
including IL-11 and IL-8. Therefore, to validate this cell-line model as a good model of 
breast cancer progression for use in investigating SEMA3B expression, it was 
essential to establish the changing expression of common key cytokines in the model. 
The data from the CBA assay measured the expression of six critical cytokines in the 
conditioned medium, and the data is presented in figure 3.5. 
IL-8 is a chemoattractant cytokine that induces chemotaxis in target cells. It is found 
to be a potent mediator of angiogenesis. IL-8 secretion is increased in inflammation 
and has been implied to have a role in cancer development (Waugh and Wilson, 2008). 
Our findings demonstrated a high expression of IL-8 in all the cell-lines with the highest 
expression found in MCF-10A and the lowest expression in T47D cells (P <0.0001). 
IFN-Y has the ability to inhibit the growth of several types of a tumour; however, 
recently it was found that IFN-Y also has a stimulating effect on tumour progression 
(Xu et al., 2009, Mojic et al., 2017). Our result showed that the expression of IFN-Y 
was very low or non-existent in all the cell-lines.  
IL-10 is a pleiotropic anti-inflammatory cytokine and has been known to have a variety 
of roles in breast cancer progression. Although IL-10 is demonstrated to have an anti-
tumour effect, IL-10 also decreases the immune response. IL-10 has been shown able 
to suppress the production of other cytokines such as IL-8, IFN-Y, IL-12 and GM-CSF. 
The secretion level of IL-10 has been found more in tumour than in normal cells e.g. 
in supernatant of breast cancer cell, the secretion of IL-10 found able to stimulate 
angiogenesis of breast cancer (Sabat et al., 2010, Hamidullah et al., 2012). However, 
our results showed that IL-10 was minimally expressed in all the cell-lines, with no 
significant differences between the cell-lines. 
In contrast, IL-11 is a member of the IL-6 family of cytokines, and its overexpression 
is associated with tumorigenesis and inflammation (Johnstone et al., 2015). However, 
our data showed low expression of IL-11 in MCF-10A and T47D cells but had 
significantly high expression of IL-11 in invasive cells including MCF-7 (P<0.0001), 
MDA-MB-231 (P<0.0001), and MDA-MB-231-BM (P<0.0001) compared with the 
normal epithelial MCF-10A cells. 
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G-CSF (Granulocyte-colony stimulating factor) has been known to stimulate neutrophil 
proliferation and maturation. It, therefore, helps to fight infection by inducing the 
production of cytokines (Xu et al., 2000). Our findings showed that G-CSF expression 
was low in the breast epithelial cell-line MCF10A, pre-malignant MCF10AT and pre-
invasive DCIS.com and T47D cell-lines, but was significantly increased in MCF-7 
(P<0.0001) and MDA-MB-231 invasive cell-lines (P<0.0001) compared with the 
normal MCF-10A cells, but reduced again in the fully bone homed MDA-MB-231-BM 
cell-line. 
GM-CSF (Granulocyte-macrophage colony-stimulating factor) that functions as a 
cytokine and has a vital role in the inactivation of VEGF. It helps decrease the 
progression of angiogenesis and metastasis of cancers (Eubank et al., 2004). 
However, our data found that the expression of GM-CSF showed an almost identical 
pattern to G-CSF, with significantly increased expression in MCF-7 (P<0.0001) and 
MDA-MB-231 invasive cell-lines (P<0.0001) compared to normal cells.  
It should be noted that the number of cells in the collected supernatant was not 
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Figure 3.5: Concentration of cytokines (pg/ml) in different cell-lines 
supernatants measured by CBA. Cells were seeded at 2x106 cells/ml in T75 flask in 
complete medium. After reaching 70-80 % confluency, the media was replaced with 
serum free medium and after 24 hours the medium was collected and centrifuged at 
1000 x g for five minutes. The supernatants were then collected to be investigated by 
CBA.These data are the mean ± SD of three independent experiments. Data was 
analysed statistically by two-way ANOVA followed by Tukey's multiple comparisons 
test, with comparisons to the normal MCF-10A cells. ****P<0.0001 with respect to 









3.3.6 SEMA3B mRNA expression in breast epithelial and cancer cell-lines 
As some studies have indicated, the expression of SEMA3B may be lost in tumour 
cells, (Tse et al., 2002, Castro-Rivera, 2005) we therefore investigated the expression 
of SEMA3B mRNA in our cell-lines representing breast cancer progression to confirm 
whether or not the SEMA3B gene is expressed. SEMA3B mRNA was determined by 
qPCR as described in 2.9. GAPDH gene was used as a housekeeping gene for all 
qPCR experiments. The relative expression of SEMA3B was quantified to determine 
the changes in steady-state mRNA levels among all the selected cell-lines and 
expressed relative to the expression level of GAPDH. As shown in figure 3.6, the 
highest SEMA3B mRNA expression was found in MCF-10A cells compared to other 
cell-lines with a gradual decrease in gene expression seen with increasing malignant 
and invasive potential of the cell-lines with the lowest expression found in MDA-MB-



















Figure 3.6: qPCR analysis of SEMA3B mRNA expression in breast normal 
/cancer cells lines: RNA was extracted from cells and cDNA was synthesised and 
was analysed by qPCR. GAPDH was used to confirm the integrity of RNA. Data are 
presented as a ratio to GAPDH. Y-axis represented the Delta Ct which was calculated 
by subtracting the mean of cell Ct from the mean of the reference gene. Data 
presented the mean +/- SD of three independent experiments. The lower the Ct level 
the higher the amount of target nucleic acid. Data was analysed statistically by one-
way ANOVA with Dunnett's multiple comparisons and P values were generated * 












3.3.7 SEMA3B protein expression in normal breast and cancer cell-lines 
Since the expression of SEMA3B mRNA was detected in all the cell-lines, but with 
reduced expression with increasing malignancy of the cells, it was important to 
determine whether this related to final protein expression of SEMA3B in these cells. 
The protein expression of SEMA3B was evaluated by Western blotting in the cell 
lysates and conditioned media from the cells. 
As shown in figure 3.7, in the cell extracts, only the normal breast epithelial (MCF-10A) 
cells expressed full-length SEMA3B (83 kDa). In all other cell-lines, the only band 
present was at 51 kDa, which was a proteolytically cleaved form of the protein. In 
contrast to the reduced mRNA expression with increasing cell malignancy, levels of 
cleaved SEMA3B protein increased with increasing malignancy with MDA-MB-231 
and MDA-MB-231-BM expressing the highest level of cleaved SEMA3B (P=0.0001). 
Interestingly additional bands were observed at ∼37 kDa present in MCF-7 and T47D 
















































Figure 3.7: Representative immunoblot of the expression of cleaved SEMA3B 
protein in breast tumour and non-tumour cell-lines. Cell lysates were separated 
on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the anti-
SEMA3B antibody. To confirm that the amount of protein in each lane was equal, the 
membrane was stripped and re-probed with anti-β-actin housekeeping protein as a 
loading control. Densitometry analysis was performed for all cells using ImageJ 
software to assess relative band densities. Data are the mean ± SD of three 
independent experiments. Data was analysed statistically by ordinary one-way 
ANOVA followed by a post hoc Dunnett’s test (* represent P<0.05 and **** represent 
P<0.0001 in comparison to the normal epithelial MCF-10A cells). The sizes of 
molecular weight markers are indicated in kDa. The bottom graph refers only to the 
cleaved form of SEMA3B. Representative immunoblot shown of n=3. 
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3.3.8 SEMA3B protein detection in conditioned medium of normal breast and 
cancer cell-lines  
SEMA3B is a secreted protein, we therefore examined the expression of SEMA3B in 
conditioned medium in all selected cells. This result showed a similar pattern of 
expression with MCF-10A cells being the only cell-line to secrete the full-length (83 
kDa) protein, and all others secreting the 51 kDa cleavage product (figure 3.8).  
Compared with the conditioned medium of normal epithelial MCF-10A cell, the highest 
level of cleaved SEMA3B expression was found in MDA-MB-231-BM (P=0.0001) and 
then in DCIS.com then MDA-MB-231 condtioned medium (P<0.05) respectively. 
However, the lowest expression of cleaved SEMA3B was found in MCF-10A 





















































Figure 3.8: Representative immunoblot of the detection of SEMA3B in 
conditioned medium of breast tumour and non-tumour cells. Conditioned medium 
was collected from cells, and was quantified by BCA and then was separated on a 
10% SDS-PAGE gel, and then blotted onto PVDF and probed with an anti-SEMA3B 
antibody. The sizes of molecular weight markers are indicated in kDa. Densitometry 
analysis was performed for all cells using ImageJ software to assess band densities 
and presented as densitometry value. Data are the mean ± SD of three independent 
experiments. Data was analysed statistically by ordinary one-way ANOVA followed by 
a post hoc Dunnett’s test (* represent P<0.05 and **** represent P<0.0001 in 
comparison to normal MCF-10A cells). Representative immunoblot shown of n=3. 
128 
 
3.3.9 Assessment of SEMA3B protein expression in human breast tissue 
Since there are limited studies on the protein expression of SEMA3B in breast cancer 
tissues we aimed to determine whether there is any correlation between protein 
expression in cell-lines and with those obtained from human tissue microarray slides, 
which included different breast tissue stages (normal, atypical hyperplasia, DCIS and 
invasive tissues). The histological analysis revealed that there was a moderate to 
strong cytoplasmic expression of SEMA3B (71.42%) in normal tissue and this 
decreased to 62.5% in atypical ductal hyperplasia and then 28.12% in the invasive 
tissue. The DCIS tissue had surprisingly high expression 75%, but there were only 
nine DCIS samples which may account for this. SEMA3B expression was identified in 
the majority of normal, pre-malignant and pre-invasive tissues, however the 
expression of lower intensity and less extensive was in invasive tissue compared with 




















Figure 3.9: A representative image of the immunohistochemical staining of 
SEMA3B in breast lesions. A) SEMA3B expression in normal breast duct (n=27), 
atypical ductal hyperplasia (n=8), DCIS.com (n=9) and invasive breast cancer tissue 
(n=31). B) The analysis of the expression of SEMA3B based on the colour intensity. 




The rationale behind this study was to determine the putative role of SEMA3B 
expression in breast cancer progression. Understanding the behaviour of cells is 
essential to determine the mechanism of the response we are investigating. Since we 
hypothesised that PPCs cleavage of SEMA3B results in inactivation of SEMA3B in 
invasive breast cancer, characterisation of cell-lines models of breast cancer 
development and determining the expression of SEMA3B in these models were 
important to our study before testing the hypothesis using different cell-based 
functional assays. Therefore, the determination of the growth characteristics, 
metabolic activity, migration and invasion of cell-lines are an important first step. 
When cell growth and metabolic activity of breast tumours and non-tumour cells was 
investigated it was found that the different human breast cell-lines demonstrate 
variability in cell growth depending on the cell behaviour and cell invasiveness. To 
minimize the variability in cell culture, all cell-lines were cultured and assayed in the 
same medium RPMI-1640 except for the normal epithelial MCF-10A cells as they 
require specific nutrients to grow. The addition of hydrocortisone, cholera toxin and 
EGF in the MCF-10A medium were used to stimulate the growth and proliferation of 
MCF-10A cells by inducing the intracellular level of cyclic adenosine monophosphate, 
which has a growth stimulatory effect and therefore increases DNA synthesis (Yang 
et al., 1981). However, the immortalized mammary epithelial cell-line, MCF-10A, which 
is non-tumorigenic, shows a significantly high cell growth compared with the other 
cells, with an increased doubling time of 16-20 hours compared to the other cell-lines 
(Osborne et al., 1987, Bessette et al., 2015). The addition of a numbers of growth 
factors to the media may play a role in this finding, however the cells do not grow or 
have a slow growth rate in the absence of the growth factors. The pre-malignant MCF-
10AT and pre-invasive DCIS.com demonstrated a longer doubling time than the MCF-
10A cells, 32.39 hours and 33.05 hours, respectively. As the growth characteristics of 
human breast cancer is also important in this study, the cell growth of invasive breast 
cancer cells was also established. The highly metastatic MDA-MB-231 and MDA-MB-
231-BM cells showed the fastest cell growth (23.22 and 25.34 hours, respectively) 
after the normal epithelial MCF-10A cells. The absence of the hormone receptors ER, 
PR and HER2 may result in the increased proliferation rate and could help them to 
proliferate faster (Holliday and Speirs, 2011). However, the low metastatic MCF-7 cells 
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which have been isolated from pleural effusions derived from two ER+/PR+ breast 
carcinomas showed a lower cell growth compared to normal epithelial MCF-10A and 
other invasive cells. The exception was the T47D cells as they had the slowest cell 
growth among all cell-lines. Despite the tumorigenic cell behaviour, the differences of 
the doubling time of the cells may have an impact on the cells behaviour as the 
doubling time of MDA-MB-231, MDA-MB-231-BM, MCF-7 and T47D are 23.22, 25.34, 
30.96 and 48.10 hours respectively as this is an index of proliferations behaved. These 
data suggest that the cell doubling time maybe contributes to the cell metabolic activity 
and the cell growth. 
Our findings observed that the invasive T47D cells were slower growing than other 
malignant and non-malignant cells used in this study. This was unexpected as 
according to ATCC datasheet, the doubling time of these cells is 32 hours while our 
results showed longer doubling time 48.10 hours. However, these findings are 
consistent with a previous study showing that growth rate assessment of a panel of 
breast cancer cells demonstrated that T47D had the slowest doubling time 47.4 hours 
(Risinger et al., 2015). Interestingly, although MCF-7 and MDA-MB-231 are the most 
commonly studied cell-lines in experimental cancer research, a previous study showed 
that T47D showed a closer correlation to human tumours in protein level and molecular 
analysis when compared to MCF-7. In addition, proteins involved in cell growth and  
carcinogenesis are highly expressed in T47D when compared to MCF-7 cells, and this 
could explain why T47D is considered to be more invasive than MCF-7 (Aka and Lin, 
2012).  
The metabolic activity relies on the mitochondrial dehydrogenase enzyme in viable 
cells and shows a different pattern in the cell-lines used in the current study. MCF-10A 
was found to have higher metabolic activity than the majority of other cells, but it was 
a slightly lower than that of MCF-10AT. This suggests mitochondrial dysfunction of the 
cancer cells used (DeBerardinis, 2008). However, when MCF-10A has been used as 
an in vitro model for normal breast cells, it was found to be karyotypically slightly 
abnormal therefore entirely could not reflecting the identical phenotype of normal 
breast cells (Soule et al., 1990, Qu et al., 2015). MCF-10AT, which is a non-
tumorigenic cell-line that was generated from transfecting MCF-10A with T24 RAS 
(Dawson et al., 1996), showed the highest metabolic activity of all the cells. These 
could be due to an alteration in the energy metabolism of MCF-10AT where these cells 
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have been transformed with RAS oncogene resulting in a high glycolytic activity and 
greater glucose uptake (Zheng et al., 2015). DCIS cell-line which is one of the 
derivatives of the MCF10A panel representing ductal carcinoma in situ (Miller et al., 
2000) had a slightly higher metabolic activity than invasive cell-lines but lower than 
premalignant cells. However, there is no previous literature with which to compare 
these results directly, but the metabolic activity does affect the glycolytic efficiency, as 
a previous study showed that aggressive tumours have a deficiency in mitochondrial 
activity and which leads a high depending on glycolytic flux for energy (DeBerardinis 
and Chandel, 2016). These cancerous cells with a high glycolytic efficiency have a 
lower metabolic activity and therefore, the lowest level of intracellular ATP. Moreover, 
the cell doubling time may also contribute to the cell metabolic activity. 
Our data also suggest that the acidification of the culture media due to glycolysis 
throughout the assay, may affect the metabolic activity of the cancers cells resulting 
in more metabolic activity in non-tumorigenic cells than in invasive cells (DeBerardinis, 
2008). Surprisingly, the bone homing metastatic cells MDA-MB-231-BM exhibited an 
increased metabolic activity when compared to the T47D invasive cells. This may 
suggest, that tumour cells may exhibit a different metabolic phenotype by having a 
different level of dehydrogenase activity. However, there are some limitations to the 
MTS assay which is used to assess metabolic activity, as cell-lines may demonstrate 
different levels of absorbance even if they have similar seeding densities and degree 
of cell confluency (Staton et al., 2009). In addition, pipetting errors could affect the 
accuracy of the results. Prolonged incubation of cells resulting in an acidic culture 
condition can affect the production of the formazan product. Also the high cellular 
density could lead to ambiguous results (Johno et al., 2010). 
In terms of cell migration and invasion the scratch (wound healing) assay was then 
performed to assess breast cancer cell migration, a process required for metastasis 
formation that is associated with dysfunction in cell adhesion. Metastasis requires 
increased cancer cell migration as well as invasion. Despite the simplicity of this assay 
and its cost-effectiveness, the scratch is generated by a pipette and the gap width is 
dependent on the pressure applied to the pipette tips. In addition, the process of 
scratching can damage the cells along the edge of the scratch, affecting the migration 
rates of cells (Liang et al., 2007). Care needs to be taken to ensure an even scratch 
(Hulkower and Herber, 2011). Moreover, the proliferation of cells can overtake the 
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migration speed, and therefore, we used mitomycin C to present cell migration (Liang 
et al., 2007). 
When the migration rate was evaluated using the scratch assay, the non-tumorigenic 
epithelial cells MCF-10A, the pre-malignant MCF-10AT and the pre-invasive 
DCIS.com cells did not migrate in the time frame of the assay and likely because they 
lack the invasive and metastatic capacity. These cells are characterized by high 
expression of E-cadherin, which plays an essential role in the adhesion of cells and is 
useful as a phenotypic marker in breast cancer and has been found downregulated in 
tumour cells (Pecina-Slaus, 2003). The findings of the current study are in agreement 
with a previous study that demonstrated that switching off E-cadherin mediates the 
migration of MCF-10A cells (Hirohashi, 1998, Park et al., 2015). However, our findings 
of a non-migratory phenotype of DCIS.com cells are not directly comparable with a 
previous published study which revealed that the untreated DCIS.com cells showed 
some migration after 16 hours. This data may be attributed to the difference in the 
protocol as the cells did not appear to be serum starved or have been treated with 
mitomycin C (Kim et al., 2016). 
In contrast, the migration rate of MCF-7 and T47D cells were reduced in comparison 
to the highly invasive and metastatic cell-lines MDA-MB-231 and MDA-MB-231-BM. 
Furthermore, we showed that T47D cells had a low level of migration, which was in 
agreement with a study using an alternative method, the Boyden chamber technique 
(Neve et al., 2006). These data are in agreement with the literature, showing that 
luminal cells MCF-7 and T47D are more differentiated and have tight cell-cell adhesion 
when compared to basal cells MDA-MB-231 and MDA-MB-231-BM, which are less 
differentiated, leading to the promotion of their migratory and invasive ability (Neve et 
al., 2006). Moreover, the loss of E-cadherin expression in the highly invasive and 
metastatic cell-lines may be implicated in the rate of cell migration and may correlate 
with these findings (Singhai et al., 2011). The ability of bone homing cells to migrate 
was inconsistent with a previous study showing that MDA-MB-231-BM cells 
demonstrated significantly decreased migration of cells in a wound-healing assay as 
it found that at 24 hours, the gap closure of MDA-MB-231-BM cells was 74.4% while 
our findings showed a 100% gap closure by 24 hours. However, this variation in the 
results may be attributed to the difference in the protocol as they seeded the cells onto 
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0.2% gelatin which was absent in our study and this could contribute to this small 
variation (Nutter et al., 2014). 
Despite differences in cell migration being observed between cells, the cell invasion 
was also investigated. The initial step of tumour cell invasion is characterized by the 
breakdown of the basement membrane and followed by the invasion by the cells. The 
Matrigel chamber invasion assay was used to mimic this process. Our findings showed 
that the non-tumorigenic epithelial cells MCF-10A, the pre-malignant MCF-10AT and 
the pre-invasive DCIS.com cells did not invade, whereas the cancer cells did. 
However, the lack of invasive and metastatic capability in non-malignant cells, in 
addition, the non-tumorigenic epithelial cells MCF-10A do not support anchorage-
independent growth, are all factors which could explain our findings (Neve et al., 
2006).  
A high number of malignant cells invaded through the transwell membrane. We cannot 
disregard the fact that differences in invasive capacity of MCF-7, T47D, MDA-MB-231 
and MDA-MB-231-BM cell-lines to invade are due to the presence and absence of ER 
and PR expression on these cells. The absence of these receptors is associated with 
the highly invasive phenotype of invasive and metastatic potential cell-lines. Moreover, 
our result in MCF-7 and T47D are consistent with a previous study that has shown a 
similar number of invaded cells after 24 hours (Zhao et al., 2011, Zheng et al., 2017). 
Interestingly, T47D does appear to be less invasive than the other invasive cell-lines. 
However, since most cell-lines were derived from distant metastatic sites or pleural 
effusions and not from primary breast tumours, this suggests that these cells could be 
more aggressive and may not reflect the behaviour of cells derived from the primary 
tumour. Despite the high cost of this assay, one limitation of conducting the invasion 
assay is that the Matrigel may not set evenly across the membrane, which can result 
in false high-invasion rates as tumour cells pass through the poorly coated area of the 
membrane (Justus et al., 2014). It is also an expensive assay to perform. 
In regards with the cytokine expression of breast epithelial/tumour cell conditioned 
media the previous studies provide convincing evidence that cytokines act as a 
regulator of inflammation and tumour progression by either promoting or inhibiting the 
development of diseases (Esquivel-Velazquez et al., 2015). However, the critical role 
of cytokines in tumour progression cannot be neglected. In response to tissue 
damage, a cascade of events take place to fight infection. Chemotactic signals, which 
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include cytokines, activate leucocytes which migrate to the site of tissue injury. It has 
been proposed that inflammation is implicated in tumour initiation and has a role in 
angiogenesis and metastasis (Esquivel-Velazquez et al., 2015). Since, cytokines are 
an essential player in tumour progression, as they play a role in the regulation of both 
induction and protection in breast cancer quantification of the expression of cytokines 
in all cell-lines would provide evidence of a possible association between their 
expression and breast cancer progression.  
The current study investigated the expression of cytokine variation in breast tumour 
and non-tumour cell-lines, including IL-8, IFN-Y, IL-10, IL-11, G-CSF and GM-CSF. 
Our data showed that the expression of IL-8, which is known to contribute to 
tumorigenesis, showed at a high level in all the cell-lines with the highest level found 
the normal epithelial MCF-10A cells. However, our findings were not in agreement with 
the previous study that showed the expression of IL-8 was significantly higher in breast 
cancer patients compared with healthy controls as we observed a high level of IL-8 in 
non-tumorigenic normal epithelial cells (Benoy et al., 2004). These could suggest that 
the changes in IL-8 levels in cells in vitro may not reflect the serum level in vivo.  
There are inconsistences in laboratory studies since Yao et al. showed suppression 
of IL-8 had no effects on cell proliferation in vitro while it did promote tumour growth in 
nude mice in vivo (Yao et al., 2007). Moreover, in a review that set to determine the 
potential influence of IL-8 in cancer progression, studies showed highly elevated IL-8 
expression in oestrogen receptor‐negative breast cancer and found enhanced 
invasiveness and metastatic potential of both ER- and ER+ breast cancer cells. IL8 is 
used to identify an early stage of breast cancer and as a marker of progression 
(Todorovic-Rakovic and Milovanovic, 2013).  
Another study conducted to identify the role of IL-8 in ER-negative breast cancer cell-
lines MDA-MB-231, revealed that inhibition of IL-8 expression, results in significant 
reductions in cell invasion (P<0.001) and decreases in neutrophil infiltration into the 
tumours (P<0.05) suggesting a potent effect of IL-8 in the regulation of breast cancer 
progression (Yao et al., 2007). Taken together, ER-positive breast cancer, expresses 
a low level of IL-8, which was in agreement with our finding in T47D cells of IL-8 
showed the lowest in these cells suggesting an inverse relationship between IL-8 
expression and oestrogen receptor status (Yao et al., 2007). Consistent with previous 
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studies using tumour cell-lines, we observed significant high expression of IL-8 in all 
invasive cell-lines. 
IFN-γ which has been known to act as an anti-tumor agent by inhibiting the growth of 
some tumours has been found to have an anti-proliferative effect on breast cancer by 
up-regulating the apoptotic members of the bcl-2 family that are essential regulators 
of controlling cell death (Garcia-Tunon et al., 2007). Previous studies indicate the 
importance of IFN-γ in homeostasis by controlling and eradicating the infections and 
some types of cancers (Gooch et al., 2000). It has been shown that IFN-γ expression 
significantly inhibited the growth of normal mammary epithelial cells, resulting in 
irreversible growth arrest of G1, however the growth of MCF-7 and MDA-MB-231 
breast cancer cells was only minimally inhibited. Harvat et al. showed that the 
difference in response to IFN-γ  between normal epithelial cells and breast cancer cells 
might be due to defects in the IFN-γ signal transduction pathway in breast cancer cells 
(Harvat and Jetten, 1996). Work of Gooch et al. reported inhibition of the growth of 
MCF-7 and MDA-MB-231cells by the expression of IFN-γ (Gooch et al., 2000). 
However, our data showed that the expression of IFN­γ was deficient in non­
tumorigenic normal epithelial MCF­10A, pre­malignant MCF­10AT, pre­invasive 
DCIS.com and low in all the invasive cell­lines. These results are in agreement with a 
previous study suggesting that the defect in IFN­ γ signalling in breast cancer cells 
(Gooch et al., 2000). In addition, our data were consistent with a previous study 
reporting decreased IFN­γ in the plasma of cancer patients (Niwa et al., 2001).  
However, it is known that IL-10 suppresses the production of IL-8, IL-12 & GM.CSF 
and regulates the tumour angiogenesis (Huang et al., 1999). The level of IL-10 in 
oestrogen receptor positive patients is significantly linked with breast cancer disease 
free survival (Bhattacharjee et al., 2016). Moreover, a previous study showed that IL-
10 mRNA expression was detected in more than 50% of the breast tumours tissue 
analysed suggesting a potential role for IL-10 in suppressing tumour activity by 
inhibiting T-cell activation, and the antigen presentation by macrophages and the 
presentation of tumour-associated antigens by tumour cells (Venetsanakos et al., 
1997). In addition, the concentration of serum IL-10 was significantly higher in breast 
cancer patients than in the normal serum and was correlated directly with the clinical 
stage of the disease (Kozlowski et al., 2003). Conversely, our results showed that the 
expression of IL-10 was very low in all cells tested with no differences observed 
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between the normal and invasive cells. Interestingly, there is further evidence 
suggesting that an inverse association between IL-10 expression and ER-positive 
breast cancer, demonstrating that low IL-10 expression is associated with poor 
survival rates, which might explain our findings (Ahmad et al., 2018). However, another 
study showed that the IL-10 was decreased in the plasma of cancer patients (Niwa et 
al., 2001). Moreover, IL-10 expression has been shown to decrease the migration of 
MCF-7 and MDA-MB-231 cells when used as a chemoattractant in Boyden Chamber-
based assays, suggesting an anti-metastatic effect on tumour invasion (Ahmad et al., 
2018). However, collectively the data from all of these studies is conflicting so further 
studies are required to determine the relevance of these cytokines. 
Likewise, IL-11 expression is increased in breast cancer compared to normal breast 
tissue and significantly higher in patients with bone metastasis compared to those 
without distant metastasis (Ren et al., 2013). It has been shown that IL-11 stimulates 
breast cancer proliferation and/or invasion in vitro (Nicolini et al., 2006). In agreement 
with this study, we found that the expression of IL-11 was at the highest level in 
invasive cells compared with the non-tumorigenic normal epithelial MCF-10A. 
In contrast, it has been demonstrated that  breast tumours express higher levels of G-
CSF cytokines than normal tissues do (Chavey et al., 2007). Our data showed that the 
expression of G-CSF was significantly lower in pre-malignant MCF-10AT and pre-
invasive DCIS.com cells and T47D compared with the non-tumorigenic epithelial MCF-
10A cells. However, a significantly high level of G-CSF expression was detected in 
MCF-7 and MDA-MB-231 cells compared with the control cell-lines. Our data was 
inconsistent with a previous report which detected very low levels of G-CSF in normal 
breast tissue whereas the G-CSF was overexpressed in breast carcinoma with no 
correlation between the expression of G-CSF and ER status, but correlation with PR-
negative tumours (Chavey et al., 2007). This study could explain why we had a lower 
level of G-CSF expression in T47D cells compared with MDA-MB-231 and MDA-MB-
231-BM cells. 
Nonetheless, GM-CSF expression was also investigated in all the cell-lines and our 
data showed that the expression of GM-CSF was significantly increased in both MCF-
7 and MDA-MB-231 invasive cell-lines compared to normal cells. Chavey et al, 
observed no detection of GM-CSF in the serum of the normal breast sample, however, 
in breast cancer tissue there was significantly overexpressing of GM-CSF, which is in 
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agreement with our findings as the expression of GM-CSF was significantly lower in 
MCF-10A compared with invasive cells (except for T47D cells) (Chavey et al., 2007).  
Overall, in the present study, seven cell-lines including MCF-10A, MCF-10AT, 
DCIS.com cell type and MCF-7, T47D, MDA-MB-231 and MDA-MB-231-BM cancer 
cells have been tested and characterised. Breast cancer subtype can be easily 
distinguished in the cell-lines used in this project. However, the variability in cell culture 
medium should be considered as some like the normal epithelial MCF-10A cells were 
cultured in DMEM/F12 medium with special supplementation for supporting their 
growth while all other cell-lines were cultured in RPMI-1640. The fast growing and the 
shorter doubling time of the normal epithelial MCF-10A cells may appear surprising, 
as these cells should grow much slower than the others but this is a limitation to be 
aware of going forward. However, observations from previous studies have shown 
similar results suggested that the increasing growth potential is likely due to the 
addition of EGF, cholera toxin and hydrocortisone to the medium (Yang et al., 1981, 
Bessette et al., 2015).  
It is important to mention that T47D cells findings are unexpected as they had the 
slowest growth rate among all other cells. It was therefore decided that T47D cells 
would be excluded from further investigations, as the behaviour of these cells is not a 
worthy target for the SEMA3B studies planned in the following chapter. Despite this 
limitation of these cells, it is important to note that the majority of cells were bought 
fresh from ATCC at the beginning of this project and so are unlikely to be 
contaminated. Despite the obvious advantages of using these different cell-lines, the 
continual culture of cell-lines may result in changes in their phenotype and genotype 
(Brodaczewska et al., 2016). In order to minimize these possible changes, low 
passage number have been used throughout the studies. 
In consideration of gene and protein expression of SEMA3B, it was important to 
assess the expression of SEMA3B in these cell-lines used, qPCR was performed to 
determine the gene expression of SEMA3B. qPCR is a highly reproducible and 
sensitive approach (Smith and Osborn, 2009) however, an appropriate internal control 
should be used to allow accurate quantification of the mRNA level (Smith and Osborn, 
2009). We used SYBR green which binds to all double‐stranded DNA, thus in order to 
avoid the generation of non-specific binding products, it was important to use primer 
pairs that are highly specific to our target sequence. Therefore, the optimized primer 
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concentrations (see section 2.1.5) were used to minimize this limitation. The primers 
were validated by melt-curve analysis and performing a standard curve analysis to 
assess efficiency, and the primers had been validated by company (GeneCopoeia and 
Primer design). 
Our data revealed that the cell-lines demonstrated different expression of SEMA3B 
mRNA with significantly lower levels in MCF-10A and moderate expression in the rest 
of the cells. This result is in agreement with a previous study that determined the levels 
of SEMA3B mRNA in different cells lines of breast cancer, ovarian carcinoma and 
renal cell carcinoma. However, out of six breast cancer cell-lines including MDA-
MB231, MDA-MB435S, MDA-436, MCF7, BT 20, BT 474, only MDA-MB-231 cells 
showed a reduction of SEMA3B expression which may correlate with increasing the 
malignancy of disease (Pronina et al., 2009). Hypermethylation of the promoter region, 
is a common event in cancers and studies have found that SEMA3B promoter 
hypermethylation is responsible for silencing its expression in breast and lung cancer 
(da Costa Prando et al., 2011, Pronina et al., 2016). It has previously been suggested 
that down-regulation of SEMA3B expression in cancer is due to methylation of the 
SEMA3B promoter. A previous study in breast cancer showed that MCF-7, T47D and 
MDA-MB-231 cell-lines exhibited complete methylation of tumour suppressor genes 
and that loss of gene expression correlated with hypermethylation of the CpG island 
promoter sequence of RASSF1A. These studies suggested that methylation of the 
SEMA3B gene, which is located upstream of RASSF1 at 3p21.3 is an important 
mechanism of SEMA3B gene inactivation (Dammann et al., 2001, Dworkin et al., 
2009, Pronina et al., 2009). Interestingly, da Costa Prando et al. showed that MCF-
10A cells did not express RASSF1A, revealed by a lack of methylation in these cells 
(da Costa Prando et al., 2011). Moreover, in gastric cancer, it was observed that the 
methylation level was significantly higher in tumour tissue when compared to normal 
tissue (P<0.05) (Chen et al., 2014). In the same study, treatment of gastric cancer 
cells with 5-Aza-2'-deoxycytidine resulted in increased expression of SEMA3B mRNA 
level (Chen et al., 2014). In another study, in lung and renal cancer, similar results of 
SEMA3B methylation were found with methylation negatively correlated with 
downregulation of SEMA3B and therefore likely to be contributing to the suppression 
function of SEMA3B gene (Loginov et al., 2015). All these findings suggest a 
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relationship between methylation status and gene expression pattern in breast cancer. 
Therefore, the SEMA3B reduction seen in our cell-lines may be due to methylation. 
The Western blotting data confirms the qPCR finding that SEMA3B is expressed in all 
cell-lines tested, and shows that the SEMA3B protein identified is in a completely 
cleaved form ∼51 kDa in most of the cell-lines. These findings are not in agreement 
with the qPCR finding, with no decreased protein expression across the sequence. 
However, the data is consistent with a previous study showing SEMA3B cleavage in 
MDA-MB-231 cells and in some lung cancer H661 cells (Varshavsky et al., 2008) 
which may be responsible for disabling its function as a tumour inhibitor.  
In addition to proteolytic cleavage, it is possible that Sema3B variants are generated 
by alternative splicing. Although alternative splicing of this gene has been reported to 
generate 15 splice variants with potential for eight of these to translate into proteins of 
different molecular sizes (Ensemble database) to my knowledge there are not studies 
in the literature reporting the existence of SEMA3B protein variants that might have 
multiple and tissue specific functions.  
SEMA3B contains the conserved pro-protein convertase (PCC) recognition sequence 
site and therefore is cleaved by furin-like pro-protein convertases to generate 
fragments of SEMA3B that are considered to be inactive (Varshavsky et al., 2008). 
This was confirmed using a furin-like pro-protein convertase inhibitor on the invasive 
MDA-MB-231 cells, which resulted in the expression of the full-length 83 kDa SEMA3B 
protein suggesting that it is the furin-like-pro-protein convertases, which generates the 
inactive ∼51 kDa SEMA3B product (Varshavsky et al., 2008). Interestingly full-length 
SEMA3B ∼83 kDa was expressed only in normal epithelial MCF-10A cell suggesting 
that active SEMA3B may be down-regulated with increasing malignancy of the lesion. 
This may be a result of increasing pro-protein convertase activity with increasing lesion 
malignancy which will be investigated in chapter 5. 
The Western blot technique was used to examine SEMA3B protein expression in our 
panel of cell-lines. Despite the advantages provided by this technique, including its 
ability to detect low levels of protein in a sample, and the sensitivity, and specificity, 
Western blotting has its limitations. It is a time-consuming and expensive technique 
and each step and conditions require optimisation. Moreover, the primary antibodies 
may show off-target effects due to interacting with other proteins (Ghosh et al., 2014). 
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With the exception of MDA-MB-231 cells, to our knowledge, this is the first study 
exploring the protein expression of SEMA3B in a panel of increasing malignancy of 
breast cell-lines of models that representing the progression of breast cancer. 
Finally, to confirm the validity of our in vitro cell-line models, immunohistochemistry 
was performed to establish any expression of SEMA3B in normal, pre-malignant, pre-
invasive and invasive breast cancer tissue. It was previously reported from our group 
that SEMA3B expression decreases when the malignancy of breast lesion increases 
(Staton et al., 2011). Our data was in agreement with this previous study and showed 
that the expression of SEMA3B was reduced with the increasing malignancy of the 
lesion, with only a small amount of expression in invasive tissues. However, in the 
present study, the immunohistochemical staining was performed on microarray tissue 
slides while the study of Staton et al. was performed on whole tissue sections, which 
may allow better assessment. Despite many advantages of using 
immunohistochemistry to visualise the antigen-antibody interaction, there are some 
limitations that could interfere with the outcomes including cross-reactivity, resolution 
of antigen localisation and the thickness of the section used. Moreover, the colour 
intensity of patterns depends on the antibody concentration, therefore, optimisation 
should be performed in order to minimise non-specific background and staining has to 
be well optimised (O'Hurley et al., 2014). The limitation of this specific antibody is that 
it will bind both to the cleaved and non-cleaved form of SEMA3B, and there is no 
specific antibody available to distinguish between the two. The cell-line data would 
suggest that in breast cancer, SEMA3B is likely to be present in the inactive cleaved 
form. Although IHC demonstrated a decrease in SEMA3B with increasing lesion 
malignancy in breast cancer, the sample size is too small to assess this statistically. 
The overall sample size (102 cases) was large, but the number of tissue subtypes in 
each group was small, especially for ductal hyperplasia and DCIS tissues. Further 
studies on a larger sample size would enhance these findings. 
In conclusion, this chapter has characterised an in vitro model of breast cancer 
development and progression and established that SEMA3B expression is reduced 
with the development of cancer. Furthermore, it has shown that when SEMA3B is 
expressed in malignant and invasive tissues, it is likely to be cleaved. There is some 
suggestion that SEMA3B may act as a tumour suppressor in lung cancer (Tomizawa 
et al., 2001). So, therefore, the next chapter will establish the effect full-length 
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SEMA3B will have on the breast cells to see if it is indeed a tumour suppressor in 























Chapter 4: The Effect of Full-length Recombinant SEMA3B (rSEMA3B) on 
Breast Epithelial and Tumour Cells. 
 
4.1 Introduction 
The data in chapter 3 demonstrated that SEMA3B mRNA expression was highest in 
normal breast epithelial cells compared to breast cancer cell-lines.  Moreover, the data 
showed that full-length SEMA3B was only found in the normal epithelial cells, and pre-
malignant, pre-invasive and invasive breast cancer cell only expressed cleaved 
SEMA3B. Previous study in endometrial cancer revealed loss of activity of the cleaved 
fragment of SEMA3B (Nguyen et al., 2011). The activity of SEMA3B was determined 
by investigating the effect of the full-length SEMA3B restoration in the cell proliferation 
and migration of HEC-1B and Ishikawa, which are endometrial cancer cell-lines and 
observed that cell proliferation was decreased in SEMA3B-transfected cells compared 
with mock transfected cells. In addition, when SEMA3B expression was restored in 
cancer cells, the number of migrated cells was significantly reduced suggesting that 
the cleavage by pro-protein convertases of tumour cells may abolish the function of 
SEMA3B in inhibition of tumorigenesis (Nguyen et al., 2011). Furthermore, the effect 
of SEMA3B restoration on invasive capabilities of ovarian cancer cells, showed a 
reduction in their invasive potential (Joseph et al., 2010). 
In the same context, the cleaved fragment of SEMA3B was unable to inhibit 
angiogenic mechanisms in a variety of in vitro assays including tube formation and 
migration (Joseph et al., 2010). In order to test this further Varshavsky et al., (2008) 
generated a point mutation in the SEMA3B gene which resulted in a protein that was 
resistant to cleavage by pro-protein convertases. They reported that this mutated 
SEMA3B was able to inhibit endothelial cell proliferation and induce apoptosis 
efficiently compared with the native SEMA3B, which is cleaved (Varshavsky et al., 
2008). The anti-angiogenic effects of SEMA3B are mediated by neuropilins, which 
originally suggested that SEMA3B may compete with vascular endothelial growth 
factor (VEGF165) for binding to neuropilins, thereby inhibiting the angiogenic effect of 
VEGF165, and controlling pathological angiogenesis (Castro-Rivera et al., 2004). 
However, SEMA3B acts as an anti-angiogenic factor of endothelial cells and 
stimulates programmed cell death in endothelial cells even in the absence of VEGF, 
suggesting that the anti-angiogenic effect of SEMA3B could be due to a direct 
143 
 
inhibitory effect of SEMA3B itself that is mediated by neuropilins without any 
competition with VEGF (Castro-Rivera et al., 2004). SEMA3B has been found to be 
inactive in lung cancer suggesting the active form might have an important role in 
preventing the tumour progression (Tomizawa et al., 2001) Furthermore, in ovarian 
cancer, transfection of the full length SEMA3B into ovarian cancer cells resulted in 
reduced anchorage-independent growth in vitro and decreased tumour formation in 
vivo (Tse et al., 2002). In breast cancer, treatment of MDA-MB-213 cells with 
conditioned medium from Cos7 cells which were transfected with the full-length 
SEMA3B resulted in a 50% reduction in MDA-MB-231 cell number suggesting a role 
for SEMA3B in tumour growth inhibition (Castro-Rivera et al., 2004). Our current study 
in chapter 3, showed that SEMA3B protein was increased in normal tissue, and tends 
to decrease with increasing disease malignancy. Moreover, wherever SEMA3B is 
expressed in pre-malignant and malignant breast tissue, it is likely to be cleaved and 
therefore inactive. 
Data from the literature shows that cleaved SEMA3B is inactive but full-length 
SEMA3B will inhibit breast cancer cell proliferation and apoptosis in lung cancer as 
well as having an effect on angiogenesis (Castro-Rivera et al., 2004). Therefore, this 
chapter aimed to test the hypothesis that full-length SEMA3B inhibits breast cancer 
progression. This hypothesis will be tested using a recombinant full-length SEMA3B 
protein in the following aims: 
    1. Establish whether full-length SEMA3B when added to the cells, is cleaved by 
proteins produced by the cells 
    2. Establish the effect of full-length SEMA3B on HUVEC as positive control cells, as 
it has previously been shown that SEMA3B inhibits migration and angiogenesis of 
HUVEC cells and therefore could have a role in angiogenesis (Varshavsky et al., 
2008).  
    3. Establish the effect of full-length SEMA3B on proliferation, migration and invasion 
of breast cells representing stages of breast cancer development, namely normal 
epithelial MCF-10A cells, pre-invasive DCIS.com and invasive MDA-MB-231 cells.  




4.2.1 Western blot analysis  
Western blotting was used to assess the integrity/stability of recombinant SEMA3B 
when exposed to breast cancer cells and normal breast epithelial cells and their 
conditioned media. Cells, cell lysates and conditioned medium were treated with 
different concentrations of rSEMA3B by two different protocols as described in section 
2.10.10. Samples were quantified and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the antibody for SEMA3B. β-actin the 
housekeeping protein was used as a loading control as described in section 2.10. In 
some instances, β-actin appeared to be present in cell conditioned media samples 
when analysed by western blotting. This was most likely due to some contamination 
of conditioned media by cells that were not efficiently removed by centrifugation during 
the conditioned media collection process. 
4.2.2 Cell counting assay  
This assay was used to investigate the effect of rSEMA3B on the growth pattern of the 
cell-lines. The work conducted measured the viability and total cell count after 24, 48 
and 72 hours of exposure. The cells were treated with different concentrations of 
rSEMA3B and were counted at the different time points as described in section 2.3.2. 
Untreated and untreated tumour and non-tumour cell-lines were seeded at 2x104 in 
12-well plates with three replicates of each condition and incubated over a 72 hours 
period, and the viable cells were counted, as described in section 2.3.1. 
4.2.3 MTS assay  
This assay was used to assess the effect of rSEMA3B on the metabolic activity of 
tumour and non-tumour breast cells. Cells were seeded at 5x103 in 96-well plate and 
treated with different concentrations of rSEMA3B for 24, 48 and 72 hours and the 
optical densities were measured at the absorbance of 490nm as described in section 
2.3.3 and 2.3.4. 
4.2.4 Scratch (wound healing) assay  
This assay was used to assess the effect of rSEMA3B on the ability of cells to migrate. 
Cells were seeded at 1x105 in 24-well plate and the scratch was made before treating 
the cells with different concentrations of rSEMA3B for 24 and 36 hours, and the gap 
closure was measured as described in section 2.4.2 and 2.5. 
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4.2.5 Invasion assay  
This assay was used to assess the effect of rSEMA3B on the invasion of the MDA-
MB-231 cells. HUVEC cells were used as a positive control for this assay. A pre-coated 
Matrigel invasion chamber was used. Cells were seeded and treated with different 
concentrations of rSEMA3B for 72 hours for MDA-MB-231 and 24 hours for HUVEC 
cells, as described in section 2.7. Photomicrographs were taken using a microscope, 
and the invaded cells were counted as defined in section 2.6.5. 
4.2.6 Statistical analysis  
All data were analysed using GraphPad Prism 7 software, with all statistical analyses 
performed by comparing treated with untreated cells. The tests used were the one-
way ANOVA test with Dunnetts multiple comparison test. Data expressed as mean ± 






















4.3.1 Effect of the cells and conditioned medium on the cleavage of recombinant 
SEMA3B  
This experiment was carried out to evaluate whether adding the recombinant SEMA3B 
to the cells for 24 and/or 48 hours will have an effect on the full-length recombinant 
SEMA3B in the conditioned medium and cell lysates and to see whether it remains 
full-length and is therefore likely to have an effect on the cells. Western blot analysis 
was carried out, and SEMA3B protein expression of all treated/untreated cells and 
conditioned medium was analysed and compared to the untreated control. Three 
different cell-lines were chosen for representing an element of breast cancer 
progression included normal MCF-10A, pre-invasive DCIS.com and invasive MDA-
MB-231 cells. 
4.3.1.1 Effect of MCF-10A cells and their conditioned medium on the full-length 
recombinant SEMA3B  
MCF-10A cells were treated with rSEMA3B and incubated for different times(24 and 
48 hours) to investigate the effect of cells and conditioned medium on the rSEMA3B 
protein expression and to find out whether adding full-length of SEMA3B will be 
cleaved by proteins produced by the cells. Our result showed that the full-length of 
rSEMA3B (83 kDa) in both MCF-10A cells and conditioned medium was detected in 
more abundance and was not being cleaved after 24 and 48 hours. However, 51 kDa 
cleaved SEMA3B fragments were observed in both untreated cells and conditioned 
medium but not in treated lanes (figure 4.1). These data suggest that MCF-10A cells 
treated with full-length recombinant SEMA3B do not cleave the SEMA3B in the assay 
conditions and therefore, the effect of full-length SEMA3B can be investigated in these 






























Figure 4.1: Effect of MCF-10A cells on the expression of rSEMA3B. Cells and 
conditioned medium were treated with recombinant SEMA3B protein (2 µg/ml) for 24 
and 48 hours. Cell lysates were extracted, and conditioned medium (CM) was 
collected and the amount of the protein was quantified by BCA for both cell lysate and 
CM, and both were separated on a 10% SDS-PAGE gel, and then blotted onto PVDF 
and probed with the anti-SEMA3B antibody. To confirm that the amount of protein in 
each lane was equal, the membrane was stripped and re-probed with anti-β-actin 
housekeeping protein as a loading control. The sizes of molecular weight markers are 
indicated in kDa. Representative immunoblot shown of n=3.  
148 
 
4.3.1.2 Effect of DCIS.com cells and their conditioned medium on the full-length 
recombinant SEMA3B  
DCIS.com cells were treated with rSEMA3B (2 µg/ml) for 24 and 48 hours. The cell 
lysates were then extracted, and conditioned medium was collected to analyse by 
Western blot. We found that after both 24 and 48 hours the recombinant SEMA3B was 
only partially cleaved yielding only a small band at 51 kDa in addition to the full-length 
band in both cell lysates and conditioned medium. However, there is far more of the 
recombinant SEMA3B present in the conditioned media, and this data suggests that 
the full-length SEMA3B is able to enter the cells where it is only partially cleaved. 
Therefore, the activity of full-length SEMA3B can be tested in these cells over a 48 

















Figure 4.2: The effect of DCIS.com cells on recombinant SEMA3B after 24 hours 
treatment. DCIS.com cells were treated with rSEMA3B (2 µg/ml) for 24 hours and 
then cell lysates were extracted and conditioned medium was collected to be 
quantified and investigated by Western blot. 20 µg of protein of both cell lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 





















Figure 4.3: The effect of DCIS.com cells on recombinant SEMA3B after 48 hours 
treatment. DCIS.com cells were treated with rSEMA3B (2 µg/ml) for 48 hours and 
then cell lysates were extracted and conditioned medium was collected to be 
quantified and investigated by Western blot. 20 µg of protein was used and separated 
on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the anti-
SEMA3B antibody. To confirm that the amount of protein in each lane was equal, the 
membrane was stripped and re-probed with anti-β-actin housekeeping protein as a 
loading control. The sizes of molecular weight markers are indicated in kDa. NC= 
negative control (medium only), PC= positive control (rSEMA3B only) and CM= 






4.3.1.3 Effect of MDA-MB-231 cells and their conditioned medium on the full-
length recombinant SEMA3B  
The cancer genome atlas (TCGA) database suggests that there is a significant 
downregulation of SEMA3B in triple negative breast cancer patients (Shahi et al., 
2017). Accordingly, since SEMA3B expression was seen at very low levels in basal 
subtypes, we thought it would be interesting to use the MDA-MB-231 cell-line as a 
model to test the effect of these cells on the full-length of recombinant SEMA3B 
protein.  
MDA-MB-231 cells treated with recombinant SEMA3B for 24 and 48 hours, were 
investigated for the evidence of the full-length SEMA3B in the lysates and conditioned 
medium of the invasive MDA-MB-231. It shows the full-length SEMA3B was partially 
cleaved yielding faint bands in treated lanes at 51 kDa after 24 hours, in addition to 
the full-length bands detected in both cell lysates and conditioned medium at 83 kDa. 
However, similar bands of full-length SEMA3B (83 kDa) were detected after 48 hours 
in both cell lysates and conditioned medium, but were faint in treated cell lysates 





























Figure 4.4: The effect of MDA-MB-231 cells on recombinant SEMA3B after 24 
hours treatment. MDA-MB-231 cells were treated with rSEMA3B (2 µg/ml) for 24 
hours, and then cell lysates were extracted, and conditioned medium was collected to 
be quantified and investigated by Western blot. 20 µg of protein of both lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 




















Figure 4.5: The effect of MDA-MB-231 cells on recombinant SEMA3B after 48 
hours treatment. MDA-MB-231 cells were treated with rSEMA3B (2 µg/ml) for 48 
hours and then cell lysates were extracted, and conditioned medium was collected to 
be quantified and investigated by Western blot. 20 µg of protein of both cell lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 
three independent experiments are shown. 
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4.3.2 Effect of recombinant full-length SEMA3B on cell growth 
To study the effect of recombinant SEMA3B protein on cell growth of cell-lines 
representing breast cancer progression, normal breast epithelial (MCF-10A), pre-
invasive (DCIS.com) and invasive (MDA-MB-231) cells were treated with a range of 
recombinant SEMA3B concentrations and the cell number and cell death measured 
after 24, 48 and 72 hours. HUVECs were used as a positive control for the experiment 
as it is known that SEMA3B inhibits the growth of these cells (Castro-Rivera et al., 
2004, Varshavsky et al., 2008).  
As shown in figure 4.6, the effect of rSEMA3B on the cell growth of the normal 
epithelial cells MCF-10A showed no significant differences between the treated and 
untreated cells over 72 hours. In addition, the effect of rSEMA3B on the viability of 
MCF-10A cells has no effect either on killing or on inhibiting the cell growth (figure 
4.6). However, in DCIS.com cells, 48 hours of treatment with SEMA3B significantly 
inhibited their cell growth (P<0.01; one way ANOVA) achieving significance at 0.5, 1 
and 2 µg (P=0.0168, Dunnett’s test). After 72 hours the growth was even more 
significantly inhibited (P<0.0001; One-way ANOVA). In contrast, there was no killing 
effect on cell viability (figure 4.7). Similarly, the effect of rSEMA3B on invasive MDA-
MB-231 cells after 48 and 72 hours showed significantly reduced cell growth 
(P<0.0001; one way ANOVA) at a dose equal to 0.5, 1 and 2 µg (P <0.0001, Dunnett’s 
test) compared with the untreated control. However, rSEMA3B inhibited cell growth 
but did not cause cell death (figure 4.8). 
We observed similar behaviour in HUVEC cells. The effect of rSEMA3B after 48 and 
72 hours, significantly decreased the cell growth of HUVEC cells (P<0.0001, one way 
ANOVA) at a dose equal to 1 and 2 µg (P <0.0001, Dunnett’s test) compared to 
untreated control (figure 4.9), these data suggest that full-length SEMA3B is more 
likely to inhibit the cell growth by causing cell cycle arrest rather than apoptosis, 











Figure 4.6: The effect of rSEMA3B on the cell growth and viability of normal 
epithelial MCF-10A cells. Cells were seeded at 2x104 in 12-well plates and incubated 
with the rSEMA3B treatment for 24, 48 and 72 hours. The cell growth was observed 
and measured by counting the cell number using a cell counting chamber (left). The 
percentage cell viability was measured (right). Data are presented as mean ± SD from 
three independent experiments and it was analysed statistically by one-way ANOVA 














Figure 4.7: The effect of rSEMA3B on the cell growth and viability of pre-invasive 
DCIS.com. Cells were seeded at 2x104 in 12-well plates and incubated with different 
concentrations of rSEMA3B treatment (0, 0.5,1 and 2 µg ) for 24, 48 and 72 hours. 
The cell growth was observed and measured by counting the cell number using a cell 
counting chamber (left). The percentage cell viability was measured (right). Data are 
presented as mean ± SD from three independent experiments, and it was analysed 
statistically by one-way ANOVA, Dunnett’s multiple comparison test was used to 
compare the treated cells with the untreated control cells (left). * indicates P=0.0168, 





















Figure 4.8: The effect of rSEMA3B on the cell growth and viability of invasive 
MDA-MB-231 cells. 2x104 cells were seeded at 12-well plate. The effect of rSEM3B 
was evaluated by treating the cells with different concentrations of rSEMA3B (0, 0.5, 
1 and 2 µg). Cell growth was measured at three-time intervals (24, 48 and 72 hours) 
by counting the cell number using a cell counting chamber (left). The percentage of 
cell viability was measured (right). Data are presented as mean ± SD of three 
independent experiments. Data was analysed statistically by one-way ANOVA, 
Dunnett’s multiple comparison test was used to compare the treated with the untreated 
control cells. **** indicates P <0.0001. 
Figure 4.9: The effect of rSEMA3B on the cell growth and viability of HUVEC 
cells. 2x104 cells were seeded at 12-well plate. The effect of rSEM3B was evaluated 
by treating the cells with different concentrations of rSEMA3B (0, 0.5, 1 and 2 µg). Cell 
growth was measured at three-time intervals (24, 48 and 72 hours) by counting the 
cell number using a cell counting chamber (left). The percentage of cell viability was 
measured (right). Data presented the mean ± SD of three independent experiments. 
Data was analysed statistically by one-way ANOVA, Dunnett’s multiple comparison 
test was used to compare the treated with the untreated control cells. *** indicates 
P=0.0001 and **** indicates P <0.0001.  
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4.3.3 Effect of recombinant SEMA3B on metabolic activity  
The effect of rSEMA3B on cellular metabolic activity was evaluated using the MTS 
assay, which measures the activity of a mitochondrial dehydrogenase. Normal 
epithelial MCF-10A cells, pre-invasive DCIS.com and invasive MDA-MB-231 cells in 
addition to HUVEC cells were treated with different concentrations of rSEMA3B (0, 
0.5, 1 and 2 µg) and compared with the control (untreated cells). The cellular response 
was measured at three-time intervals, namely 24, 48 and 72 hours, as described in 
section 2.3.4. The rSEMA3B showed no effect on the cellular metabolic activity of 
normal epithelial cells (figure 4.10), pre-invasive DCIS.com cells (figure 4.10), invasive 
MDA-MB-231 cells (figure 4.11) and HUVECs cells (figure 4.11) compared with the 
untreated control cells suggesting that rSEMA3B has no effect on metabolism of cells 
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Figure 4.10: Effect of rSEMA3B on the cellular metabolic activity of normal 
epithelial MCF-10A and DCIS.com cells. MCF-10A cells (left) and DCIS.com cells 
(right) were seeded at 5x103 in 96-well plate and incubated with different 
concentrations of rSEMA3B (0,0.5,1 and 2 µg) for 24, 48 and 72 hours. MTS reagent 
(20 µl) was added and incubated for three hours before the absorbance was measured 
by a spectrophotometer at 490 nm. Data are presented as mean ± SD from three 
independent experiments, and it was analysed statistically by one-way ANOVA. 
Figure 4.11: Effect of rSEMA3B on the cellular metabolic activity of MDA-MB-231  
and HUVEC cells. MDA-MB-231 (left) HUVEC cells (right) were seeded at 5x103 in 
96-well plate and incubated with different concentrations of rSEMA3B (0,0.5,1 and 2 
µg) for 24, 48 and 72 hours. MTS reagent (20µl) was added and incubated for three 
hours before the absorbance was measured by a spectrophotometer at 490nm. The 
data are presented as mean ± SD from three independent experiments. Data was 
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4.3.4 Effect of recombinant SEMA3B on cell migration 
As recombinant SEMA3B had a significant effect on cell growth of DCIS.com, MDA-
MB-231 and HUVECs, it was next interesting to study its effect on migration by testing 
the ability of the cells to migrate in the presence of rSEMA3B. However, MCF-10A and 
DCIS.com cells did not migrate as shown in chapter 3, and therefore, the effect of 
SEMA3B on the migration of these cells was not assessed. The effect of rSEMA3B 
was evaluated by treating the MDA-MB-231 cell-lines with different concentrations of 
rSEMA3B (0, 0.5, 1 and 2 µg) and measuring scratch closure over 24 and 36 hours 
as described in 2.5. HUVEC cells were used as a positive control in this assay as 
SEMA3B is known to inhibit angiogenic processes.  
The result showed that MDA-MB-231 cells migrated to close the wound when 
untreated, and when they were treated with rSEMA3B, the migration was slowed. 
Indeed, rSEMA3B caused a significant, concentration-dependent inhibition in 
migration of MDA-MB-231 cells over 24 and 36 (P<0.01, one way ANOVA) achieving 
significance at 1 µg/ml (P = 0.0436, Dunnett’s test) and 2 µg/ml (P<0.0001, Dunnett’s 
test) compared with the untreated cells (figure 4.12).  
Similarly HUVEC migration was significantly decreased in the presence of rSEMA3B 
after 24 hours (P=0.05, one-way ANOVA) at a dose equal to 0.5 µg/ml (P=0.0355, 
Dunnett’s test), 1 µg/ml (P =0.0010, Dunnett’s test) and 2 µg/ml (P<0.0001, Dunnett’s 
test). Moreover, after 36 hours, the migration was more significantly inhibited 
(P<0.0001, one-way ANOVA), at 0.5, 1 and 2 µg/ml (P<0.0001, Dunnett’s test) (figure 
4.13). Thus, the presence or expression of full-length SEMA3B is likely to inhibit the 







































Figure 4.12: Effect of rSEMA3B on the migration of invasive MDA-MB-231 cells. 
A) The scratch assay was conducted in untreated/treated MDA-MB-231cells. Gap 
closure was measured at 0, 24 and 36 hours after cells were scratched using ImageJ 
software. Cell migration was calculated and expressed as the percentage of gap 
closure relative to the untreated control cells. Scale bar = 200 µm. B) Data is 
presented as the percentage of the gap closure for both time points 24 and 36 hours. 
These data are the mean ± SD of three independent experiments. Data was analysed 
statistically by two way ANOVA. Tukey's multiple comparisons test was used to 
compare the treated cells to untreated control. * represents P= 0.0436, ** represents 









Figure 4.13: Effect of rSEMA3B on the migration of HUVEC cells. A) The scratch 
assay was conducted in untreated/treated HUVEC cells. Cell migration was measured 
at 24 and 36 hours after cells were scratched, and it was analysed using ImageJ 
software. Scale bar = 100 µm. B) Data present the percentage of the gap closure for 
both time points 24 and 36 hours. These data are the mean ± SD of three independent 
experiments. Data was analysed statistically by two-way ANOVA, Tukey's multiple 
comparisons test was used to compare the treated to the untreated control cells.*P= 
0.0355, **P= 0.0010 and ****P<0.0001.  
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4.3.5 Effect of SEMA3B on the invasion of MDA-MB-231 and HUVEC cells 
Invasion is a feature of malignant cells that potentially contributes to cancer 
progression, and therefore the effect of full-length recombinant SEMA3B was tested 
on the invasion of these cells. As the experiments in Chapter 3 demonstrated that 
MCF-10A and DCIS.com cells did not invade, the effect of rSEMA3B was only 
investigated in the invasive MDA-MB-231 and HUVEC cells. Cell invasion of MDA-
MB-231 and HUVEC cells was measured at 72 and 24 hours, respectively, as 
described in 2.7.  
The recombinant SEMA3B significantly inhibited invasion of the MDA-MB-231 cells 
after 72 hours in a dose-dependent manner (P<0.0001, one way ANOVA). Compared 
to the untreated cells, rSEMA3B at 0.5, 1 and 2 μg/ml suppressed invasion by ~50%, 
84.83% and 89.6 % respectively (P<0.0001, Dunnett’s test) (figure 4.14). Moreover, 
rSEMA3B treatment significantly decreased invasion in HUVEC cells after 24 hours 
(P<0.0001, one way ANOVA). Compared with the untreated cells, rSEMA3B at 1 μg/ml 
(P= 0.0009, Dunnett’s test) and 2 μg/ml (P<0.0001, Dunnett’s test) significantly 
reduced invasion by 55.6 % and 75.4 % respectively (figure 4.15). These data showed 













































Figure 4.14: rSEMA3B inhibits MDA-MB-231 cell invasion. A) Photomicrographs 
of stained MDA-MB-231 cells that invaded through a transwell membrane in the 
presence of untreated control and different concentrations of rSEMA3B. Scale bar = 
200 µm. B) The graph representing the number of invaded cells/ field of view (10x) 
that invaded through a porous transwell insert in the presence of different 
concentrations SEMA3B (0.5,1, 2 µg/ml) compared with untreated control. These data 
are the mean ± SD of three independent experiments. Data was analysed statistically 




Figure 4.15: rSEMA3B inhibits HUVEC cell invasion. A) Photomicrographs of 
stained HUVEC cells that invaded through a transwell membrane in the presence of 
untreated control and different concentrations of SEMA3B (0, 0.5, 1 and 2 µg/ml). 
Scale bar = 100 µm. B) The graph representing the number of invaded cells/ field of 
view (10x) that invaded through a porous transwell insert in the presence of different 
concentrations rSEMA3B compared with untreated control. These data are the mean 
± SD of three independent experiments. Data was analysed statistically by one-way 
ANOVA, Dunnett's multiple comparisons test was used to compare the treated to 







4.3.6 Effect of cell lysate and conditioned medium on the full-length recombinant 
SEMA3B 
The data presented so far in this chapter suggest that full-length SEMA3B is active in 
breast cancer cells, but the Western blots suggest that breast cancer cells produce 
more cleaved SEMA3B than normal and pre-invasive cells. To assess whether the 
full-length SEMA3B can be cleaved by proteins produced by the cells, cell lysates and 
conditioned medium were generated from the cells and then incubated with rSEMA3B 
for 3 hours to establish whether any of the proteins present in the lysates and/or 
conditioned medium may be capable of cleaving SEMA3B. The same three chosen 
cell lines were used representing normal, pre-invasive and invasive cell-lines as 
described in 2.10.10. 
4.3.6.1 Effect of MCF-10A cell lysate and conditioned medium on the full-length 
recombinant SEMA3B 
Cell lysates and conditioned medium were generated from MCF-10A cells and were 
incubated with rSEMA3B as described in 2.10.10. Our results showed that the full-
length rSEMA3B in both lysate and the conditioned medium had not been 
proteolytically cleaved to a 51 kDa fragment compared to the untreated lysate and 
conditioned medium (figure 4.16). An 83 kDa fragment corresponds to the active 
SEMA3B while the 51 kDa fragment is the product of the processing of 83 kDa by 
furin-like pro-protein convertases which corresponds to the inactive form of SEMA3B. 
This result demonstrates that cell lysate and conditioned medium from MCF-10A cells 
are incapable of cleaving rSEMA3B to produce a 51 kDa fragment, when compared 
to the generated fragments in untreated lanes. Unexpectedly, the endogenous 51 kDa 
protein could no longer be detected in lysates that were incubated with SEMA3B. It is 
not clear why this occurred and further tests would be needed to establish whether 
this was associated with further cleavage/degradation of the endogenous fragment or 
other reasons. This was specific for the MCF-10A cells and not the other cell lines. 
These data suggested that different processing takes place during intercellular 



































Figure 4.16: Effect of MCF-10A cell lysate and conditioned medium on the full-
length recombinant SEMA3B. MCF-10A cell lysates and conditioned medium were 
generated from the cells to be treated with rSEMA3B (2µg/ml) for three hours, and 
then cell lysates were extracted, and conditioned medium was collected to be 
quantified and investigated by Western blot. 20 µg of protein of both cell lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. An 83 kDa indicates the active form of SEMA3B 
and the 51 kDa inactive form of SEMA3B. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 
three independent experiments are shown. Presence of β-actin in conditioned media 




4.3.6.2 Effect of DCIS.com cell lysate and conditioned medium on the full-length 
recombinant SEMA3B 
In the same manner as in MCF-10A, the pre-invasive DCIS.com cell lysates and 
conditioned medium were generated and treated with rSEMA3B for three hours as 
described in 2.10.10 to be investigated by Western blot. As shown in figure 4.17, the 
result showed that in treated lysate, two fragments were generated at 51 kDa and 83 
kDa. The cell lysate was able to cleave the full-length of rSEMA3B partially suggesting 
that the cell lysate contains a factor that can cleave the full-length recombinant 
SEMA3B. In comparison, there is only a faint 51 kDa band in the treated conditioned 
medium in addition to a clear band detected as well at 83 kDa suggesting that there is 








































Figure 4.17: Effect of DCIS.com cell lysate and conditioned medium on the full-
length recombinant SEMA3B. DCIS.com cell lysates and conditioned medium were 
generated from the cells to be treated with rSEMA3B (2 µg/ml) for three hours and 
then cell lysates were extracted and conditioned medium was collected to be 
quantified and investigated by Western blot. 20 µg of protein of both lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. An 83 kDa indicates the active form of SEMA3B 
and the 51 kDa inactive form of SEMA3B. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 
three independent experiments are shown. 
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4.3.6.3 Effect of MDA-MB-231 cell lysate and conditioned medium on the full-
length recombinant SEMA3B 
MDA-MB-231 cell lysate and conditioned medium were generated from the cells and 
treated with rSEMA3B for three hours and investigated by Western blot as described 
in 2.10.10. Our result of treated MDA-MB-231 cell lysate and conditioned medium 
showed that the full-length of rSEMA3B in both lysate and conditioned medium has 
not been completely cleaved. However, the cleaved form at 51 kDa in the treated 
lysate was much stronger than in all other cells suggesting that the severity of cells 
could play a role in this. Moreover, there were faint bands at 250 kDa in the treated 
conditioned medium lane which were not detected in the treated lysate lane 






































Figure 4.18: Effect of MDA-MB-231 cell lysate and conditioned medium on the 
full-length recombinant SEMA3B. MDA-MB-231 cell lysates and conditioned 
medium were generated from the cells to be treated with rSEMA3B (2 µg/ml) for three 
hours and then cell lysates were extracted and conditioned medium was collected to 
be quantified and investigated by Western blot. 20 µg of protein of both cell lysate and 
conditioned medium was used and separated on a 10% SDS-PAGE gel, and then 
blotted onto PVDF and probed with the anti-SEMA3B antibody. To confirm that the 
amount of protein in each lane was equal, the membrane was stripped and re-probed 
with anti-β-actin housekeeping protein as a loading control. The sizes of molecular 
weight markers are indicated in kDa. An 83 kDa indicates the active form of SEMA3B 
and the 51 kDa inactive form of SEMA3B. NC= negative control (medium only), PC= 
positive control (rSEMA3B only) and CM= conditioned medium. Immunoblots from 
three independent experiments are shown. 
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4.4 Discussion  
The data in chapter 3 demonstrated that when SEMA3B is expressed by breast cancer 
cells, it is cleaved to a 51 kDa protein. Previous studies have suggested that although 
SEMA3B is a tumour suppressor, when it is cleaved it is less active suggesting 
proteolytic processing may be a reason for a less potent SEMA3B in cancer 
(Varshavsky et al., 2008). Therefore, this study aimed to investigate whether full-length 
SEMA3B acts as a tumour suppressor by inhibiting cell growth, metabolic activity, 
migration and invasion of normal breast epithelial cells, pre-invasive and invasive 
breast cancer cell-lines. As SEMA3B is known to inhibit angiogenesis the data with 
the breast cell-lines was compared to HUVEC, which are known to respond to 
recombinant SEMA3B (Varshavsky et al., 2008). To the best of our knowledge, the 
present study is the first report to document the effect of breast tumour and non-tumour 
cells on the stability of the exogenous recombinant SEMA3B and the impact of this 
protein on cell based functional assays. Recombinant SEMA3B protein full-length was 
tested at various concentrations including (0, 0.5, 1 and 2 µg). However, it was first 
important to establish whether exogenous recombinant SEMA3B would be cleaved by 
the breast cell-lines, particularly as their own SEMA3B is cleaved. We demonstrated 
that MCF-10A and DCIS.com cells do not cleave the recombinant SEMA3B by 48 
hours suggesting that if it was added to an assay for less than 48 hours, then it would 
remain as full-length. As stated above, unexpectedly, in experiments where cells were 
incubated with rSEMA3B, the endogenous 51 kDa fragments could no longer be 
detected. It may be that the endogenous protein degraded during the duration of the 
incubation. The endogenous protein may be more difficult to fold correctly if 
exogenous protein was present at a high concentration. Additionally, high exogenous 
recombinant protein may interfere with the expression of the endogenous protein when 
added to live cells.  
MDA-MB-231 cells showed partially cleavage of the full-length SEMA3B after 24 
hours, but this increased over 48 hours in both cells and conditioned medium 
suggesting that the full-length of rSEMA3B in invasive cells may be cleaved by a 
protein produced inside the cells potentially contributing negatively with the anti-
tumorigenic activities of SEMA3B. However, the full-length SEMA3B was partially 
cleaved in these cells suggesting that the fragment of the full-length SEMA3B can be 
active and its effect can be tested in functional assays. The abundance of cleaved 
bands of rSEMA3B in invasive cells showed a time-dependent increase. 
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These observations are supported by a previous study that demonstrated that the 
cleavage product of SEMA3B generated by furin-like pro-protein convertases, which 
are usually increased in the tumour, show lack of bioactivity and unable to perform its 
normal function or to support the antiangiogenic activity (Varshavsky et al., 2008).  
Next, we examined the effect of the recombinant SEMA3B on cell growth of the chosen 
cells. Treatment with recombinant SEMA3B protein significantly reduced the growth 
of pre-invasive DCIS.com and invasive MDA-MB-231 cells when compared to the 
untreated control. However, in the normal epithelial MCF-10A cells, we observed no 
effect of rSEMA3B on the cell growth of these cells. In our growth assay, our data 
demonstrate similar findings to those previously reported with the same effect of 
SEMA3B on the growth inhibition of MDA-MB-231 breast cancer cell-line in response 
to full-length SEMA3B, as with a 50-60 % inhibition in cell growth by the transfected 
conditioned medium of SEMA3B (Castro-Rivera et al., 2004).  
Moreover, our findings agree with the results of Shahi et al. who reported the effect of 
SEMA3B overexpression in MDA-MB-231 cells using a colony formation assay, as 
demonstrating inhibition of cellular proliferation and colony formation in cells 
expressing SEMA3B (Shahi et al., 2017). The findings using Western blot showed that 
rSEMA3B is partially cleaved in invasive cancer cells, but it is more likely to be still 
active. However, these findings indicate that the rSEMA3B contributed to decreasing 
tumour cell growth, suggesting that the anti-tumour effect of SEMA3B could be used 
as a new approach in the treatment of breast cancer.  
In addition to the effect on cell growth, an effect on the metabolism of the cells and the 
viability of cells over a 72 hours period was measured. In contrast to the data on cell 
growth, recombinant SEMA3B had no significant effect on metabolism or viability in 
the breast cells, strongly suggesting that SEMA3B affects cell cycle progression. 
There is no previous literature published in breast cancer using the same assay. 
However, a previous study in oesophagal squamous cell carcinoma demonstrated that 
SEMA3B is able to arrest oesophagal cancer cell-lines at the G1/S checkpoint by 
inhibition of phosphatidylinositol 3-kinase/AKT signalling and upregulation of p53 and 
p21 expression, which may support our findings (Tang et al., 2016).  
In contrast, our MTS assay results of breast tumour and non-tumour cells are 
contradictory to those reported by Tse et al, who showed that the metabolic activity of 
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ovarian cancer cells, identified using the XTT assay, was lower in SEMA3B transfected 
cells by 1.2-1.6 fold change, when compared to control cells (>2-fold higher) (Tse et 
al., 2002).  
We then analysed the functional consequences of HUVEC treated with rSEMA3B. It 
is important to point out that the HUVEC cell-line was used as a positive control for the 
effect of SEMA3B as it has been shown that SEMA3B inhibits their cell migration and 
angiogenesis (Varshavsky et al., 2008). Expression of rSEMA3B significantly 
decreased the HUVEC cell growth when compared to untreated cells. In agreement 
with our result, the previous published study demonstrated that mutated SEMA3B 
(resistance to cleavage by PPCs) regulates HUVEC by decreasing their proliferation 
and cell viability (Varshavsky et al., 2008). However, the recombinant SEMA3B did not 
affect HUVEC cells viability in term of cellular metabolism, as we did not observe any 
differences between the treated and untreated cells in response to rSEMA3B.  
Although class 3 semaphorin is normally found highly expressed in endothelial cells, 
it inhibited their proliferation and migration. During vascular development, endothelial 
cells produce autocrine chemorepulsive signals to the endogenous semaphorin, which 
localize at adjacent adhesive sites in spreading endothelial cells. These 
chemorepulsive signals result in disruption to the endogenous semaphorin function, 
leading to stimulation of integrin-mediated adhesion and migration to the extracellular 
matrices, to fix that disruption. However, the exogenous semaphorin protein 
antagonizes the integrin activation and consequently its function as a suppressor 
protein and therefore suppresses the HUVEC cell proliferation and migration. This is 
a possible explanation of how the SEMA3B inhibits the function of HUVEC cells (Serini 
et al., 2003).  
Having established that recombinant SEMA3B could inhibit cell growth, it was 
essential to establish whether the full-length SEMA3B protein would also affect 
migration and invasion, both of which are important aspects of tumour development 
and metastasis. Initially, we investigated the effect of recombinant SEMA3B on cell 
migration using the scratch assay. The data presented here were generated in the 
presence of mitomycin C to ensure that only migration was quantified as described 
earlier in chapter 3. The invasive MDA-MB-231 cells in the presence of rSEMA3B were 
unable to fill the gap in the scratch assay, as rSEMA3B inhibited the migration of these 
cells. This observation is supported by a previous study which revealed that MDA-MB-
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231 cells expressing SEMA3B failed to fill the gap when compared with the control 
(Shahi et al., 2017).  
Moreover, our data demonstrate that SEMA3B can inhibit invasion of the invasive 
breast cancer cells MDA-MB-231 cells suggesting that SEMA3B may potentially inhibit 
breast cancer invasion. Our findings are in agreement with a previous report 
performed in ovarian cancer cells in which overexpression of SEMA3B significantly 
reduced cell invasion (Joseph et al., 2010).  
Furthermore, our data showed that rSEMA3B inhibited the cell migration of HUVEC 
cells. This finding was in agreement with the previous study showing that the migration 
of HUVEC cells, was inhibited by the overexpression of SEMA3B as identified by 
transwell chamber inserts (Rolny et al., 2008). These results suggest that SEMA3B 
may perhaps be able to function as an inhibitor of angiogenesis, since SEMA3B 
signals through NP1 which is found expressed on endothelial cells as well and that 
SEMA3B inhibits the migration of endothelial cells and hence can function as an 
inhibitor of angiogenesis (Varshavsky et al., 2008). However, there is no previous 
literature to compare these results to.  
These data suggest that full-length SEMA3B may be acting as a tumour suppressor 
agent by inhibiting breast cancer cell growth, migration and invasion. However, as data 
from chapter 3 demonstrated in the breast cancer cells, SEMA3B is expressed as a 
smaller cleaved protein. In order to establish whether a protein produced in the cells 
and/or released into the conditioned media is responsible for cleaving SEMA3B, 
experiments were performed that incubated recombinant SEMA3B with cell lysates or 
conditioned medium for three hours and then determined the presence or absence of 
full-length SEMA3B. 
The data from this experiment showed that MCF-10A cell lysate and conditioned 
medium were unable to cleave the recombinant SEMA3B while the DCIS.com cell 
lysates achieved partial cleavage, However, in the treated conditioned medium from 
DCIS.com cells, the intensity of the band was much less at 51 kDa as it was faint 
compared to the full-length band. This result showed a very high level of 83 kDa 
SEMA3B detected in the conditioned medium compared with the treated lysate, which 
may suggest the activity of this fragment is much more in conditioned medium. A 
similar finding was observed in the MDA-MB-231 cell lysate with a slight increase in 
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band intensity detected in the treated conditioned medium and lysate at 51 kDa 
compared to DCIS.com cells suggesting that MDA-MB-231 may be able to cleave the 
full-length more than the pre-invasive cells. These data suggested a specific 
mechanism is likely to exist inside the cell that cleaves the full-length SEMA3B. This 
finding does not exclude the possibility that the furin-like pro-protein convertases might 
also have a role in this process. The limitation of these experiments was with using 
treated lysate, the protein has degraded after three hours, and it could be more 
effective if we have incubated for longer periods of time. Previous studies revealed 
that the cleavage at the recognition site of PPCs is usually responsible for inactivation 
of SEMA3B (Adams et al., 1997, Varshavsky et al., 2008). Thus, our data could 
suggest the cells themselves are producing proteins capable of cleaving SEMA3B, 
which may be able to inhibit the anti-tumorigenic activities of SEMA3B. It should be 
noted that in these experiments the positive control of rSEMA3B was mixed with fresh 
medium but it was not incubated for the duration of the experiment at 37oC (3 hours) 
in identical conditions to those used for the test samples. It would be important to test 
the stability of rSEMA3B in normal serum-free medium under the conditions of the 
assay, to exclude the possibility that rSEMA3B was cleaved by autoproteolytic 
degradation. It should also be mentioned that protease inhibitors that were used when 
lysates were extracted for analysis of rSEMA3B cleavage (see sections 2.10.10 and 
4.3.6). Protease inhibitors were used in order to prevent excessive proteolytic 
degradation when cells were lysed. Although the inhibition action of the protease 
inhibitors used is reversible, there is still the possibility that some PPCs were also 
inhibited and therefore their full effect on cleaving rSEMA3B may have been masked.  
The findings presented in this chapter might suggest a potential role for SEMA3B in 
breast cancer cells that may be of prognostic and therapeutic value, however, 
additional investigations are required to understand what regulates this protein 
cleavage as breast disease progress. Therefore, to complement this work, further 
experiments should determine the relative importance of how the expression of pro-
protein convertases can affect the expression of SEMA3B since previous literature 
has suggested that the pro-protein convertase family of proteins may actively cleave 
class 3 semaphorins. The next chapter will establish the expression of pro-protein 
convertases in the cell-line models and breast cancer tissues to identify whether there 
is a correlation between pro-protein convertases expression and SEMA3B cleavage. 
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The data presented in the previous chapter demonstrated that full-length recombinant 
SEMA3B has a significant effect on decreasing the growth, migration and invasion of 
breast cancer cells (Chapter 4). Expression of SEMA3B however, was completely 
cleaved in breast cancer cell lines, compared to normal breast epithelial cells as shown 
by Western blot analysis (performed in Chapter 3). This cleavage is thought to 
inactivate the tumour suppressor function of SEMA3B (Varshavsky et al., 2008). It is 
known that SEMA3B contains a PPC consensus cleavage motif RXK/RR (Barr, 1991, 
Varshavsky et al., 2008) as shown in figure 5.1. Therefore, it is likely that in breast 
cancer increased expression of PPCs results in cleavage of SEMA3B near the 
carboxyl terminus resulting in the generation of 51 kDa isoforms seen on Western 
blots, and inactivating the tumour suppressor function of the protein. 
PPCs, are a family of subtilisin/Kexin-type serine endoproteases, which are usually 
responsible for the conversion of immature precursors to mature protein (Seidah and 
Prat, 2012), rather than inactivating proteins. However, several studies have shown 
that PPCs can regulate semaphorins by proteolytic activity (Adams et al., 1997, 
Varshavsky et al., 2008, Casazza et al., 2012), and PPCs are usually found to 
inactivate class-3 semaphorins (Adams et al., 1997, Varshavsky et al., 2008). That 
said, the functional consequence of the proteolytic processing events appears variable 
within the semaphorin family. Some members of the family demonstrate functional 
loss as a result of PPC cleavage e.g. SEMA3B (Varshavsky et al., 2008), SEMA3F 
(Futamura et al., 2007) and SEMA3A (Adams et al., 1997), while other family 
members, such as SEMA3E gained a pro-metastatic phenotype from PPC cleavage 
(Christensen et al., 2005).This is in contrast to activity of the un-cleaved full-length of 


















Importantly for this thesis, SEMA3B undergoes differential processing by PPCs at the 
different cleavage recognition sites in the protein (Figure 5.1) during the intercellular 
maturation process, generating several isoforms with distinct properties.  
 
Initially, SEMA3B is synthesized as an inactive precursor. The sequence of SEMA3B 
has a cleavage site at the N-terminal where the first cleavage takes place at position 
24-25 to remove the signal peptide (1-24) in order to activate the protein. In addition, 
there are six possible cleavage sites for PPCs in the C-terminal, which generate 
differing length fragments that alter in their activity. For example cleavage at KRRFRR 
sequence able to generate a ∼51 kDa NH2-terminal fragment and ∼20 kDa at C-
terminal while cleavage at KGRNRR found cross reactive with SEMA3A sequence 
where the furin processing sites found in SEMA3A (Parker et al., 2013).  
Figure 5.1: Sequence of SEMA3B showing the PCC cleavage sites. There is a 
cleavage site at N-terminal to make the protein active by removing the signal peptide 
and the pro-domain in turquoise. There are six potential PPC cleavage sites, which all 
highlighted in red present in C-terminal, and it is thought that cleavage at these sites 
could make the protein inactive or interfere with their activity. It is likely that the 
cleavage at SEMA3B sequence KRRFRR is the most common cleavage site for PCCs 
and this will generate a ∼51 kDa NH2-terminal fragment and ∼20 kDa at C-termin l, 




It has been shown that SEMA3B cleavage to the p65 form inhibits the ability of 
SEMA3B to reduce the growth and metastasis of breast tumours. However, cleavage 
to the p83 form of SEMA3B is essential for SEMA3B to acquire an inhibitory phenotype 
in breast cancer (Varshavsky et al., 2008). PPCs have been shown to be involved in 
this cleavage process based on cleavage site mutation and furin-like pro-protein 
convertase inhibition studies (Adams et al., 1997, Varshavsky et al., 2008). 
Previous studies have commonly claimed that furin is responsible for cleavage of 
SEMA3B and other class 3 semaphorins (Varshavsky et al., 2008, Toledano et al., 
2019), but these experiments have used inhibitors which are not specific for furin, but 
actually inhibit the entire pro-protein convertase family, of which furin is just one 
member. Experiments which specifically inhibit furin show significant potential 
implications in treating some diseases such as human immunodeficiency virus 
(Hallenberger et al., 1992) and head and neck cancer (Bassi et al., 2001b) while the 
overexpression of furin enhances the acceleration of the disease status such as in 
ovarian cancer (Adams et al., 1997, Page et al., 2007). Indeed, the family of furin-like 
pro-protein convertases is now thought to be essential for the development of many 
diseases including cancer and pathogenic infections (Seidah and Prat, 2012) and 
overexpression of some members of the PPC family have been linked to 
carcinogenesis and contribute to invasiveness of cancer cells (Seidah and Prat, 2012). 
However, not all members of the PPC family have been implicated in cancers.  
That said, due to upregulation of many of the furin-like pro-protein convertases in 
different cancers and metastases, they have been suggested as a potential 
therapeutic target to inhibit cancer progression (Seidah and Prat, 2012). However, 
previous attempts in mice to knock-out some members of the family such as furin, 
PCSK5 and PCSK8 resulted in embryonic lethality, which raises a potential concern 
of using inhibitors that knock out these molecules due to the possibility of unwanted 
toxic side-effects upon use in clinical settings (Essalmani et al., 2006, Creemers and 
Khatib, 2008).  
In breast cancer, only a few members of the PPC family, including furin, PCSK6, 
PCSK7 and PCSK9 have previously been associated with breast cancer 
tumorigenicity, or investigated. Indeed, the role of the pro-protein convertase family 
and the possible involvement of these proteins in processing and/or degradation of 
SEMA3B is not clearly understood in breast cancer.  
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As SEMA3B is expressed in breast cancer, but in a fully cleaved form in both pre-
invasive and invasive breast cancer and SEMA3B contains PPC cleavage sites we 
hypothesised that furin-like pro-protein convertases are expressed in breast cancer 
and cleave SEMA3B to produce inactive fragments. Therefore, qPCR, Western 
blotting and immunohistochemistry were performed on a panel of breast cell 
lines/tissues representing models of breast cancer progression to establish the 
expression of PPCs across the progression of breast cancer. Finally, attempts were 
made to inhibit PPC activity to establish whether it is a member of the PPC family that 
is responsible for SEMA3B cleavage in breast cancer.   
Therefore, this chapter aimed to:  
1. Establish the expression of PPCs in the cell line model of breast cancer 
progression (mRNA and protein) and relate this to both disease progression and 
SEMA3B cleavage. 
2. Establish the expression of PPCs in breast tissue and relate this to disease 
progression. 
3. Inhibit the activity of PPCs and to establish whether this will inhibit the cleavage 













5.2.1 Quantitative PCR analysis 
This technique was performed to investigate the mRNA expression of Furin and other 
pro-protein convertases in all cell lines using qPCR. RNA was extracted from the 
breast cell lines, then cDNA was synthesized to determine gene expression of all 
PPCs using SYBR® Green qPCR Master Mix relative to GAPDH housekeeping gene 
as described in 2.9. The validated PPCs qPCR primers ID and sequences are listed 
in table 2.1.4. 
5.2.2 Western blot analysis 
This analysis was used to assess the protein expression of all the PPCs in all cell 
lines. Total cell lysates were separated by 10% SDS-PAGE, and then transferred to a 
PVDF membrane using a semi-dry transfer machine and incubated with the relevant 
antibody. Chemiluminescence was used to detect any bands, with β-actin being used 
as a loading control as described in 2.10 
5.2.3 Cytospin experiment 
This method was used to confirm the Western blot and to assess the expression of 
proteins where antibodies did not work properly in Western Blots e.g. PCSK5 and 
PCSK8. Cells were trypsinised, cytospun onto slides and then immunocytochemistry 
used to confirm protein expression in the cells as described in 2.12. 
5.2.4 Cell pellet experiment  
Cell pellets were generated by trypsinising cells, spinning them into a pellet, and fixing 
them in 10% neutral buffered formalin (NBF) overnight at 4oC. The fixative was 
removed, and cell pellets were covered gently by 300 µL molten agarose (2 g of 
agarose was added into distilled water and warmed up in a microwave until dissolved). 
The agar-cell pellet was left to solidify for a minute or so and then it was gently lifted 
from the bottom of the tube using a small spatula. The agarose was placed in labelled 
cassette and immersed in 70% ethanol ready for processing into wax and then 
sectioning (5 µm sections) by a skilled operator (Maggie Glover). All slides were 
processed by immunocytochemistry in the same manner as for immunohistochemistry 




This method was performed to investigate the PPC expressions in human microarray 
tissues representing a model of breast cancer development as detailed in table 2.10, 
along with relevant positive control tissues for each PPC. Each specimen was 
immunohistochemically stained for all PPCs members, then Semi-quantitative grading 
of staining from 0 (no stain) to 3 (strong stain) was carried out in both epithelial/tumour 
cells as described in 2.11 and 3.2.8.  
 
5.2.6 Inhibition of proteolytic cleavage of furin-like pro-protein convertase  
In order to determine the effect of inhibiting pro-protein convertase activity on the 
cleavage of SEMA3B, cells were treated with two different pan-inhibitors; namely, CMK 
and α-PDX as follows.  
5.2.6.1 Decanoyl-RVKR-CMK inhibitor (CMK) 
Decanoyl-RVKR-CMK is a potent and irreversible pan-inhibitor for furin-like pro-
protein convertases (Couture et al., 2011). 1mg of CMK inhibitor was dissolved in 100 
µl of DMSO and then used in the experiment at the relevant concentration dissolved 
in media. DCIS.com and MDA-MB-231 cells were cultured and seeded as previously 
described in 2.2.2. Then, they were incubated with and without 135 and 200 μmol/L 
CMK inhibitor for 24 hours. Cell lysates were then extracted, and conditioned medium 
was collected from the cells and was separated on a 10% SDS-PAGE gel, blotted onto 
PVDF, and probed with both anti-MT1-MMP (used as a positive control for this assay) 
and with an anti-SEMA3B antibody as described 2.10.  
5.2.6.2 Alpha 1-PDX inhibitor (α-PDX) 
Alpha1-PDX is a potent and selective inhibitor of furin and some PPCs, that contain a 
minimal furin consensus sequence, RXXR in its reactive loop which able α-PDX to 
block the activity of PPCs (Tsuji et al., 1999). According to the manufacturer, for a PPC 
inhibition assay, cells should be treated within the range of 8.0-20 µM. DCIS.com and 
MDA-MB-231 cells were cultured and seeded, as previously described in section 
2.2.2. Then, they were incubated with and without 20 µM α-PDX inhibitor for 24 hours. 
Cell lysates were extracted, and conditioned medium was collected for Western blot 
as described in 2.10. Proteins were separated on a 10% SDS-PAGE gel, blotted onto 
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PVDF, and probed with both anti-MT1-MMP (used as a positive control for this assay) 




5.3 Results  
As SEMA3B is cleaved in breast cancer cell lines and contains several PPC cleavage 
recognition sites, mRNA expression of all the PPC family members were first 
established in the cell lines representing different stages of disease progression. Then 
these mRNA data were compared with protein expression data in the cell lines, and 
then in tissue microarray slides, again containing different breast tissue stages 
(normal, atypical hyperplasia, DCIS and invasive tissues).   
5.3.1 Furin mRNA expression in breast epithelial and cancer cell-lines  
Furin is overexpressed in some cancers where it correlates with metastatic 
progression (Bassi et al., 2000) , and it is also thought to cleave SEMA3B (Varshavsky 
et al., 2008). Therefore, we determined the expression of furin mRNA by qPCR using 
the same cell lines as described 2.9 to establish whether expression of furin is 
associated with progression of breast disease. 
As shown in figure 5.2, the non-malignant MCF-10A and pre-malignant MCF-10AT 
breast cell lines expressed significantly higher levels of furin mRNA compared to other 
cells. When the levels of furin mRNA were compared to the normal MCF-10A, 
DCIS.com (P= 0.0010, Dunnett’s test), MCF-7 (P<0.0001, Dunnett’s test), T47D (P= 
0.0005, Dunnett’s test) and MDA-MB-231 cells (P<0.0001, Dunnett’s test) had a 
significantly lower expression of furin mRNA. That said, furin was more highly 
expressed in the metastatic bone homing MDA-MB-231-BM cells than the pre-invasive 
































Figure 5.2: qPCR analysis of furin mRNA expression in breast normal/cancer 
cells lines. RNA was extracted from cells and cDNA was synthesised and was 
analysed by qPCR. GAPDH was used to confirm the integrity of RNA. Data are 
presented as a ratio to GAPDH. Delta Ct is presented on the Y-axis and was calculated 
by subtracting the mean of cell Ct from the mean of the reference gene. Data is 
presented as the mean +/- SD of three independent experiments. The lower the Ct 
level, the greater the amount of target nucleic acid in the sample. Data was analysed 
statistically by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P 
values were generated, and ** represent P<0.01, *** represent P<0.001 and **** 




5.3.2 PCSK1 mRNA in breast epithelial and cancer cell-lines  
PCSK1 is known to be expressed primarily in neuronal and endocrine cells (Seidah et 
al., 1991). However, little is known about its role in breast cancer. The PCSK1 mRNA 
expression was therefore investigated in all breast cell lines as described 2.9.  
As shown in figure 5.3, the expression pattern of PCSK1 mRNA was similar to that of 
SEMA3B with a significantly higher level of PCSK1 expression detected in MCF-10A 
cells compared to all other cell lines, which had significantly lower levels of PCSK1 



















Figure 5.3: qPCR analysis of PCSK1 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was synthesised 
and was analysed by qPCR. GAPDH was used to confirm the integrity of RNA. Data 
are presented as a ratio to GAPDH. The Y-axis represented the Delta Ct, was 
calculated by subtracting the mean of cell Ct from the mean of the reference gene. 
Data is presented as the mean +/- SD of three independent experiments. The lower 
the Ct level, the greater the amount of target nucleic acid in the sample. Data was 
analysed statistically by one-way ANOVA with post hoc Dunnett’s multiple 
comparisons. P values were generated, and ** represent P<0.01, *** represent 
P<0.001 and **** represent P<0.0001 compared to the expression of PCSK1 in normal 
epithelial MCF-10A cells.  
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5.3.3 PCSK2 mRNA in breast epithelial and cancer cell-lines  
A previous study revealed that PCSK2 is not important for normal embryonic 
development, but it helps to control the maturation of several regulatory precursor 
proteins (Scamuffa et al., 2006). However, mutations in PCSK2 have been linked with 
multiple defects and disease such as hypoglycemia and a deficiency in circulating 
glucagon (Scamuffa et al., 2006), but its role in cancer has not been clearly identified 
yet. Therefore, it was interesting to study this member of the PPC family across the 
breast cell lines. As shown in figure 5.4, the expression of PCSK2 was fairly low in the 
non-malignant MCF-10A and pre-invasive DCIS.com cells and compared to the 
normal MCF-10A, the gene expression of PCSK2 was significantly increased in MCF-
10AT (P=0.0026, Dunnett’s test), MCF-7 (P=0.0462, Dunnett’s test), T47D (P=0.0026, 
Dunnett’s test) cells. Moreover, the highest expression of PCSK2 was detected in 
metastatic bone homing MDA-MB-231-BM cells (P<0.0001, Dunnett’s test) suggesting 
that generally PCSK2 is increased in breast cancer cells compared to non-cancerous 


















Figure 5.4: qPCR analysis of PCSK2 mRNA expression in expression in breast 
normal/cancer cells lines. RNA was extracted from cells and cDNA was synthesised, 
and that was analysed by qRT-PCR. GAPDH was used to confirm the integrity of RNA 
and data are presented as a ratio to GAPDH. The Y-axis represented the Delta Ct, 
was calculated by subtracting the mean of cell Ct from the mean of the reference gene. 
Data is presented as the mean +/- SD of three independent experiments. The lower 
the Ct level, the greater the amount of target nucleic acid. The data was analysed 
statistically by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P 
values were generated and * represent P=0.0462, ** represent P=0.0026 and **** 




5.3.4 PCSK4 mRNA in breast epithelial and cancer cell-lines  
PCSK4 has been shown to be expressed highly in reproductive tissues including 
testes, ovaries, and placenta, and the absence of PCSK4 is associated with male and 
female infertility in mice (Gyamera-Acheampong and Mbikay, 2009). However, there 
is no previous study that has looked at its expression in breast cancer. Therefore, it 
was interesting to study the expression of PCSK4 in the panel of breast cell lines as 
described in 2.9. As shown in figure 5.5, the majority of the cell lines tested showed 
similar, fairly low levels of PCSK4 expression, except for T47D cells which had a 


















Figure 5.5: qPCR analysis of PCSK4 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was synthesised, 
and that was analysed by qRT-PCR. GAPDH was used to confirm the integrity of RNA 
and data are presented as a ratio to GAPDH. The Y-axis represented the Delta Ct, 
was calculated by subtracting the mean of cell Ct from the mean of the reference gene. 
Data is presented as the mean +/- SD of three independent experiments. The lower 
the Ct level, the greater the amount of target nucleic acid. The data was analysed 
statistically by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P 
values were generated, and ** represent P=0.0069 compared to the expression of 
PCSK4 in normal epithelial MCF-10A cells. 
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5.3.5 PCSK5 mRNA in breast epithelial and cancer cell-lines  
PCSK5 has a widespread tissue distribution, but the highest density of PCSK5 is found 
in adrenal cortex and intestine small intestine (Essalmani et al., 2006). However, 
studies linking PCSK5 to cancer are limited (Sun et al., 2009) and indeed, one previous 
study failed to detect expression of PCSK5 mRNA in breast cancer cells (Cheng et al., 
1997). However, that study did not include all the cell lines in the panel used in this 
thesis, and therefore qPCR was performed on these cells as described 2.9. As shown 
in figure 5.6, there was low expression of PCSK5 mRNA detected in all the cell lines 
with MCF-7 cells showing the highest expression across all the investigated cell lines 
and was significantly higher than the normal breast epithelial cell line, MCF-10A 
(P=0.01, Dunnett’s test). In contrast the lowest expression of PCSK5 was in T47D and 
MDA-MB-231 cells where expression was significantly lower than MCF-10A cells 



















Figure 5.6: qPCR analysis of PCSK5 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was 
synthesised, and that was analysed by qRT-PCR. GAPDH was used to confirm the 
integrity of RNA and data are presented as a ratio to GAPDH. The Y-axis represented 
the Delta Ct, was calculated by subtracting the mean of cell Ct from the mean of the 
reference gene. Data is presented as the mean +/- SD of three independent 
experiments. The lower the Ct level, the greater the amount of target nucleic acid. The 
data was analysed statistically by one-way ANOVA with post hoc Dunnett’s multiple 
comparisons. P values were generated and * represents P=0.01 and *** represents 
P= 0.0002 compared to the expression of PCSK5 in normal epithelial MCF-10A cells. 
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5.3.6 PCSK6 mRNA in breast epithelial and cancer cell-lines  
PCSK6 is located on the same chromosome as furin, chromosome 15, so it is possible 
that it may have similar regulation, expression and function to furin. Indeed, a previous 
study has demonstrated that PCSK6 is linked with breast cancer progression (Wang 
et al., 2015). Therefore, qPCR was performed on the representative cell lines of breast 
disease progression as described in 2.9. However, as shown in figure 5.7, although 
PCSK6 mRNA expression was detected in all cell lines, there was no significant 






















Figure 5.7: qPCR analysis of PCSK6 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was 
synthesised, and that was analysed by qRT-PCR. GAPDH was used to confirm the 
integrity of RNA and data are presented as a ratio to GAPDH. The Y-axis represented 
the Delta Ct, was calculated by subtracting  the mean of cell Ct from the mean of the 
reference gene. Data is presented as the mean +/- SD of three independent 
experiments. The data was analysed statistically by one-way ANOVA. The lower the 
Ct level, the greater the amount of target nucleic acid. 
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5.3.7 PCSK7 mRNA in breast epithelial and cancer cell-lines  
There is some evidence in the literature to suggest that PCSK7 may have a role in 
breast cancer as overexpression of PCSK7 was identified in aggressive breast 
cancers (Cheng et al., 1997). Therefore, since we believed that one of the PPC family 
is responsible for the cleavage of SEMA3B, the gene expression of PCSK7 was 
investigated in all cell lines used as described in 2.9. As shown in figure 5.8, PCSK7 
was detected in all the cell lines with T47D and DCIS.com expressing the most. When 
compared to the normal MCF-10A cells this increase in expression was significant 
(T47D cells; P<0.0001, Dunnett’s test and DCIS.com P<0.0001, Dunnett’s test). In 
contrast, the expression of PCSK7 in all other cell lines was significantly reduced 
compared to the MCF-10A cells; MCF-10AT (P=0.0011, Dunnett’s test), MCF-7 
(P<0.0001, Dunnett’s test), MDA-MB-231 (P<0.0001, Dunnett’s test) and MDA-MB-
















Figure 5.8: qPCR analysis of PCSK7 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was synthesised, 
and that was analysed by qRT-PCR. GAPDH was used to confirm the integrity of RNA 
and data are presented as a ratio to GAPDH. The Y-axis represented the Delta Ct, 
was calculated by subtracting the mean of cell Ct from the mean of the reference gene. 
The lower the Ct level, the greater the amount of target nucleic acid. Data is presented 
as the mean +/- SD of three independent experiments. The data was analysed 
statistically by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P 
values were generated and ** represents P=0.0011, *** represents P= 0.0005 and **** 




5.3.8 PCSK8 mRNA in breast epithelial and cancer cell-lines  
Previous studies have shown that expression of PCSK8 mRNA was decreased in lung 
cancer tissue compared to normal lung tissue (Demidyuk et al., 2013), however, 
nothing is known about its role or expression in breast cancer. Therefore, PCSK8 
mRNA was investigated by qPCR as described in 2.9 in all our breast cell lines. As 
shown in figure 5.9, PCSK8 mRNA was detected in all cell lines with T47D showing 
the highest level of expression (P<0.0001, Dunnett’s test compared to the normal 
MCF-10A cells). MCF-10A, DCIS.com and MDA-MB-231-BM cells had similar levels 
of expression with significantly lower expression seen in MCF-10AT (P=0.01, 
Dunnett’s test), MCF-7 (P=0.01, Dunnett’s test) and MDA-MB-231 (P=0.02, Dunnett’s 
















Figure 5.9: qPCR analysis of PCSK8 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was 
synthesised, and that was analysed by qRT-PCR. GAPDH was used to confirm the 
integrity of RNA and data are presented as a ratio to GAPDH. The Y-axis represented 
the Delta Ct, was calculated by subtracting the mean of cell Ct from the mean of the 
reference gene. The lower the Ct level, the greater the amount of target nucleic acid. 
Data is presented as the mean +/- SD of three independent experiments. The data 
was analysed statistically by one-way ANOVA with post hoc Dunnett’s multiple 
comparisons. P values were generated and * represents P=0.01, ** represents P=0.02 
and **** represents P<0.0001 compared to the expression of PCSK8 in normal 
epithelial MCF-10A cells. 
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5.3.9 PCSK9 mRNA in breast epithelial and cancer cell-lines  
PCSK9 has been shown to be a vital regulator of lipid metabolism and associated with 
cholesterol homeostasis (Levy et al., 2013), with high expression of PCSK9 leading to 
increase the level of cholesterol. A previous study found a strong association between 
the increased level of cholesterol due to PCSK9 and the risk of breast cancer (Nelson 
et al., 2014), suggesting a possible role of PCSK9 in breast cancer progression. In 
order to assess the PCSK9 mRNA expression in our breast cancerous and non-
cancerous cells, qPCR was performed as described in 2.9. As shown in figure 5.10, 
PCSK9 was expressed in all cell lines, with maximal expression in MCF-10A and 
MDA-MB-231 cells, and only a slight (non-significant) reduction in MCF-10AT cells. 
PCSK9 expression was significantly reduced in all malignant cells except MDA-MB-
231 cells when compared to MCF-10A cells; DCIS.com (P<0.0001, Dunnett’s test), 
MCF-7 (P<0.0001, Dunnett’s test), T47D (P<0.0001, Dunnett’s test) and MDA-MB-















Figure 5.10: qPCR analysis of PCSK9 mRNA expression in expression in breast 
normal/cancer cells lines: RNA was extracted from cells and cDNA was synthesised, 
and that was analysed by qRT-PCR. GAPDH was used to confirm the integrity of RNA 
and data are presented as a ratio to GAPDH. The Y-axis represented the Delta Ct, 
was calculated by subtracting the mean of cell Ct from the mean of the reference gene. 
The lower the Ct level, the greater the amount of target nucleic acid. Data is presented 
as the mean +/- SD of three independent experiments. The data was analysed 
statistically by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P 
values were generated and *** represents P= 0.0002, and **** represents P<0.0001 
compared to the expression of PCSK9 in normal epithelial MCF-10A cells. 
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5.3.10 Furin protein expression in normal breast and cancer cell-lines and 
conditioned medium   
Having established that furin mRNA was present in the breast cell lines, it was 
important to establish whether this was translated to protein, as it would be protein 
that would be responsible for SEMA3B cleavage. Presence of furin protein was 
determined by western blotting on the same breast cancer cell extracts as described 
in 2.10, with HepG2 cells used as a positive control as furin has previously been 
identified in these cells (Mori et al., 1999). 
Furin protein expression, determined in cell lysates using antibodies directed against 
the C-terminal of furin of human origin (figure 5.11) was seen in all cell lines in two 
main forms, the full-length at ∼97 kDa which is known to be inactive and the mature 
form at ∼70 kDa (active form) (Rehemtulla et al., 1992). The full-length form, was 
found to be most highly expressed in the normal, pre-malignant and pre-invasive cell 
lines compared to the invasive cells. In contrast, the expression of the mature form 
(∼70 kDa), gradually increased with increasing malignancy of disease and was 
significantly higher in most of the invasive breast cancer cell lines, including T47D 
(P=0.0468, Dunnett’s test), MDA-MB-231 (P=0.0324, Dunnett’s test) and MDA-MB-
231-BM (P=0.0233, Dunnett’s test) compared to MCF-10A cells. However, in MCF-7 
cells, the expression of furin was similar to that in non-cancerous cells with no 
significant differences. 
In conditioned medium, the full-length furin (∼97 kDa) was not seen in any cell line 
conditioned medium. However, the expression of furin at 70 kDa was found to be the 
most expressed in the conditioned medium of MDA-MB-231 cells with faint expression 
detected in other cells except for MCF-10A and MDA-MB-231-BM (figure 5.12). These 
findings suggest that furin may be responsible for the cleavage of SEMA3B protein; 





































Figure 5.11: Furin protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-furin antibody. Hep-G2 was used 
as a positive control for furin expression. To confirm that the amount of protein in each 
lane was equal, the membrane was stripped and re-probed with anti-β-actin 
housekeeping protein as a loading control. Densitometry analysis was performed for 
all cells using ImageJ software to assess relative band densities. Data is represented 
as the mean+/- SD of three independent experiments. Data was analysed statistically 
by one-way ANOVA with post hoc Dunnett’s multiple comparisons. P values were 
generated, and * represent P<0.01 and *** represent P= 0.0002 compared to the 
expression of furin in normal epithelial MCF-10A cells. The sizes of molecular weight 



































Figure 5.12: Furin protein detection in conditioned medium of normal breast and 
cancer cell-lines as determined by Western blot. Cells were seeded and starved 
for 24 hours and conditioned medium was generated to be collected and separated 
on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the anti-furin 
antibody. Hep-G2 lysate was used as a positive control for furin expression. 
Densitometry analysis was performed for all cells using ImageJ software to assess 
band densities and presented as densitometry value. Data are the mean ± SD of three 
independent experiments. Data was analysed statistically by ordinary one-way 
ANOVA followed by a post hoc Dunnett’s test (* represent P= 0.0282, *** represent P= 
0.0002 and **** represent P<0.0001 in comparison to normal MCF-10A cells). 
Representative immunoblot shown of n=3. 
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5.3.11 PCSK1 protein expression in normal breast and cancer cell-lines and 
conditioned medium 
To evaluate whether the PCSK1 gene expression observations were translated to the 
protein level, Western blot was performed in all the cell line lysates and conditioned 
medium, with cell lysates extracted and conditioned medium was collected and 
investigated as described in 2.10. HepG2 cells were again used as positive controls 
as they have previously been shown to express this protein (ProteinAtlas). 
As shown in figure 5.13, in cell lysates, the antibody used detected two different 
isoforms of PCSK1, one at 84 kDa, which is active form, and one at 66 kDa which is 
also active and thought to be the most catalytically active form of PCSK1, although 
this isoform is thought to be less stable than the 84 kDa form (Blanco et al., 2015). 
The protein expression of the largest isoform did not correlate with the gene 
expression, as the lowest expression of PCSK1 protein was detected in MCF-10A at 
84 kDa. However, compared to the normal MCF-10A cells, in all other cells, there was 
a strong expression of PCSK1 and that was significantly higher in MCF-10AT 
(P<0.0001, Dunnett’s test), DCIS.com (P=0.0002, Dunnett’s test), MCF-7 (P<0.0001, 
Dunnett’s test), T47D (P=0.0002, Dunnett’s test), MDA-MB-231 (P<0.0001, Dunnett’s 
test) and MDA-MB-231-BM (P<0.0001, Dunnett’s test) than in MCF-10A cells. This 
pattern matches somewhat with the cleavage of SEMA3B suggesting that this protein 
has the potential to be involved in SEMA3B cleavage. Interestingly, the expression of 
PCSK1 at 66 kDa, the most active form of the protein, was only detected in MCF-10A 
and MCF-10AT cells, suggesting that this is less likely to be responsible for SEMA3B 
cleavage. In conditioned medium, the PCSK1 protein was detected only as the 84 kDa 
form which was the highest in MCF-10A while the 66 kDa was not secreted in any 
cells, in contrast to cell lysates which could suggest the degradation of this form due 









































Figure 5.13: PCSK1 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK1 antibody. Hep-G2 was 
used as a positive control for PCSK1 expression. To confirm that the amount of protein 
in each lane was equal, the membrane was stripped and re-probed with anti-β-actin 
housekeeping protein as a loading control. Densitometry analysis was performed for 
all cells using ImageJ software to assess relative band densities. Data is represented 
as the mean+/- SD of three independent experiments. Data was analysed statistically 
by one-way ANOVA with post hoc Dunnett’s multiple comparisons. The P values were 
generated and ** represent P=0013, *** represent P=0.0002 and **** represents 
P<0.0001 compared to MCF-10A. The sizes of molecular weight markers are indicated 
































Figure 5.14: PCSK1 protein detection in conditioned medium of normal breast 
and cancer cell-lines as determined by Western blot. Cells were seeded and 
starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK1 antibody. Hep-G2 lysate was used as a positive control for PCSK1 
expression. Densitometry analysis was performed for all cells using ImageJ software 
to assess band densities and presented as densitometry value. Data are the mean ± 
SD of three independent experiments. Data was analysed statistically by ordinary one-
way ANOVA followed by a post hoc Dunnett’s test (* represent P= 0.0368 and *** 
represent P= 0.0003 in comparison to normal MCF-10A cells). Representative 
immunoblot shown of n=3. 
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5.3.12 PCSK2 protein expression in normal breast and cancer cell-lines and 
conditioned medium   
Again, Western blot analysis was performed on all cell line lysates and conditioned 
medium to establish whether mRNA expression translated into protein expression.  
HepG2 was used as a positive control as it has previously been shown to express 
PCSK2 (R & D system). 
All cell lines expressed PCSK2 protein at 71 kDa which is the inactive form of this 
protein (Tzimas et al., 2005). T47D cells showed a significant low expression of 
PCSK2 compared to MCF-10A (P<0.0001, Dunnett’s test) (Figure 5.15). Interestingly 
additional bands were observed in MCF-7, T47D and Hep-G2 at a higher molecular 
weight, 100 kDa, which is likely to be the pro-form of PCSK2. A faint band was 
detected at 68 kDa only in MCF-7 and previous studies have suggested that this is the 
active form (Mbikay et al., 1997, Tzimas et al., 2005). If this is the only active form of 
the protein, this expression pattern does not match that of SEMA3B cleavage and it is 
unlikely that this protein is responsible for that cleavage. 
In conditioned medium, the PCSK2 protein was detected only as the 71 kDa form but 
these bands appeared very faint in MCF-7, T47D, MDA-MB-231 and MDA-MB-231-








































Figure 5.15: PCSK2 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK2 antibody. Hep-G2 was 
used as a positive control for PCSK2 expression. To confirm that the amount of protein 
in each lane was equal, the membrane was stripped and re-probed with anti-β-actin 
housekeeping protein as a loading control. Densitometry analysis was performed for 
all cells using ImageJ software to assess relative band densities. Data is represented 
as the mean+/- SD of three independent experiments. Data was analysed statistically 
by one-way ANOVA with post hoc Dunnett’s multiple comparisons. The P-value was 
generated and **** represent P<0.0001 compared to MCF-10A. The sizes of molecular 































Figure 5.16: PCSK2 protein detection in conditioned medium of normal breast 
and cancer cell-lines as determined by Western blot. Cells were seeded and 
starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK2 antibody. Hep-G2 lysate was used as a positive control for PCSK2 
expression. Densitometry analysis was performed for all cells using ImageJ software 
to assess band densities and presented as densitometry value. Data are the mean ± 
SD of three independent experiments. Data was analysed statistically by ordinary one-
way ANOVA followed by a post hoc Dunnett’s test (* represent P= 0.0150, ** represent 
P=0.0010 and **** represent P<0.0001 in comparison to normal MCF-10A cells). 
Representative immunoblot shown of n=3. 
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5.3.13 PCSK4 protein expression in normal breast and cancer cell-lines and 
conditioned medium   
This experiment was carried out to detect PCSK4 protein expression and was 
determined by Western blotting on the same breast cancer cell extracts and 
conditioned medium as described in 2.10. Ovarian cell lysates were used as a positive 
control for PCSK4 as its expression has previously been identified in these cells 
(Gyamera-Acheampong and Mbikay, 2009). 
PCSK4 has two isoforms, which are found at 82 kDa and 26 kDa (Basak et al., 2008) 
and as shown in figure 5.17, in cell lysates, only the 26 kDa isoform was detected in 
these experiments. MCF-10A, MCF-10AT, MCF-7 and T47D cells expressed similar 
levels of PCSK4 26 kDa protein to the positive control, with DCIS (P=0.0004, Dunnett’s 
test) and MDA-MB-231 cells (P=0.0324, Dunnett’s) expressing significantly less 
protein than the MCF-10A cells. MDA-MB-231-BM cells did not express the PCSK4 
protein in any experiment as shown by an absence of band.  
In conditioned medium, the PCSK4 was faintly secreted only by DCIS.com at 26 kDa 
with no secretion detected in other cells (figure 5.18). To our knowledge, this is the 
first study that has identified the expression of PCSK4 in a different spectrum of breast 































Figure 5.17: PCSK4 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK4 antibody. Ovarian lysate 
was used as a positive control for PCSK4 expression. To confirm that the amount of 
protein in each lane was equal, the membrane was stripped and re-probed with anti-
β-actin housekeeping protein as a loading control. Densitometry analysis was 
performed for all cells using ImageJ software to assess relative band densities. Data 
is represented as the mean+/- SD of three independent experiments. Data was 
analysed statistically by one-way ANOVA with post hoc Dunnett’s multiple 
comparisons. The P-value was generated and* represent P=0.0324 and **** represent 
P=0.0001 compared to MCF-10A. The sizes of molecular weight markers are indicated 

























Figure 5.18: PCSK4 protein detection in conditioned medium of normal breast 
and cancer cell-lines as determined by Western blot. Cells were seeded and 
starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK4 antibody. Ovarian lysate was used as a positive control for PCSK4 
expression. The sizes of molecular weight markers are indicated in kDa. 
Representative immunoblot shown of n=3. 
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5.3.14 PCSK5 protein expression in normal breast and cancer cell-lines and 
conditioned medium   
Western blot was carried out to assess the expression of PCSK5 as we did with other 
PPC family members, however; it was not possible to detect the protein expression by 
Western blot for this protein, despite changing protocol and antibodies. Therefore, the 
protein expression in cells was assessed by cytospin technique to establish whether 
or not PCSK5 protein is expressed in breast cells. The data from these experiments 
are shown later (5.25). 
5.3.15 PCSK6 protein expression in normal breast and cancer cell-lines and 
secretion in conditioned medium   
Previous studies have shown that PCSK6 is associated with the progression of breast 
cancer and we demonstrated mRNA expression in all the breast cell lines detected. 
Therefore, the protein expression of PCSK6 was assessed by Western blot as 
described in 2.10. HepG2 cell lysates were used as a positive control for PCSK6 as 
its expression has previously been identified in these cells (Couture et al., 2015). As 
shown in figure 5.19, in cell lysates, little or no protein was detected in most of the cell 
lines, with protein expression detected in MCF-10A, MCF-10AT, DCIS.com and MDA-
MB-231-BM cells. This is in contrast to the gene expression data where PCSK6 mRNA 
was identified in all these cells. T47D cells had the highest expression of PCSK6 
protein, with very low expression detected in MCF-7 and MDA-MB-231 cells. 
In conditioned medium, no protein was secreted in the conditioned medium of MCF-
10A, MCF-10AT and DCIS.com. However, T47D had the most secretion of PCSK6 
while in MDA-MB-231 and MCF-7 only faint bands were detected (figure 5.20). These 
data do not mirror the cleavage of SEMA3B suggesting that this protein is less likely 
































Figure 5.19: PCSK6 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK6 antibody. HepG2 lysate 
was used as a positive control for PCSK6 expression. To confirm that the amount of 
protein in each lane was equal, the membrane was stripped and re-probed with anti-
β-actin housekeeping protein as a loading control. Densitometry analysis was 
performed for all cells using ImageJ software to assess relative band densities. Data 
is represented as the mean+/- SD of three independent experiments. Data was 
analysed statistically by one-way ANOVA. The sizes of molecular weight markers are 

























Figure 5.20: PCSK6 protein detection in conditioned medium of normal breast 
and cancer cell-lines as determined by Western blot. Cells were seeded and 
starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK6 antibody. Hep-G2 lysate was used as a positive control for PCSK6 
expression. Densitometry analysis was performed for all cells using ImageJ software 
to assess band densities and presented as densitometry value. Data are the mean ± 
SD of three independent experiments. Data was analysed statistically by ordinary one-
way ANOVA followed by a post hoc Dunnett’s test (**** represent P<0.0001 in 




5.3.16 PCSK7 protein expression in normal breast cancer cell-lines and 
conditioned medium   
To evaluate the protein expression of PCSK7 in the cell lines, Western blot was carried 
out as described in 2.10. HepG2 cell lysates were used as a positive control for PCSK7 
as its expression has previously been identified in these cells (Mori et al., 1999). 
As shown in figure 5.21, in cell lysates, two different molecular weight bands were 
detected in each lane. The higher molecular weight at 86 kDa represents the pro-form 
of PCSK7 (inactive), while the lower molecular weight 64 kDa represents the 
processed form of PCSK7 (active). The expression of the pro-form of PCSK7, 86 kDa, 
was largely unchanged across the sequence with no significant differences, with the 
exception of no expression being detected in T47D and only a very faint band detected 
in MDA-MB-231-BM. At the lower molecular weight 64 kDa, similar level of expression 
was observed in MCF-10A and MCF-10AT with a significantly increased expression 
of PCSK7 detected in DCIS.com (P=0.0043, Dunnett’s test), MCF-7 (P=0.0014, 
Dunnett’s test) and MDA-MB-231 (P=0.0279, Dunnett’s test) compared to MCF-10A 
cells. However, there was no protein expression of PCSK7 detected in T47D and 
MDA-MB-231-BM cell lines at 64kDa. This lack of protein expression in T47D cells is 
in complete contrast to the mRNA data where T47D cells demonstrated the highest 
expression.   
In conditioned medium experiment, we observed clear similarities between the 
malignant and non-malignant cells at 64 kDa with slightly high intensity of bands seen 
in MDA-MB-231. However, no secretion of PCSK7 was detected in T47D in 


































Figure 5.21: PCSK7 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK7 antibody. HepG2 lysate 
was used as a positive control for PCSK7 expression. To confirm that the amount of 
protein in each lane was equal, the membrane was stripped and re-probed with anti-
β-actin housekeeping protein as a loading control. Densitometry analysis was 
performed for all cells using ImageJ software to assess relative band densities. Data 
is represented as the mean+/- SD of three independent experiments. Data was 
analysed statistically by one-way ANOVA. The P-value was generated and * 
represents P=0.0279 and** represent P=0.0043 & P=0.0014 compared to MCF-10A 


























Figure 5.22: PCSK7 protein detection in conditioned medium of normal breast 
and cancer cell-lines as determined by Western blot. Cells were seeded and 
starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK7 antibody. Hep-G2 lysate was used as a positive control for PCSK7 
expression. Densitometry analysis was performed for all cells using ImageJ software 
to assess band densities and presented as densitometry value. Data are the mean ± 
SD of three independent experiments. Data was analysed statistically by ordinary one-
way ANOVA followed by a post hoc Dunnett’s test (** represent P=0.0081 and **** 
represent P<0.0001 in comparison to normal MCF-10A cells). Representative 




5.3.17 PCSK8 protein expression in normal breast and cancer cell-lines   
Again, Western blot of PCSK8 was carried out on all cell lines, but as with PCSK5, it 
was not possible to detect the protein in Western blots using the only antibodies 
available. This suggests that it is in part due to the quality of the antibodies. Therefore, 
the PCSK8 protein expression in cells was assessed by cytospin and by cell pelleting 
and subsequent staining, the results of which are described later in this chapter.  
5.3.18 PCSK9 protein expression in normal breast and cancer cell-lines and 
conditioned medium  
Finally, PCSK9 protein expression was investigated in all the cell lines and conditioned 
medium by Western blot as described in 2.10. HepG2 cell lysates were used as a 
positive control for PCSK9 as its expression has previously been identified in these 
cells (Dubuc et al., 2004). As shown in figure 5.23, there was a single band at 62 kDa 
(active form) (Glerup et al., 2017) seen in all breast cell lines with a slight increase in 
expression seen with increasing malignancy of the cell line achieving significance in 
comparison to MCF-10A cells, in T47D (P=0.0028, Dunnett’s test), MDA-MB-231 
(P=0.0471, Dunnett’s test) and MDA-MB-231-BM cells (P=0.0028, Dunnett’s test). 
However, the protein level of PCSK9 did not reflect the gene expression levels as the 
gene expression was highest in MCF-10A, MCF-10AT and MDA-MB-231 cells.  
In conditioned medium results revealed that PCSK9 existed in the conditioned medium 
of MCF-7, T47D, MDA-MB-231 and MDA-MB-231-BM. Moreover, there were faint 
bands detected in both MCF-10AT and DCIS.com. However, the expression of PCSK9 
in the conditioned medium was lower than that in the cell lysate, possibly because of 
the processing before secretion (figure 5.24). The PCSK9 in conditioned medium of 
MCF-10A was not detected. These results could suggest the possible role of PCSK9 
































Figure 5.23: PCSK9 protein expression in normal breast and cancer cell-lines as 
determined by Western blot. Cell lysates were separated on a 10% SDS-PAGE gel, 
and then blotted onto PVDF and probed with the anti-PCSK9 antibody. HepG2 lysate 
was used as a positive control for PCSK9 expression. To confirm that the amount of 
protein in each lane was equal, the membrane was stripped and re-probed with anti-
β-actin housekeeping protein as a loading control. Densitometry analysis was 
performed for all cells using ImageJ software to assess relative band densities. Data 
is represented as the mean+/- SD of three independent experiments. Data was 
analysed statistically by one-way ANOVA followed by Dunnett’s test. The P-value was 
generated and * represents P=0.0471 and ** represent P=0.0028 compared to MCF-
10A cells. The sizes of molecular weight markers are indicated in kDa. Representative 































Figure 5.24: PCSK9 protein detection in conditioned medium of normal breast 
epithelial and cancer cell-lines as determined by Western blot. Cells were seeded 
and starved for 24 hours and conditioned medium was generated to be collected and 
separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed with the 
anti-PCSK9 antibody. Hep-G2 lysate was used as a positive control for PCSK9 
expression. Densitometry analysis was performed for all cells using ImageJ software 
to assess band densities and presented as densitometry value. Data are the mean ± 
SD of three independent experiments. Data was analysed statistically by ordinary one-
way ANOVA followed by a post hoc Dunnett’s test (** represent P=0.0021 and **** 
represent P<0.0001 in comparison to normal MCF-10A cells). The sizes of molecular 




5.3.19 Measurement of protein expression of all PPCs in cell-lines using cytospin 
technique  
As it was not possible to detect some of the pro-protein convertases by Western 
blotting, the cytospin technique was performed to study protein expression by 
concentrating the cells into a small area and doing immunocytochemistry as described 
in 2.12. Heamatoxylin was used to stain the nucleus and analysis was performed by 
assessing intensity of brown stain in the cells. 
As shown in 5.25 and 5.26, brown stain indicating the presence of PPCs were seen in 
nearly all cell lines for nearly all proteins. However, again, in agreement with the 
Western blots, it was not possible to detect PCSK8 in any cell line under any condition 
using this technique. MCF-10A showed weak expression of PCSK1, PCSK2, PCSK4, 
PCSK5, PCSK7 and moderate expression of furin, PCSK6 and PCSK9. The pre-
malignant MCF-10AT showed moderate expression of PCSK1, PCSK2, furin, and 
PCSK4, and there was a strong expression of PCSK5, PCSK6, PCSK7, and PCSK9 
in these cells. The pre-invasive DCIS.com cells showed only a moderate expression 
of PCSK1 while all other PPCs were strongly expressed in these cells. In invasive 
cells, MCF-7 had moderate expression of PCSK1, furin, PCSK4, PCSK6, PCSK7 and 
a strong expression of PCSK2, PCSK5 and PCSK9. T47D cells had moderate 
expression of all PPCs except for PCSK9, which was strongly expressed. MDA-MB-
231 cells showed a strong expression of all PPCs in these cells with no obvious 
differences between them. MDA-MB-231-BM cells showed similar expression of PPCs 
to those found in MDA-MB-231 cells, with the exception of a lower level of PCSK4.  
Taken together these data suggest that PCSK1, PCSK2, PCSK4, PCSK5 and PCSK7 
show the pattern of low expression in MCF-10A and higher expression in all other cell 
lines that match with reduced SEMA3B cleavage in MCF-10A cells and full cleavage 




























































































































































































































































































































Figure 5.26: Representative cytospin analysis of PPCs in all cell-lines. The images 
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5.3.20 Protein expression using cell pellet in cell-lines 
PCSK8 was not detected in either Western blots or using the cytospin technique. As 
the antibody data sheet stated that it could be used for immunohistochemistry, the 
protein expression of PCSK8 in the cell lines was investigated by a different technique 
called cell pelleting as described in 5.2.4. The cell pellets were fixed and processed to 
wax and immunohistochemistry was used to determine PCSK8 expression. As shown 
in figure 5.27, strong expression of PCSK8 was seen in all cell lines suggesting that 
this protein is expressed in breast tumour and non-tumour cells in similar levels. All 
the cells showed good contrast and the dye stained almost all cells cytoplasm and 
membrane with the slightly different colour intensity found in MCF-10A cells. This data 















Figure 5.27: Representative images of breast normal and cancer cells processed 
by cell pellet technique. Cells were trypsinized, and the cell pellet collected and 
solidified by adding the molten agarose to be placed into a cassette for processing. 
The cells were probed by the PCSK8 antibody (1:50), and counterstained with 
haematoxylin. The scale bar = 500px 
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5.3.21 Assessment of pro-protein convertases protein expression in human 
breast tissue 
In order to investigate whether the pro-protein convertases are expressed in human 
breast tissues of similar morphology to the cell lines, and whether the pattern of 
expression seen in cell lines matches those seen in human tissues of breast disease, 
immunohistochemical staining was performed on tissues representing different breast 
cancer stages as described 2.11. Each tissue microarray slide was stained for different 
pro-protein convertases and scored to assess the intensity of staining as described in 
2.11.2. The data were analysed by correlation with SEMA3B and with disease 
progression.  
Furin expression has not been previously investigated at a protein level in breast 
cancer. As shown in figure 5.28, a moderate to strong cytoplasmic expression of furin 
was seen in 63% of normal tissues, 56% of atypical ductal hyperplasia (ADH) and 50% 
of ductal carcinoma in situ (DCIS), and this expression was decreased with increasing 
severity to invasive cancer tissue where 33% of the samples had moderate to high 
expression. Stats data obtained from the staining intensity analysis using spearman’s 
non-parametric correlation showed that there was a weak positive correlation between 
SEMA3B and furin expression (Spearman’s rho= 0.290, P= 0.015) and significant 











Figure 5.28: Expression of furin in breast tissue lesions. A) Representative 
photographs of furin staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 




Cytoplasmic expression of PCSK1 seen in 64% of normal tissues, and increasing to 
89% in ADH and 100% in DCIS tissues. In invasive tissue, the strongest expression 
was decreased to 54.54% (figure 5.29) Like in furin, there was a positive correlation 
between SEMA3B and PCSK1 expression (Spearman’s rho = 0.348, P=0.003), but no 
















High levels of PCSK2 expression were seen in pre-malignant and pre-invasive tissues 
with strong cytoplasmic staining in 71 % of the normal breast ducts, and increasing 
slightly to 78% in ADH and 87% in DICS. In contrast, the expression of PCSK2 
decreased in invasive cancer sections so that only 42 % had strong staining. There 
was no significant relationship between PCSK2 and SEMA3B or with increasing lesion 
malignancy (figure 5.30). However, this is in agreement with the Western blotting 
findings but not with the gene expression result. 
 
Figure 5.29: Expression of PCSK1 in breast tissue lesions. A) Representative 
photographs of PCSK1 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as 

















Figure 5.30: Expression of PCSK2 in breast tissue lesions. A) Representative 
photographs of PCSK2 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 
percentage of cases with each expression intensity.  
 
Strong cytoplasmic expressions of PCSK4 was detected in 100% of normal tissues, 
90% of ADH and 65.5% of DCIS, decreasing to 30% of invasive breast cancer tissues. 
Moreover, there was a positive correlation between SEMA3B and PCSK4 expression 
(Spearman’s rho = 0.460, P=0.01), and a strong inverse correlation between PCSK4 

















Figure 5.31: Expression of PCSK4 in breast tissue lesions. A) Representative 
photographs of PCSK4 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 
percentage of cases with each expression intensity. 
 
High levels of PCSK5 expression were seen with intense cytoplasmic staining in 100% 
of the ducts of a normal breast, ADH and DCIS. In contrast, invasive carcinoma tissues 
had reduced expression of PCSK5 with 82% showing strong staining compared with 
the normal tissue. There was a weakly inversely correlation of PCSK5 with the 
















Figure 5.32: Expression of PCSK5 in breast tissue lesions. A) Representative 
photographs of PCSK5 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 
percentage of cases with each expression intensity. 
 
Strong cytoplasmic expression of PCSK6 was detected in 73.91% of normal ductal 
tissues. This expression was decreased to 28.57% in ADH and 25% in DCIS. The 
expression of PCSK6 in invasive tissue was increased to 45.45% compared to ADH 
and DCIS; however, this was still lower than in normal tissues. It should be noted that 
the small sample size of both ADH and DCIS may account for some of these 
differences. There was no correlation between PCSK6 expression and SEMA3B or 
















Figure 5.33: Expression of PCSK6 in breast tissue lesions. A) Representative 
photographs of PCSK6 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 
percentage of cases with each expression intensity. 
 
There was a strong expression of PCSK7 in the cytoplasm of epithelial cells in of 54%  
normal breast ducts and this expression increased slightly to 67% in ADH, and 75% 
in DCIS, but was reduced down to 33% in invasive cancers (figure 5.34). This resulted 
in a positive correlation between PCSK7 and SEMA3B expression (Spearman’s rho= 



























In contrast to the other PPCs, PCSK8 expression was much weaker in normal breast 
tissue with only 4% of lesions expressing strong levels of PCSK8 in the epithelial cells. 
PCSK8 expression increased in ADH, with 10% of the lesions strongly expressing and 
80% moderately expressing PCSK8, and further increased in DCIS with 12.5% of the 
lesions strongly expressing and 87.5% moderately expressing PCSK8. The 
expression was further increased in invasive tissue with 51.51% showing strong 







Figure 5.34: Expression of PCSK7 in breast tissue lesions. Representative 
photographs of PCSK7 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. Each sample was scored for intensity of stain and presented graphically as the 
















Figure 5.35: Expression of PCSK8 in breast tissue lesions. A) Representative 
photographs of PCSK8 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 
percentage of cases with each expression intensity 
 
Strong expression of PCSK9 was identified within the cytoplasm of 100% of the normal 
ductal epithelium, and decreased with increasing lesion malignancy to 66.66% of ADH, 
26% of DCIS and 12.12% of invasive tissues. PCSK9 was therefore positively 
correlated with SEMA3B expression (Spearman’s rho= 0.415, P=0.01), and strongly 
inversely correlated with the class/increasing lesion malignancy (Spearman’s rho = -
















Figure 5.36: Expression of PCSK9 in breast tissue lesions. A) Representative 
photographs of PCSK9 staining by immunohistochemistry in normal breast ducts 
(normal), atypical ductal hyperplasia (ADH), DCIS and invasive cancer tissues 
(invasive). All images were taken using a x20 objective lens and the scale bar = 100 
µm. B) Each sample was scored for intensity of stain and presented graphically as the 















5.3.22 Inhibition of PPCs activity in DCIS.com and MDA-MB-231 breast cancer 
cells 
Having shown that SEMA3B expression correlates with a number of PPCs in breast 
cancer tissues, and that the pattern of expression of some of the PPCs is high in cell-
lines where SEMA3B is cleaved and low in the MCF-10A cells where full-length 
SEMA3B is present, it was necessary to investigate whether this SEMA3B cleavage 
was indeed caused by PPCs. In order to do this, pan-PPC inhibitors were used to treat 
DCIS and MDA-MB-231 cells and see if SEMA3B cleavage was inhibited using 
Western blot analysis for the presence of full-length and cleaved SEMA3B. MT1-MMP 
was used as a positive control for the inhibitors as it is known that MT1-MMP is 
processed by PPC cleavage to a shorter, active form, and that pan-inhibitors of PPCs 
prevent this (Cepeda et al., 2016). 
 Using decanoyl-RVKR-CMK inhibitor 
Initially different concentrations of the pan-PPC decanoyl-RVKR-CMK inhibitor (0,135, 
200 µM/L) were used to treat DCIS and MDA-MB-231 cells for 24 hours. As shown in 
figure 5.37, the activity of the inhibitor was confirmed as it prevented cleavage of MT1-
MMP in the MDA-MB-231 cells. However, the cleavage of SEMA3B was not inhibited 
in either DCIS.com or MDA-MB-231 breast cancer cells either in cell lysates or in 
conditioned medium, as confirmed by lack of an ~83 kDa band. Due to the toxicity 
effect of this inhibitor on cells (Varshavsky et al., 2008), it was not possible to use a 



















Figure 5.37: Inhibition of PPCs activity using decanoyl-RVKR-CMK inhibitor. 
Representative immunoblots of treated and untreated (A) DCIS.com and (B) MDA-
MB-231 cells with PPCs inhibitor. Both DCIS.com and MDA-MB-231 cells were 
incubated with (+) and without (-) 135, 200 µmol/L decanoyl-RVKR-CMK inhibitor for 
24 hours. Cell lysates were extracted, and conditioned medium was collected from the 
cells and was separated on a 10% SDS-PAGE gel, blotted onto PVDF, and probed 
with an anti-SEMA3B antibody. (C) MT1-MMP was used as a positive control. To 
confirm that the amount of protein in each lane was equal, the membrane was stripped 
and re-probed with anti-β-actin housekeeping protein as a loading control. The sizes 
of molecular weight markers are indicated in kDa. For A, B and C, representative 
immunoblots shown of n=3. 
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 Using α1-antitrypsin Portland (α1-PDX ) inhibitor  
Although α1-PDX was originally considered a selective and potent furin inhibitor in 
vitro, it has been found that α1-PDX inhibits some of the other pro-protein convertases 
(Benjannet et al., 1997). This suggests that this inhibitor may be useful in determining 
whether furin and/or other PPCs are involved in SEMA3B cleavage. The cells were 
therefore treated with α1-PDX, and investigated by Western blot, as described in 2.10. 
The DCIS.com and MDA-MB-231 cells were treated with α1-PDX (20 µM) for 24 hours 
and then cell lysates and conditioned media were collected as described in 5.2.6.2. 
MT1-MMP was again used as a positive control (Coppola et al., 2008). 
As shown in figure 5.38, the α1-PDX was shown to be active by the presence of the 
full-length pro-form of MT1-MMP in the treated MDA-MB-231 cells. When probing the 
media and lysates for SEMA3B, in all untreated cell lysates and conditioned media 
there is only a 51 kDa band seen, consistent with the data described in chapter 3. 
However, treatment with α1-PDX resulted in the appearance of different molecular 
weight bands in both cell lysates and conditioned media including higher molecular 
weight at 65 kDa (cleaved form) and at 83 kDa (full-length form) suggesting that the 
cleavage of SEMA3B was partially inhibited by the α1-PDX, leading to the generation 




































Figure 5.38: Inhibition of PPCs activity in DCIS.com and MDA-MB-231 breast 
cancer cells using α1-PDX. A) Representative immunoblots of treated and untreated 
DCIS.com and MDA-MB-231 cell lysates and conditioned media with α1-PDX 
inhibitor. Both DCIS.com and MDA-MB-231 cells were incubated with (+) and without 
(-) 20 µM α1-PDX inhibitor for 24 hours. Cell lysates were extracted, and conditioned 
medium was collected from the cells and was separated on a 10% SDS-PAGE gel, 
blotted onto PVDF, and probed with an anti-SEMA3B antibody. MT1-MMP was used 
as a positive control. B) The activity of the α1-PDX inhibitor was confirmed using MDA-
MB-231 cells and detecting MT1-MMP expression. To confirm that the amount of 
protein in each lane was equal, the membrane was stripped and re-probed with anti-
β-actin housekeeping protein as a loading control. The sizes of molecular weight 
markers are indicated in kDa. For A and B, representative immunoblots shown of n=3. 
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5.4 Discussion  
Previous studies have suggested that cleavage of SEMA3B is due to furin, but these 
studies were flawed in that they used a pan-PPC inhibitor (Varshavsky et al., 2008) 
and are thus unable to exclude the possibility that other proteins may be involved. The 
aim of this chapter was therefore to establish which, if any, of the pro-protein 
convertases are expressed in breast cell-lines and tissues, and could therefore be 
responsible for cleaving SEMA3B. The IHC data in this chapter show that a number 
of the PPCs, including furin, PCSK1, PCSK4, PCSK5, PCSK7 and PCSK9, had 
protein expression that correlated with SEMA3B expression in the tissue samples. The 
expression of some of these PPCs was low where full-length SEMA3B was found in 
the cell-lines, i.e. in MCF-10A cells, but higher in the other cell-lines where SEMA3B 
was cleaved, based on cytospin (PCSK1, PCSK4, PCSK5, PCSK7 and PCSK9) and 
Western blot (furin, PCSK1 and PCSK7) analyses. As a result, two PPC inhibitors 
were used to see whether they could inhibit SEMA3B cleavage in breast cancer cell-
lines. Treatment with one of the inhibitors, α1-PDX, did result in the production of full-
length SEMA3B, suggesting that at least some of the PPCs are responsible for 
SEMA3B cleavage in breast cancer.  
Since the expression of many of the PPCs has not previously been described, or has 
only been studied in a very limited way, each will be discussed here in turn. 
Gene and protein expression analysis of pro-protein convertases within breast 
tumour and non-tumour cells and tissues  
The gene expression of each of the PPCs was first examined in breast cell-lines in 
order to explore whether there is a differential expression between non-malignant and 
malignant cells and whether there is a potential correlation with SEMA3B cleavage. 
We found in chapter three that the highest amounts of SEMA3B mRNA were found in 
normal MCF-10A cells compared to other cell-lines (figure 3.6). In this current chapter, 
we screened seven malignant and non-malignant breast cell-lines, MCF-10A, MCF-
10AT, DCIS.com, MCF-7, T47D, MDA-MB-231 and MDA-MB-231-BM, for the 
expression of the nine members of the human convertases gene and protein family. 




5.4.1 Furin expression in breast cancer progression 
Previous studies have suggested that furin is widely distributed across several human 
tissues, but that it expresses at a low level in normal tissues (Paleyanda et al., 1997). 
Our findings, however, showed that furin mRNA expression was higher in normal cells 
than in invasive breast cancer cells. This observation is consistent with that found in 
respect to SEMA3B in chapter 1. Furthermore, the furin gene expression in the MCF-
7, T47D and MDA-MB-231 breast cancer cell lines is similar to that reported in a study 
by Cheng et al. (1997). In contrast to our finding, however, Cheng et al.’s study showed 
that there was no detectable expression of furin in normal breast tissue while we 
showed high levels of furin mRNA expression in normal breast cells. The differences 
between these findings may be due to the use of normal breast tissues whilst we used 
normal breast MCF-10A cells in our experiment. Another study examining furin 
expression in lung cancer also reported results that contrast with ours, with Northern 
blot analysis showing higher expression of furin mRNA in non-small-cell lung 
carcinoma compared to relatively low expression in normal lung tissues (Schalken et 
al., 1987). Our results concerning furin, however, are similar to those in Mbikay et al.’s 
(1997) study showing furin mRNA expression to be three times higher in non-
malignant tissues than in small-cell lung carcinomas.  
Despite the assumption that protein expression should reflect the gene expression 
level, such a correlation does not always exist in the same cell lines (Yu et al., 2007). 
Our data, for example, shows that the protein level of furin did not reflect that observed 
in the gene. At a protein level, the processed and active form of furin was expressed 
at significantly higher levels in invasive cells than in MCF-10A cells, while the gene 
expression was at the lowest level in invasive cells. These findings are in agreement 
with a previous study that suggested that an extracellular form of furin (the shedded 
form) could be involved in the processing of some precursor proteins, although this 
study was not able to establish whether these proteins process to their functional form 
as a result of the membrane‐anchored form of furin or its shed entity (Denault et al., 
2002). In our data, the higher molecular weight of the protein that was highly expressed 
in the pre-malignant cells (97 kDa) suggest that it could represent the pro-form. If so, 
it would suggest that the post-translational cleavage occurs within the cell and that the 
smaller (70 kDa) form, which lacks the transmembrane domain, represents the shed 
furin which is the active form that may be responsible for SEMA3B cleavage. 
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Furin undergoes two autocatalytic cleavages to be fully active. When activated, it 
cycles between the trans-Golgi network, the cell surface and endosomes (Jaaks and 
Bernasconi, 2017). It is enriched in the trans-Golgi network, where it works to cleave 
other proteins and many substrates. Studies indicate, however, that the cleavage of 
the substrate by furin might take place intracellularly, or it could be cleaved and 
released by the fusion of endocytic furin-containing compartments, which contain 
substrate (Band et al., 2001). Although some studies have shown that furin-mediated 
cleavage is associated with promoting substrate functions e,g metalloproteinases, 
others suggest that cleavage by furin could have a negative effect on substrate 
functions (Lee et al., 2001, Jaaks and Bernasconi, 2017).  
Furin has been known to mediate cleavage at the paired basic amino acid recognition 
site (Adams et al., 1997). The sequence alignment of SEMA3B contains recognition 
sites for the endoprotease furin (K/RXRR) which is conserved in its sequence. Indeed, 
there are three different sites in the SEMA3B sequence that contain the furin-like pro-
protein cleavage site, namely KRRFRR (positions 549–554), RRLRRR (positions 
632–637) and KGRNRR (positions 726–731) on the C-terminal (figure 5.1) where 
cleavage of PPCs usually taken place (UniProt). Despite the fact that SEMA3B has 
multiple furin protease recognition motifs, each of which might lead to the release of 
the C-terminal of this protein, there is no previous study explaining the exact cleavage 
site of furin-like pro-protein convertases within the SEMA3B sequence. That said, 
when cleavage occurs after position 555, which previous studies have assumed is the 
most common cleavage site, the resulting 60 kDa fragment has been found to be 
inactive (Varshavsky et al., 2008). Cleavage at position 555 could impair the binding 
of SEMA3B to its receptors, as it has been suggested that the C-terminal is involved 
in neuropilin binding (Adams et al., 1997), which can suggest the loss of SEMA3B 
activity in some biological settings. 
In our data, we found that the active (70 kDa) protein form of furin was higher in 
invasive cells than in normal cells, which may explain why any SEMA3B present in 
these cells was completely cleaved, whereas the 97 kDa form that was highly 
expressed in normal cells is not thought to cause cleavage. In agreement with this 
finding, a previous study on SEMA3F showed that furin deficient cells produce the 
unprocessed form of SEMA3F while the processed form was only found in cells that 
overexpressed furin (Parker et al., 2010). Furthermore, in agreement with our 
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observations, furin protein expression has been identified to be upregulated in several 
cancers, including non-small-cell lung carcinomas, where it has been shown to 
correlate with the invasive potential of non-small-cell lung carcinoma cell lines (Bassi 
et al., 2017). Bassi et al. (2001) investigated the protein expression level of furin in 
head and neck squamous cell carcinoma cell lines and found that the highest level of 
furin was found in the most invasive head and neck squamous carcinoma cell lines, 
which is also in agreement with our data. (Bassi et al., 2001b). 
Little is known about the expression of the pro-protein convertases and their 
localisation in human breast cancer tissues; therefore, the expression of PPCs in the 
normal and malignant breast tissue was investigated in this study using 
immunohistochemistry. The localisation of the staining in respect to most PPCs was 
mostly cytoplasmic but, with some proteins, plasma membrane staining was noted. 
The result obtained from the microarray tissue slides showed that there was moderate 
to strong cytoplasmic staining of most of the PPCs whose expression decreased with 
increased disease malignancy. In the present study, the strong staining of furin 
reduced by 29.63% from normal tissue to invasive tissue, but this was non-significant. 
In contrast, a previous study in lung cancer revealed that the most invasive tissue of 
squamous lung cell carcinoma showed elevated furin expression (Lopez de Cicco et 
al., 2002). To our knowledge, this is the first study exploring the expression of furin 
protein in breast cancer tissue.  
5.4.2 PCSK1 expression in breast cancer progression 
PCSK1, like other pro-protein convertases, is important for homeostasis and is 
involved in the control of a number of physiological processes in health and disease 
(Demidyuk et al., 2013). In particular PCSK1 has been linked to cancers with 
neuroendocrine features, although its role is not restricted to those tissues (Mbikay et 
al., 1997). Duhamel et al. (2015) found that PCSK1 is expressed in macrophages and 
lymphocytes, and that there is a link between inhibition of PCSK1 expression and the 
activation of macrophages that promote the cytotoxic immune response and therefore 
inhibit cancer cell viability (Duhamel et al., 2015). 
Little is known, however, about PCSK1’s role in normal breast cells or in breast cancer. 
Our observations showed that PCSK1 mRNA expression was lower in invasive cells 
compared to normal ones. This result contrasts with Cheng et al. (1997), who 
demonstrated a higher expression of PCSK1 in MCF-7, T47D and MDA-MB-231 
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breast cancer cells than in normal breast tissues. Zhang et al. (2013) also reported 
that the PCSK1 gene expression was higher in breast tumour tissues than in normal 
breast tissue. Similarly, the Northern blot analysis in Creemers et al. (1992) found 
PCSK1 mRNA expression to be abundant in lung cancer cells but undetectable in 
normal lung cells. 
Importantly, however, our study shows that the protein expression of PCSK1 is not 
correlated with its gene level, since our observations of higher expression of PCSK1 
mRNA in normal cells compared to invasive cells are reversed at the protein level: 
more, PCSK1 protein (with a molecular weight of 84 kDa) was detected in invasive 
cells than in normal cells which was detected at (66 kDa). A previous study found that 
87 kDa PCSK1 has lower enzymatic activity than the 66 kDa form, which is less stable 
but more active, and also that these forms (87 and 66 kDa) are accumulated in dense-
core secretory granules prior to secretion (Hoshino et al., 2011). Interestingly, we 
observed the 66 kDa form only in the MCF-10A and MCF-10AT cell lines, suggesting 
the activity of PCSK1 in non-malignant cells. This would then correlate with the gene 
expression results. Furthermore, on the PCSK1 protein sequence, we found that there 
is cross-reactivity with PCSK2 at RRGDL, position 517-521, and this could explain 
why PCSK1 requires an additional action of PCSK2 to accomplish the proteolytic 
cleavage of some substrates (Stijnen et al., 2016). 
Although there have been only a few studies on PCSK1 in breast cancer, a study on 
human breast adenocarcinoma has shown upregulation of proPCSK1 in tumour 
tissues by Western blot, which is in agreement with our findings (Zhang et al., 2013). 
Zhang et al.’s study did not mention the difference between the two fragments of 
PCSK1, however. We suggest that the 84 kDa fragment that we detected in the 
invasive cells may not be as active as the 66 kDa one detected in normal cells. 
The immunohistochemistry data, however, seems to suggest that there is a reduction 
in the expression of PCSK1 in invasive breast cancer tissue, suggesting that PCSK1 
may be have less beneficial effects in breast cancer progression. On the other hand, 
the positive correlation between the PCSK1 and SEMA3B expressions suggests that 




5.4.3 PCSK2 expression in breast cancer progression 
In contrast to furin and PCSK1, a high level of PCSK2 mRNA expression was detected 
in invasive T47D and MDA-MB-231-BM cells (figure 5.4). This finding contradicts the 
previous study of Cheng et al. (1997), who reported a lack of PCSK2 mRNA gene 
expression in human breast cancer by qPCR, and also Zhang et al. (2013), who 
observed a higher gene expression of PCSK2 in normal breast tissues compared to 
breast adenocarcinoma tissues (P<0.05). In agreement with our data, however, a 
previous study using Northern blot analysis showed PCSK2 mRNA to be more 
abundant in small cell lung carcinomas compared to the non-malignant tissues (Zhang 
et al., 2013). 
In the current study, expression of PCSK2 was similar for both gene and protein, with 
both being higher in invasive cells than normal cells. In agreement with our findings 
but in lung cancer, Mbikay et al. (1997) observed higher expression of PCSK2 in lung 
cancer cells at 68 kDa than in normal cells, and concluded that the 68 kDa fragment 
represents the most active form of this protein. Interestingly, we observed this band at 
68 kDa only in MCF-7 cells. This finding could suggest that PCSK2 is more likely to 
be involved in the progression of breast cancer. 
Our immunohistochemistry data, however, did not match the Western blot data since 
the expression of PCSK2 decreased with increasing malignancy. A previous study of 
Zhang et al. 2013, revealed higher expression of PCSK2 in normal breast tissue than 
in tumour breast tissue, which was in agreement with our observation. 
5.4.4. PCSK4 expression in breast cancer progression 
In respect to PCSK4, this study was the first to explore PCSK4 mRNA expression in 
breast cancer, observing higher expression in invasive cells. As with PCSK2, the 
protein expression of PCSK4 was correlated with its gene level since we found high 
expression of PCSK4 in invasive cells with the highest expression detected in T47D 
cells with the 26 kDa isoform. According to the (UniProt) website, there are two 
isoforms for PCSK4 (82 and 26 kDa). The 82 kDa form is predicted to be the pro-form 
of PCSK4. In most of the cell lines we tested, however, we detected the 26 kDa form 
of PCSK4, except for the DCIS.com and MDA-MB-231-BM cell lines.  
Although the identity and the activity of the 26 kDa fragment is not fully understood, 
since there is no previous data to compare this data to, it is predicted to be the active 
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form of PCSK4 on the basis that this fragment has an active site at its C-terminal, 
suggesting that it forms part of the activation process of PPCs. The 
immunohistochemistry staining showed a positive correlation between the protein 
expression of PCSK4 and SEMA3B in breast tissues, suggesting that PCSK4 may be 
involved in SEMA3B cleavage, but there is no previous literature with which to 
compare these results directly. 
5.4.5 PCSK5 expression in breast cancer progression 
Two differentially spliced isoforms of PCSK5 have been identified, including a short 
915 aa soluble PCSK5 A (Lusson et al., 1993) and a long membrane-bound 1877 aa 
PCSK5 B (Nakagawa et al., 1993). The function of PCSK5 in breast tissues and breast 
cancer has not previously been addressed, however. Our results showed high levels 
of PCSK5 mRNA expression in invasive MCF-7 cells (figure 5.6). In contrast, the only 
previous study to have investigated the expression of PCSK5 in breast cancer, 
reported an absence of PCSK5 gene expression in human breast cancer (Cheng et 
al., 1997). In agreement with our present data but in lung cancer, Bassi et al. (2005) 
observed a correlation between the level of PCSK5 expression and the 
aggressiveness of both lung cancer and head and neck derived squamous cell 
carcinoma cell lines, characterised by a high expression of PCSK5. We were not able 
to detect the protein expression of PCSK5 due to the limitations of the antibody. Faced 
with this failure of the Western blot analysis, however, we used cytospin to assess the 
expression of PCSK5 in cells. The cytospin data matched the gene expression since 
a strong expression of PCSK5 was detected in invasive cells. The data may potentially 
be improved by repeating the experiment using different antibodies, but time 
constraints prevented this. The immunohistochemistry staining showed a weak 
inverse correlation between the protein expression of PCSK5 and the class and lesion 
intensity in breast tissues, but there is no previous literature to compare these results 
directly. Nonetheless, it appears that the gene and protein expression of PCSK5 
followed the same pattern, i.e. lower in normal cells and tissues. These data suggest 
that PCSK5 may correlate with the SEMA3B cleavage since low expression of PCSK5 




5.4.6 PCSK6 expression in breast cancer progression 
As both furin and PCSK6 are located on the same chromosome (Nour et al., 2005), it 
has been suggested that they might share a similar function and that they may be 
responsible for the cleavage of SEMA3B. In our data, PCSK6 mRNA expression was 
detected in all cell lines with no significant differences. This is in contrast to a previous 
study which showed a higher expression of PCSK6 in human breast cancer compared 
to normal breast tissue (Cheng et al., 1997). Using normal breast tissue rather than 
cell-lines could explain the differences between our findings. In another study, Wang 
et al. (2015) confirmed the importance of PCSK6 in breast cancer progression since 
they reported that silencing the PCSK6 gene in MDA-MB-231 cells led to a significant 
decrease in the invasiveness of breast cancer (Wang et al., 2015). 
Through Western blot, PCSK6 expression was detected in invasive cells, with the 
highest expression found in T47D cells, although this data did not match with the 
PCSK6 gene expression. The impact of PCSK6 expression in breast cancer is not yet 
clearly understood, however, to our knowledge, there has been no previous work that 
we can compare with ours that has used Western blot analysis to determine on the 
expression of PCSK6 in breast cancer. Nevertheless, a study looking at spindle cell 
carcinoma in mice described a significant upregulation of PCSK6 protein in these cells, 
suggesting its involvement in the malignancy of tumour cells, and this is consistent 
with our findings (Hubbard et al., 1997). In contrast with this, Bassi et al. (2001b) 
investigated PCSK6 expression in human head and neck cancer cell lines, including 
those with high invasive abilities (SCC71, A253 and Detroit 562, as well as Fadu, 
which is characterised as the most aggressive cell line). Bassi et al.’s study showed 
only faint PCSK6 expression in most of these cells, with no expression at all detected 
in the most aggressive Fadu cells. Interestingly, there is a debate in the literature about 
the role of PCSK6 expression in carcinogenesis. Some observations revealed that 
overexpression of PCSK6 enhances the cell invasiveness, e.g. in skin, lung and 
prostate cancer, while others showed reduced PCSK6 expression with increasing 
malignancy in some cancers such as ovarian cancer (Mahloogi et al., 2002, Fu et al., 
2003). Our IHC data demonstrated a clear pattern of decreasing PCSK6 expression 
with increasing malignancy by 27.45%. No previous studies have used IHC staining, 
however, and thus there is nothing to compare our results to, although a study 
conducted on non-small cell lung cancer demonstrated that the expression of PCSK6 
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in these tissues was significantly higher than in normal lung tissues, and that this 
expression increased with increasing disease malignancy (Lin et al., 2015) which was 
inconsistent with our data.  
5.4.7 PCSK7 expression in breast cancer progression 
The RT-PCR results revealed that PCSK7 mRNA level expression was high in 
DCIS.com and T47D cells and fluctuated in the other cells compared with the normal 
MCF-10A cells. Our result is partly consistent with the previous report by Cheng et al. 
(1997), since this also showed PCSK7 mRNA expression to be high in T47D breast 
cancer cells. Whereas our study showed PCSK7 mRNA to be lower in MCF-7 and 
MDA-MB-231 cell lines than in normal cells, however, the Cheng et al. (1997) study 
reported high expression in these cell lines. Comparatively little is known about the 
expression of PCSK7 in breast cancer progression, although PCSK7 expression is 
decreased in ovarian cancer cells compared to normal ones (Page et al., 2007). 
To investigate whether the differential expression of PCSK7 mRNA was maintained at 
the protein level, cell lines were screened by Western blotting. Generally, we observed 
two different protein fragments in each lane, but for some, like T47D and MDA-MB-
231-BM, no PCSK7 protein expression was detected. The intensity of the upper band 
at 86 kDa was slightly less than that of the lower one at 64 kDa. The lack of protein 
expression in T47D was particularly striking since PCSK7 gene expression was high 
in this cell line. However, PCSK7 protein expression was detected at 64 kDa in both 
MCF-7 and MDA-MB-231 cells suggesting that the more invasive cells may express 
more PCSK7 than less invasive ones. 
Although the PCSK7 mRNA expression was higher in breast cancer cells (Cheng et 
al., 1997), until now, there have been no reports regarding the protein expression of 
PCSK7 in breast cancer. A study characterising the properties of the protein sequence 
of PCSK7, however, has shown that this protein can cleave substrates at paired basic 
residues, which can provide evidence for how PCSK7 functions as a member of PPCs. 
The sequence of the 89 kDa protein also corresponds to the zymogen cleavage site 
of PCSK7 (Munzer et al., 1997). Since PCSK7 is expressed at only a low level in MCF-
10A, in which we have confirmed the presence of the full-length of SEMA3B, this might 
suggest a role of PCSK7 in SEMA3B cleavage. The result obtained from the 
microarray tissue slides, however, revealed a moderate to strong cytoplasmic 
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expression of PCSK7 (63.84%) which downregulated with increasing lesion 
malignancy of breast cancer. There was a positive correlation between SEMA3B 
expression and the expression of PCSK7 in the breast cancer tissues. 
5.4.8 PCSK8 expression in breast cancer progression 
Our present study seems to be the first attempt to assess the expression of PCSK8 in 
breast cancer. The qPCR data showed that PCSK8 expression was highest in T47D 
cells and decreased in normal cells. The PCSK8 protein is synthesised as a 148 kDa 
form, which is a pro-form (zymogen) that is processed to the membrane, and a 106 
kDa form, which is a processed form of PCSK8 that transforms into a 98 kDa active 
form of the protein (Seidah et al., 1999). For reasons we were not able to ascertain, 
however, attempts to detect the protein by both Western blot and cytospin assay failed 
for all cell lines. As a result, we sought to study protein expression using a different 
assay, known as cell pellet followed by immunohistochemistry.  
The cell pellet assay showed a strong expression of PCSK8 in all cell lines with no 
significant differences observed between the normal and the invasive cells. The 
immunohistochemistry data of PCSK8 was the only protein among the nine PPCs that 
was found to increase with increasing malignancy. Interestingly, while our data 
showed a positive correlation between PCSK8 and lesion malignancy, it also showed 
an inverse correlation between SEMA3B and PCSK8, with SEMA3B down‐regulated 
in the developing tumours. 
5.4.9 PCSK9 expression in breast cancer progression 
Our evaluation of PCSK9 mRNA levels in malignant and non-malignant breast cells 
showed higher expression in both normal MCF-10A and invasive MDA-MB-231 cells 
compared with other cells. There are no other studies of PCSK9 in breast cancer with 
which to compare our results to, although it is known that PCSK9 regulates low-density 
lipoprotein (LDL) cholesterol homeostasis and that loss of function in the PCSK9 gene 
is associated with hypocholesterolaemia while increased function is associated with 
hypercholesterolaemia (Abifadel et al., 2003). PCSK9 controls the LDL level by 
binding to its receptor (LDLR) cell surface for degradation (Sun et al., 2012). This is 
interesting since elevation of the cholesterol level is strongly linked with an increased 
risk of breast cancer (Hu et al., 2012), which could suggest an indirect effect of PCSK9 
in breast cancer progression. There is no direct study in the literature investigating the 
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expression of PCSK9 in breast cancer. However, a previous study has looked at 
PCSK9 in human hepatocellular carcinoma, observing that PCSK9 mRNA expression 
is lower in human hepatocellular carcinoma compared to normal control tissue 
(P=0.02), while serum levels of PCSK9 were significantly higher among patients with 
hepatocellular carcinoma (Bhat et al., 2015). The study of Bhat et al., might suggest 
different mechanisms taking place between the expression of PCSK9 mRNA and the 
protein processing. In our findings, the protein level of PCSK9 was correlated with the 
gene expression in MDA-MB-231, whereas the protein expression was lower in normal 
cells than in invasive ones. This agrees with the previous work that suggests a link 
between PCSK9 and breast cancer through its promotion of LDL-cholesterol, as 
discussed above (Hu et al., 2012, Laisupasin et al., 2013). To our knowledge, 
however, no work has been done on the direct effect of PCSK9 in breast cancer. The 
IHC result exhibited a different pattern of PCSK9 expression which did not match the 
Western blot data. There was a strong cytoplasmic expression of PCSK9 (100%) in 
normal tissues but expression reduced with increasing lesion malignancy in breast 
cancer.  
It is not easy to explain why there are these dissimilarities between our findings and 
other studies. In respect to the qPCR results, however, it is most likely due to variances 
in the experimental platforms used: qPCR, RT-PCR and Northern blot analysis. In 
addition, differences in the extraction methods for PCR may have played a role in the 
discrepancies (Mahittikorn et al., 2005). One other possible reason that could interfere 
with the qPCR result is the use of an inappropriate internal control gene. Using stable 
reference genes is important for accurate quantification of mRNA levels. To minimise 
this issue, in this study, GAPDH was used as a normalising gene and to confirm the 
integrity of RNA. It has been found that GAPDH and ACTB (β-actin) were the most 
stable reference genes in basal breast cancer MDA-MB-231 cells and in ER+ breast 
cancer MCF-7 and T47D cell lines (Liu et al., 2015). Similarly, Morse et al. (2005) 
found that GAPDH is the least variable gene in the MCF-10A cell line. For these 
reasons, GAPDH was chosen for its stability expression in all cell lines used. 
Moreover, variations in results could be attributed to the use of different laboratories 
and the high passage number of cell lines. Cells are known to exhibit phenotypic drift 
with increasing passage number so in order to minimise these alterations, low passage 
numbers were used in this project.  
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This study showed a different pattern of PPC genes expressions in different breast 
cancer cell lines, suggesting that breast cancer cells are likely to react differently with 
different members of the PPC family. Our immunostaining data did not correlate with 
the protein expression of the cell lines obtained from Western blot analysis. Unlike the 
cell lines expression data, most of the PPCs expressions in tissue decreased with 
increased disease malignancy; however, it is unclear whether these proteins are active 
or not in these tissues as there are currently no antibodies that will distinguish between 
the active and inactive forms of the proteins. Moreover, detection of the target proteins 
depends on the antibodies that are used, since choosing a good and specific antibody 
is crucial for both Western blotting and immunohistochemistry (Liu et al., 2016). For 
some PPCs, we used the same antibodies for both applications and they were 
selected on the basis of their performance in Western blot analyses. This decision was 
based on a previous study that identified that antibodies that detect a single band 
consistent with the mass of the protein of interest are more likely to be specific in IHC 
analyses (Uhlen et al., 2016). However, that said, some of our antibodies detected 
more than one band, however, which may in part explain the lack of correlation 
between some of the Western blot and IHC findings. In addition, the differences in how 
samples are treated in different applications can interfere with the ability of the 
antibody to bind to its target. Sample preparation and sample size are also likely to 
make a difference.  
Interestingly, our data shows an inverse correlation between SEMA3B and the disease 
progression; in other words, as a lesion malignancy increases SEMA3B expression 
decreased, a finding that is in line with the previous study of (Staton et al., 2011). On 
the other hand, furin, PCSK1, PCSK2, PCSK4, PCSK7 and PCSK9 were all positively 
correlated with the expression of SEMA3B to varying degrees, which suggests that if 
these PPCs are all active when SEMA3B is present it is likely to be cleaved. To 
conclude, our data have established that there is a different expression of PPCs in a 





























Table 5.1: A comparison of the mRNA expression and protein expression of the 
PPCs in the cell lines used. 
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5.4.10 Inhibition study of PPCs 
The gene and protein expression data presented here indicate that at least some of 
the PPCs have expression patterns that suggest that they are present in the correct 
places to cleave SEMA3B; i.e. they correlate with SEMA3B in tissues and are low in 
normal breast cells and high in breast cancer cell lines. Based on this, it was then 
necessary to determine whether inhibition of these proteins would restore the full-
length of SEMA3B. Two different inhibitors were used in this assay, the pan-PPC 
decanoyl-RVKR-CMK and alpha1-PDX inhibitor.  
CMK is a potent PPC inhibitor and is able to act intracellularly, where it reduces 
cleavage of some of the PPCs substrates (Bassi et al., 2003). Although the study 
presented in this chapter using the CMK inhibitor did result in inhibition of MT1-MMP 
processing to the active shorter form, it did not result in re-expression of full-length 
SEMA3B. This result is in apparent conflict with those of others who have shown that 
CMK does inhibit furin-like pro-protein convertases to produce full-length SEMA3B 
(Varshavsky et al., 2008). This discrepancy can be explained by differences in the 
method conditions, however, since Varshavsky and colleagues used MDA-MB-231 
cells that had been transfected to express recombinant SEMA3B, rather than the 
untransformed cells and native SEMA3B expression used in this study.  
Interestingly, the CMK inhibitor blocks the activity of PPCs by blocking the catabolic 
pocket activity at RVKR sites (Tian and Jianhua, 2010). Since these are only found in 
the protein alignments of PCSK4, PCSK6 and PCSK8, however, CMK may not be as 
effective at inhibiting the other PPC proteins. That said, the 3D structure of this 
catabolic pocket in these three PPCs is similar to that found in furin, where the site is 
[K/R]-X-V-X-K-R, and this may suggest that this inhibitor will also inhibit furin (Tian and 
Jianhua, 2010). Since MT1-MMP cleavage was inhibited by CMK in our study, and 
this protein is known to be cleaved by furin (Bassi et al., 2003), this would suggest that 
the CMK inhibitor can inhibit furin, and that furin, PCSK4, PCSK6 and PCSK8 are not 
involved in SEMA3B cleavage.  
A second inhibitor, α1-PDX, which is highly selective for furin and some other of the 
PPCs such as PCSK5 and PCSK6 (Tsuji et al., 1999, Hada et al., 2012), was then 
used to inhibit PPC activity in DCIS and MDA-MB-231 cell lines. Treatment of cells 
with α1-PDX (20 µM) resulted in inhibition of activation of MT1-MMP, as demonstrated 
by the appearance of the full-length pro-form on the Western blot. This was as 
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expected since α1-PDX effectively blocks processing of precursor proteins at RXK/RR 
sites, which are found in MT1-MMP, and is in agreement with a study that showed that 
α1-PDX inhibits furin in head and neck squamous cell carcinoma, as well as inhibiting 
activation of MT1-MMP (Bassi et al., 2001a). Importantly for the current study, α1-PDX 
treatment resulted in the appearance of higher molecular weight SEMA3B proteins (at 
51 kDa and at 83 kDa), and we also observed a decrease in the cleaved form of 
SEMA3B compared to untreated cells. These data would suggest that at least one of 
the PPCs inhibited by α1-PDX is involved in cleavage of SEMA3B. On the other hand, 
full inhibition of SEMA3B cleavage was not achieved, suggesting either that the 
experimental conditions were not ideal for full inhibition of the PPCs, or that other 
proteins are involved in SEMA3B cleavage. 
In conclusion, this chapter has shown for the first time that the majority of the PPC 
family are expressed in human breast cancer, both in cell lines and in tissues. In many 
cases, the expression in tissues shows an inverse relationship with increasing lesion 
malignancy, suggesting that these proteins may be switched off as breast cancer 
progresses. Furthermore, the data suggest that furin, PCSK1, PCSK4, PCSK5, 
PCSK7 and PCSK9 have the right expression pattern to be candidates for SEMA3B 
cleavage. The data from the inhibitors, however, would suggest that furin and PCSK4 
are not involved in SEMA3B cleavage, since CMK, which is known to inhibit these 
proteins, did not inhibit SEMA3B cleavage. Treatment with α1-PDX did not fully restore 
all SEMA3B to full-length and therefore further work is required to establish which PPC 











Chapter 6: General Discussion 
 
6.1 Summary of main outcomes and general discussion  
Class 3 Semaphorins are a family of secreted proteins that are important for the 
development of different physiological systems and maintenance of many tissues. 
Class 3 semaphorins are known for their roles in nervous system development, where 
they have been identified as axonal growth cone guidance molecules (Yazdani and 
Terman, 2006). Recently, they have been shown to play an inhibitory role in tumour 
progression and angiogenesis (especially SEMA3B and SEMA3F). Several studies 
have explored the inhibitory effects of SEMA3B on tumour progression and 
angiogenesis as potential therapeutic agents for cancers such as lung cancer (Castro-
Rivera et al., 2004) and ovarian cancer (Joseph et al., 2010). However, the 
contribution of SEMA3B to breast cancer progression remains relatively unclear in 
comparison to other vertebrate semaphorins. 
Recent findings suggest that loss or mutations in SEMA3B may contribute to the 
development of breast cancer. Indeed SEMA3B is one of the known frequent allelic 
losses (up to 40%) in the LUCA region (3p21.3) in breast cancer, emphasizing its 
potential role in tumour development (Senchenko et al., 2004). In addition to allelic 
loss, methylation appears to be a mechanism of SEMA3B gene inactivation, and a 
previous study in breast cancer has shown that increased methylation in invasive 
breast cancer results in silencing of SEMA3B gene and therefore a loss of SEMA3B 
protein (Burbee et al., 2001, da Costa Prando et al., 2011). 
Although the majority of previous studies focused on methylation and allelic loss of 
SEMA3B (Burbee et al., 2001, Tse et al., 2002, Pronina et al., 2009, da Costa Prando 
et al., 2011), as playing a role in the tumorigenesis process, other studies suggested 
that post-translational processing including proteolysis were linked with some of the 
functional effects of SEMA3B. Proteolytic cleavage by furin-like pro-protein 
convertases of semaphorins is essential for activity of some semaphorins, but 
additional cleavage can result in inactivation, depending on where the cleavage occurs 
and on which semaphorin is cleaved. Cleavage of SEMA3B by furin-like pro-protein 
convertases resulted in the secretion of two fragments whose sizes corresponded to 
those expected from cleavage at the conserved dibasic consensus sites (Varshavsky 
245 
 
et al., 2008). These 61 kDa and 20 kDa fragments are believed to be inactive forms of 
SEMA3B (Varshavsky et al., 2008). Varshavsky and colleagues used a pan inhibitor 
of the pro-protein convertase family to demonstrate that this family could cleave 
SEMA3B in breast cancer cells that were transformed to overexpress the protein 
(Varshavsky et al., 2008), but their work did not make it clear which of the PPCs was 
responsible. Indeed, very little was known regarding the expression of the PPC family 
of enzymes in the development of breast cancer. Therefore, this thesis aimed to test 
the hypothesis that pro-protein convertase cleavage of SEMA3B results in inactivation 
of SEMA3B in invasive breast cancer.  
The work performed in chapter 3 of this thesis demonstrated that the gene expression 
of SEMA3B in the majority of breast cancer cells was decreased compared to normal 
MCF-10A cells (figure 3.6). These results are in agreement with a previous study 
identifying a decrease in SEMA3B mRNA in invasive breast cancer (Pronina et al., 
2009), and would suggest that this may be due to allelic deletion or promoter 
hypermethylation, in agreement with previous studies (Tse et al., 2002, Castro-Rivera 
et al., 2004, da Costa Prando et al., 2011). In addition, the IHC data in the tumour 
microarrays also suggested that protein expression was reduced with increasing 
breast cancer lesion malignancy (figure 3.9) which was in agreement with previous 
literature that found decreases in SEMA3B expression with increasing lesion 
malignancy of breast cancer (Staton et al., 2011). Again, this down-regulation of 
SEMA3B expression could be due to a combination of allelic deletion and promoter 
hypermethylation. It is important to note however, that the antibodies used for IHC 
cannot distinguish between full-length and cleaved SEMA3B, so it was unclear 
whether the SEMA3B present in the tissues was full-length or cleaved. Indeed, at 
present there are no commercially available antibodies that can answer this question. 
In order to start investigating this, Western blotting in the cell-lines was performed, and 
showed that the full-length SEMA3B protein was seen only in normal MCF-10A cells 
while in all other cell-lines any SEMA3B present, was completely cleaved (figure 3.7). 
This finding therefore suggested that where SEMA3B is present in breast cancer it is 
likely to be cleaved, and previous studies have shown that the cleaved 61 kDa 
SEMA3B protein is inactive (Varshavsky et al., 2008). As SEMA3B is thought to act 
as a tumour suppressor (Castro-Rivera et al., 2004), this would suggest that cleavage 
of SEMA3B would mean that it can no longer inhibit tumour growth/progression. 
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However, there are very few studies that have investigated the effect of full-length 
SEMA3B in breast cancer (Castro-Rivera et al., 2004).  
One study suggested that transfecting breast cancer cells with full-length SEMA3B 
would enable studying the full-length protein in breast cancer cells (Castro-Rivera et 
al., 2004). This study showed that full-length SEMA3B did inhibit 50 % of the cell 
growth of breast cancer MDA-MB-231 cell-line. An alternative attempt to study the 
effect of full-length SEMA3B inhibited the activity of pro-protein convertases thereby 
restoring full-length SEMA3B and this study showed that SEMA3B had inhibition effect 
on tumour formation in MDA-MB-435 melanoma cells (Varshavsky et al., 2008).  
As the above studies suggested that full-length SEMA3B acts as a tumour suppressor, 
but the evidence for this in breast cancer is limited we chose to investigate this in a 
different way. In chapter 4, we examined the activity of full-length recombinant 
SEMA3B on the proliferation, metabolic activity, migration and invasion of breast 
cancer cells. Our approach was to investigate the role of SEMA3B in breast cancer by 
demonstrating the effect of the full-length SEMA3B on the cell growth and metabolic 
activity of breast cancer progression. In this study, the tumour suppressor activity of 
the rSEMA3B has been profiled across a panel of cells, representing normal MCF-10A 
cells, pre-invasive DCIS.com and invasive MDA-MB-231 cells, using different 
functional assays. In the cell-counting assay, rSEMA3B was found to inhibit the cell 
growth of DCIS.com and MDA-MB-231 cells in a dose-dependent manner (figure 4.7 
and 4.8). This finding suggests that full-length SEMA3B is efficient as a tumour 
suppressor on its own with respect to its ability to inhibit the proliferation of the pre-
invasive and invasive cells, and can exert direct effects on these cells but had no effect 
on their cell viability and metabolic activity. Therefore, the data in this thesis 
demonstrate that full-length SEMA3B can produce an anti-proliferative effect in vitro 
indicating that SEMA3B can act directly on target cells. These findings were in 
agreement with a previous study that showed that SEMA3B overexpression had an 
inhibition effect on cellular proliferation of breast cancer MDA-MB-231 cell-line (Shahi 
et al., 2017). The anti-proliferative effect of SEMA3B may be due to the ability of 
SEMA3B to down-regulate the Akt pathway, which modulates the function of several 
substrates included in the regulation of cell survival and cellular growth (Castro-Rivera 
et al., 2008). 
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In the same context, we showed that full-length SEMA3B was able to decrease the 
migration of MDA-MB-231 cells compared to control cells (figure 4.12). However, there 
is no previous literature with which to compare these results directly.  
The initial stage of cancer metastasis involves phenotypical and genotypical 
alterations indicating the acquisition of metastatic potential. SEMA3B was shown to 
inhibit invasion in ovarian cancer (Joseph et al., 2010). In this current study, the 
invasion ability of breast cancer MDA-MB-231 cells was significantly inhibited by the 
full-length SEMA3B in comparison to control cells (figure 4.14), suggesting the 
effectiveness of exogenous SEMA3B expression in reducing the invasive potential of 
breast cancer cells through Matrigel. In light of the previous study of the regulation and 
function of SEMA3B in ovarian cancer that showed inhibition of MMP-9 and MMP-2 
activity by SEMA3B, this may be one mechanism by which SEMA3B may potentially 
diminish metastatic development, including migration and cell invasion (Joseph et al., 
2010). However, further work is needed to confirm these findings and to establish 
whether this is the only mechanism by which SEMA3B is working to inhibit invasion. 
So far, our results suggest that SEMA3B can function as a potent tumour suppressor 
of breast cancer invasion. 
As class 3 semaphorins are known to inhibit angiogenesis, to ensure that the 
recombinant protein was active in our experimental systems, we used the same 
concentrations of SEMA3B on human umbilical vein endothelial cells. In all cases 
SEMA3B inhibited proliferation (figure 4.9), migration (figure 4.13) and invasion (figure 
4.15) demonstrating its activity as an anti-angiogenic protein in agreement with 
previous studies which showed similar anti-angiogenic activity in vitro (Rolny et al., 
2008, Varshavsky et al., 2008). Our finding is also supported by the fact that SEMA3B 
can regulate angiogenesis and metastasis by competing with VEGF family members 
for neuropilin binding (Castro-Rivera et al., 2004), suggesting that SEMA3B-mediated 
suppression of tumour growth was associated with an anti-angiogenic phenotype. 
In order to ensure that the recombinant full-length SEMA3B protein remained full-
length for the duration of the assays and therefore that the activity seen was due to 
this and not a cleaved protein, we incubated the breast cell-lines with the recombinant 
SEMA3B. Interestingly, we found that MCF-10A and DCIS.com did not induce 
cleavage of full-length SEMA3B protein over 48 hours suggesting that the recombinant 
protein would retain activity within that time period (figure 4.1, 4.2 and 4.3). However, 
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the invasive MDA-MB-231 cells demonstrated partial cleavage of the full-length 
SEMA3B over 48 hours as cleavage of SEMA3B was observed in both cells and 
conditioned medium suggesting that the full-length of SEMA3B may be affected in 
these cells in a time-dependent manner.  
In a similar manner, we incubated the breast cell lysates with the recombinant 
SEMA3B protein for three hours. We found that both MCF-10A cell lysate and 
conditioned medium were unable to cleave the full-length SEMA3B. However, the full-
length SEMA3B showed a partial cleavage in the invasive MDA-MB-231 cell lysate 
and to a lesser extent in DCIS.com lysate. This data suggests that there are proteins 
produced inside the cells that may be responsible for this cleavage (figure 4.4 and 
4.5). This data was in agreement with a previous study of Varshavsky et al.,2008, who 
suggested that SEMA3B cleavage in MDA-MB-231 cells is most likely to be due to the 
activity of furin. However, their study had used pan-PPC inhibitors, and therefore other 
members of the PPCs family could have a role cleaving SEMA3B and may contribute 
to enhancing the malignant phenotype. 
Therefore, in chapter 5, we examined the presence of all the PPCs in the breast cell-
lines, surprisingly, the gene expression of furin (figure 5.2), PCSK1 (figure 5.3), and 
PCSK9 (figure 5.10), were the highest in normal MCF-10A with a gradual decrease in 
gene expression seen with increasing the malignant and invasive potential of the cell-
lines. However, the gene expression pattern of most PPCs was lowest in MCF-10A 
cells compared to the other cells suggesting the possibility that some of the PPCs have 
increased expression with increasing malignancy of breast cancer, and it may be those 
PPCs that could be responsible for SEMA3B cleavage. Very few studies have 
investigated PPC gene expression, and some of these findings were in contrast with 
a previous study of Cheng et al., 1997 who observed that the expression of PCSK1 
and furin were upregulated in breast cancer cells compared to the normal breast 
tissues (Cheng et al., 1997). It should be noted that the study of Cheng et al., used 
normal human breast tissues in their experiment instead of using normal epithelial 
MCF-10A cell-lines that we used in this current study, which may account for some of 
the differences seen. 
However, the protein levels did not fully match up with the mRNA expression and in 
the cell-lines, the expression of furin, PCSK1, PCSK2, PCSK6, PCSK7 and PCSK9 
were lower in normal breast cells compared to the invasive cells. This suggests that 
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there may be enhanced translation of the mRNA resulting in increased protein 
concentrations in invasive breast cancer cells. In addition, post transcriptional 
modifications that occur after mRNA is translated into protein could influence protein 
stability and a protein’s half-life. This can result in differences in protein levels 
independent of transcript levels and that may explain the reasons for the discrepancy 
between the levels of mRNA and protein in some cell lines (Liu et al., 2016). Similarly, 
these data suggest that one or more of these PPCs may be involved in SEMA3B 
cleavage, as there were low levels of them detected in MCF-10A where full-length 
SEMA3B is found.  
However, it may not be as simple as that as, for example, despite the detection of high 
levels of 84 kDa PCSK1 in invasive cells, a previous study suggested that this protein 
may not be as active as the 66 kDa PCSK1 detected in normal cells (Hoshino et al., 
2011). Therefore, if the 66 kDa PCSK1 is more active, and this was detected in both 
MCF-10A and MCF-10AT, this may well exclude the possibility of PCSK1 being 
responsible for SEMA3B cleavage. Although several studies have demonstrated a 
possible role of furin in cleavage of SEMA3B in lung and ovarian cancers, its role on 
SEMA3B in breast cancer is not yet understood. Furthermore, to our knowledge, there 
are no previous studies which have investigated the protein expression of PCSK2, 
PCSK6, PCSK7 and PCSK9 using Western blot in breast cancer and therefore it is 
not known if they have a role in SEMA3B cleavage. 
The question remains as to where and when SEMA3B produced by the cells is 
cleaved. The cleaved SEMA3B product is found in the cell lysates and is also released 
into the medium, which could possibly suggest that SEMA3B is cleaved inside the 
cells, maybe in the Golgi where the PPCs are known to be active. This is important 
when we consider the expression pattern of PPCs in cell lysates compared to the 
PPCs released into the media. Indeed, in the conditioned media only the active forms 
of the PPCs were detected compared to the cell lysates where different PPCs bands 
were identified with some representing inactive and some active enzymes. However, 
the differences between amounts of the PPCs found in the conditioned media was not 
as pronounced as in the lysates, and generally less protein was found. In some ways 
this is unsurprising as measuring the protein expression in the culture medium is 
known to be challenging as the presence of serum residues in cell culture due to 
improper washing of cells may yield different protein concentrations (Chevallet et al., 
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2007). In order to minimize this, cells were incubated in serum-free media for 24 hours 
to avoid any cross-reactivity between the FBS and the antibodies of interest and then 
their conditioned medium was collected for investigation. 
As so few previous studies have investigated the expression of PPCs in breast cancer, 
we then identified the expression of these enzymes in breast tissue using IHC. 
Interestingly, generally all PPCs except PCSK8 are expressed in normal epithelium, 
but for the most part their expression decreases with increasing malignancy of the 
lesion, suggesting that as breast cancer progresses they are no longer active. 
However,  protein expression of PPCs in cell-lines were not similar to that detected in 
tissues as in cell-lines, furin, PCSK1, PCSK2, PCSK6, PCSK7 and PCSK9 detected 
at the lowest level in normal cells compared to invasive cells while in tissues, all PPCs 
appeared expressed at the highest level in normal tissue compared to invasive tissue. 
These differences could be because the antibodies used are not specific for the active 
isoforms of PPCs, and therefore any PPC present will be detected whether it is active 
or not.   
Interestingly there was a positive correlation between SEMA3B expression and the 
expression of furin, PCSK1, PCSK2, PCSK4, PCSK7 and PCSK9, in the breast cancer 
tissues. This suggests that these proteins are active when SEMA3B is present, and 
therefore may potentially cleave the SEMA3B thereby abolishing the ability of 
SEMA3B to act as tumour suppressor as breast cancer progresses. Cleavage of 
SEMA3B to its inactive form by furin-like PPCs has been demonstrated in cell-lines 
but whether SEMA3B inactivation by furin or other PPCs family members is 
responsible for invasiveness of cancer cells or cancer development is currently not 
well-explained. Thus, we next attempted to show whether or not inhibition of PPCs 
activity will restore the full-length of SEMA3B in the breast cancer cells.  
The majority of PPCs inhibitors work by targeting the catalytic site of the enzyme, but 
these inhibitors are not specific for single PPCs (Fugere et al., 2002). CMK, is a highly 
potent inhibitor of PPCs, although not specific for one individual protein, and has 
previously been used to suggest a role for PPCs in SEMA3B cleavage (Varshavsky et 
al., 2008). However, in this thesis even when high concentrations of CMK (200 µM) 
were used, no effect was seen on SEMA3B, with full cleavage still happening in DCIS 
and MDA-MB-231 cells. This could possibly suggest that the PPCs have no role in 
SEMA3B cleavage, but this is unlikely as one previous study demonstrated that CMK 
251 
 
at the same concentration was effective in reducing the cleavage of SEMA3B 
(Varshavsky et al. 2008). Interestingly despite suggestions that CMK is a pan-PPC 
inhibitor there are some studies which suggest that although CMK can inhibit PCSK6 
in skin squamous cell carcinoma cell-lines resulting in reduced tumour development 
(Bassi et al., 2010), and can inhibit furin activity, it had no effect on the activity of 
PCSK7 (Bessonnard et al., 2015). Furthermore, there is a suggestion that CMK 
inhibitor has poor cell permeability (Basak, 2005), and it is known that the PPCs mostly 
act in the Golgi. Taken together these data suggest that CMK may not be the best 
inhibitor to confirm an effect of PPCs on SEMA3B cleavage so an alternative inhibitor 
was used.   
Although previous studies identified α1-PDX as a selective inhibitor for furin (Anderson 
et al., 1993) more recently evidence has appeared that α1-PDX inhibits other PPCs 
family members including PCSK1, PCSK5 and PCSK6 (Vollenweider et al., 1996, 
Benjannet et al., 1997). Importantly, we have shown that α1-PDX has effectively 
resulted in inhibition of activation of PPCs as demonstrated by the appearance of the 
full-length SEMA3B form on the Western blot (figure 5.35). These data therefore 
confirm that SEMA3B is cleaved by at least one or more of the PPC family members, 
although exactly which PPC remains to be seen. 
6.2 Limitations of the study 
One of the main limitations of this study is conducting work with cultured cell-lines, as 
this has obvious disadvantages, including contamination with mycoplasma, genotypic 
and phenotypic drift, which can alter the behaviour of the cells, and these develop 
during their continual culture (Geraghty et al., 2014). Therefore, the majority of cell-
lines used were bought fresh from the ATCC to avoid any contamination that may raise 
of using old cryopreserved cells in-house, regular mycoplasma testing was carried out 
in order to ensure that cells are mycoplasma free, and low passage numbers were 
used throughout this thesis work. In addition it would have been advantageous to 
undertake fingerprint analysis for all cell-lines; however, this was not performed due 
to time and money constraints. It is also important to note, that cell-lines used by 
different laboratories may show a difference in their biological properties, even with 
having a similar karyotype, due to differences in the culturing conditions before 
storage. Indeed, some groups will grow the breast cancer cell-lines in DMEM whereas 
we used RPMI and this may alter their behaviour slightly. It should also be noted that 
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direct comparison between the different cell-lines used in this study was difficult as 
although we managed to grow most of the cell-lines in the same media with the same 
supplements this was not possible for MCF10A cells. The MCF-10A required different 
media including large amount of supplements, including cholera toxin, EGF, 
hydrocortisone and insulin. Without these, this cell-line would not grow, but this 
difference in media supplements may result in some of the differences seen between 
the cell-lines. For future work it would be advantageous to use the same media for all 
the cell lines tested to ensure results seen were a result of the cell-line and not the 
supplements. The limitations of the different proliferation assays have already been 
discussed in chapter 3, but other in vitro phenotypic assays also had limitations. For 
example, in the scratch (wound healing) assay, creating identical scratches was 
difficult to re-produce among experiments resulting in different size scratches. The 
other limitation of this assay is that scratching of the monolayer can lead to damage 
of the extracellular matrix components, and cells resulting in the release of factors that 
may change the cell migration activity. In order to get round these difficulties the 
transwell migration or Boyden chamber assays could have been used, but money 
constraints prevented this.  
As mentioned throughout the thesis there were some difficulties relating to some of 
the antibodies, with not all of them working in both Western blotting and IHC. 
Furthermore, the antibodies tended to be designed to pick up all cleavage products of 
the protein and not to distinguish between active and inactive forms. This is a common 
restriction of antibody based data where it is difficult to design antibodies to pick up 
only specific protein cleavage products.   
For investigating the different proteins in breast tissue using IHC, tissue microarray 
slides were used, where a core was taken from each different breast tissue and then 
included into the same block and were subjected to the same conditions including 
temperature, solutions concentrations and the same period of incubations which are 
providing more consistent results. This is useful for consistency of staining, however 
the cores from each tissue were small (5mm) so only a small sample is taken from 
each patient sample, so some interesting observations may be missed using this 
method. It would have been good, had ethical approval been in place, to use whole 
sections of key tissues to get a bigger picture of what was happening. The advantage 
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of the microarray is that there was a large overall sample size, but a limitation was that 
the number of specimens in each group was relatively small. 
Another limitation to this study is that we relied on using PPCs inhibitors including CMK 
and α1-PDX, and although the CMK inhibitor was effective in a previous study 
(Varshavsky et al., 2008), it showed no effect on our cells. However, one limitation of 
the CMK inhibitor is that is a pan-inhibitor which is a non-selective inhibitor of all 
individual PPCs. In addition, it has been reported to exhibit some cytotoxic effects and 
poor stability (Remacle et al., 2010), which prevented us from using more than 200 
µmol/L to avoiding potential downsides of toxicity. 
6.3 Future perspectives 
The data shown in this thesis suggests that full-length SEMA3B inhibits breast cancer 
cell activity in vitro and that SEMA3B is cleaved in breast cancer cell-lines compared 
to normal breast epithelial cells. Although previous studies have suggested that the 
cleaved SEMA3B is inactive, it would be interesting to generate recombinant cleaved 
SEMA3B and treat the cells with it to confirm this supposition. In addition, one of the 
next key steps would be to design antibodies that distinguish between full-length and 
cleaved SEMA3B to truly establish whether the SEMA3B expressed in human tissue 
samples is cleaved with progression to breast cancer.  
As our data suggest that PPCs are present where SEMA3B is expressed, with 
expression correlating, and the data from the α1-PDX study suggests that at least 
some of the PPCs may be involved in SEMA3B cleavage, the next step would be to 
identify which PPCs are involved. This could be done by using siRNA for specific PPCs 
to investigate which member is involved in SEMA3B cleavage. RNA interference by 
siRNA is a process in which double-stranded RNA complexes can target specific 
genes for silencing through transfection to allow genes in cultured cells to be silenced 
(Leung and Whittaker, 2005) and therefore suppress the relevant PPCs expression 
with varying degrees of efficacy which will allow to confirm the endogenous processing 
of SEMA3B and identify the convertase(s) involved in this processes. This is important 
since SEMA3B is a tumour suppressor so methods to generate full-length SEMA3B 
may be an effective anti-tumour agent. Hence, SEMA3B expression can be measured 
in PPCs knockdown cells by qRT-PCR and Western blotting and compared these cells 
to scrambled siRNA treated cells in order to assess their activity in phenotypic assays. 
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As α1-PDX resulted in the expression of full-length SEMA3B, it would be good to then 
investigate whether α1-PDX had an effect on tumour cell biology and could therefore 
be used as a potential therapy. This could be done by treating the cells in vitro and 
then analysing their proliferation, migration and invasion in comparison to untreated or 
vehicle treated control. Should α1-PDX treatment in vitro have an inhibitory effect on 
breast cancer cells, the studies could progress in vivo to establish whether α1-PDX 
will inhibit breast cancer growth and/or progression depending on the model used. The 
in vivo studies will also give an idea of the safety of the α1-PDX when used as a 
treatment in a whole body situation. 
The other aspect of SEMA3B biology, which has not been investigated in this thesis, 
is that SEMA3B signals through a complex involving plexins and NP-1 and NP-2. This 
signalling complex is responsible for the downstream activity of SEMA3B in breast and 
endothelial cells, and therefore it would be advantageous to study plexin and NP-1 
and NP-2 expression in a panel of breast diseases cells, and compare them to normal 
and benign tumours, and correlate them with SEMA3B expression. This would give a 
more complete picture of SEMA3B potential in the development of breast cancer. 
6.4 Final conclusion 
In conclusion, the data in this thesis have shown that wherever SEMA3B is expressed 
in pre-malignant and malignant breast tissue, it is likely to be cleaved and therefore 
inactive. The full-length SEMA3B has an anti-proliferative effect on cell growth of pre-
invasive and invasive breast cancer cells and has a cytostatic effect on the proliferation 
of these cells, causing cell cycle arrest, but not apoptosis. In addition, full-length 
SEMA3B has proved successful in decreasing cancer cell migration and invasion in 
breast cancer. Our results further suggest that PPCs may contribute to tumour 
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Figure 1: SEMA3B protein expression in mouse brain lysate. Mouse brain lysate 
was separated on a 10% SDS-PAGE gel, and then blotted onto PVDF and probed 
with the anti-SEMA3B antibody. It was used as a positive control for SEMA3B 
expression. Negative control is medium only. The size of molecular weight markers 


























Figure 2: Positive tissue controls used for the IHC assay. The positive tissue 
controls were used at the same concentration as the experimental antibody for 
immunohistochemistry staining. Representative photographs of PPCs staining by 
immunohistochemistry in placenta tissue for furin, mouse brain tissue for PCSK1 and 
PCSK2, prostate tissue for PCSK4, colon tissue for PCSK5, plasenta tissue for 
PCSK6, colon tissue for PCSK7,PCSK8 and PCSK9. All images were taken using a 


























Figure 3: Isotype controls. The isotype controls were used at the same concentration 
as the experimental antibody for immunohistochemistry staining. Isotype controls did 
not bind non-specifically to breast tissues; demonstrating antibody binding was 
specific. Representative photographs of PPCs staining by immunohistochemistry in 
breast ducts tissues. All images were taken using a x20 objective lens and the scale 
bar = 200 µm.  
 
 
 
 
 
 
 
